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Sub-Saharan Africa carries a disproportionate burden of the HIV-1 epidemic. The Duffy 
Antigen Receptor for Chemokines (DARC)-null polymorphism is a predictor of ethnic 
neutropenia which commonly occurs in persons of African ethnicity and is thought to account 
for up to 11% of HIV-1 infections on the African continent. Neutrophils are recognised for 
their killing mechanisms and have been noted for their regulatory mechanisms in recent years. 
For example, a role for neutrophils in natural killer (NK) cell priming in the periphery has been 
suggested, and neutrophil deficiency has been implicated in contributing to NK cell immaturity 
and dysfunction. While the DARC-null genotype is well associated with lower absolute 
neutrophil counts (ANCs), studies that assess the effects of the polymorphism on neutrophil 
functionality are lacking and the impact of DARC-null linked neutropenia on HIV disease 
progression is debatable. Furthermore, the influence of DARC-null neutropenia on the NK cell 
compartment is unknown. In this cross sectional pilot study, we assessed the impact of the 
DARC-null trait on neutrophil effector functions and also characterised NK cell profiles in 
Zulu/Xhosa African individuals from a high incidence HIV setting in Durban, South Africa. 
We hypothesised that in the context of the DARC-null genotype and lower ANCs in our cohort 
participants, neutrophils would have impaired functionality and would be unable to efficiently 
prime NK cells; thus affecting NK cell maturation and function, and altering NK cell 
homeostatic activities such as survival and proliferation. We further hypothesised that the 
impaired cellular responses in DARC-null individuals would be more prominent in HIV-1 
infected individuals compared to HIV negative individuals. 
Neutrophil killing mechanisms were measured in HIV-1 chronically infected (n=22) 
individuals and HIV negative (uninfected) controls (n=20). For assessment of key neutrophil 
effector functions, isolated neutrophils were evaluated for Fc receptor-mediated phagocytosis 
following uptake of IgG opsonised beads using flow cytometry; reactive oxygen species (ROS) 
emission was measured by chemi-luminesce after activation of neutrophils with phorbol 12-
myristate 13-acetate (PMA). Activated neutrophils were also visualised by fluorescent 
microscopy for neutrophil extracellular trap (NET) quantification. Assessment of the NK cell 
compartment in chronically HIV-1 infected (n=18) and uninfected (n=20) individuals using 
multi-parametric flow cytometry determined NK cell subsets, maturation profiles, cytokine 
production and degranulation. Annexin V and propidium iodide assays were used to determine 
NK cell survival, whilst CFSE staining was used to examine cytokine-activated NK cell 
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proliferation. Study subjects were genotyped for the DARC trait using TaqMan allelic 
discrimination assays and ANCs were measured by full blood count.  
Our findings confirmed a high prevalence of the DARC-null allele in the African population 
and the polymorphism was significantly associated with lower ANCs. Neutrophil functional 
analysis detected rapid and higher phagocytic activity in the absence of DARC at 10 minutes 
(p=0.05 and p=0.009) and 60 minutes (p=0.05 and p=0.07) in HIV negative and HIV-1 infected 
subjects respectively. ROS and NET production in neutrophils were mostly unaffected by 
DARC negativity irrespective of HIV status. The only exception to this was a reduction in NET 
production in neutrophils from DARC-null HIV infected subjects (p=0.04) following 
prolonged in vitro stimulation. In the NK cell compartment, individuals showed similar NK 
cell counts irrespective of HIV status. In HIV negative individuals, a marked reduction of total 
NK cell counts was noted in the absence of DARC (p=0.006) and this correlated with lower 
ANCs (p=0.002) and a weak trend towards higher CD56 bright subset proportions was noted 
in DARC-null individuals (p=0.08). HIV negative DARC-null subjects also displayed a less 
mature NK cell phenotype with higher proportions of hypo-responsive KIR-NKG2A- NK cells 
(p=0.06) and lower frequencies of terminally differentiated CD57 (p=0.02) expressing NK 
cells. However, this immature phenotype did not translate to differences in expression of NK 
cell activation markers CD69 or HLA-DR and exhaustion marker PD-1 by DARC state. 
Furthermore, no differences in relation to NK cell degranulation and cytokine production were 
detected in the absence of DARC in HIV negative subjects. In contrast to HIV negative 
individuals, HIV-1 infected subjects displayed NK cell subset redistribution marked by higher 
CD56 negative NK cells, marginally higher frequencies of less mature NK cells, accompanied 
by higher expression of activation and exhaustion markers and lower cytolytic potential. 
However, these observed phenotypic and functional differences were lost upon DARC 
stratification in HIV-1 infected persons. Lastly, examination of NK cell survival capacity 
demonstrated only marginal differences during HIV infection in the absence of DARC 
(p=0.09); no changes were detected in NK cell proliferation by DARC state in HIV negative 
or infected individuals.  
Together our data suggests that the DARC-null polymorphism and lower ANCs does not 
adversely affect neutrophil activity irrespective of HIV status. We also show that while HIV 
negative individuals with the DARC-null genotype displayed reduced NK cell counts with a 
less mature phenotype, the condition did not compromise NK cell functionality or homeostatic 
activities. Furthermore, no significant differences were exhibited in the context of DARC 
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during HIV infection, suggesting that any advantage that the DARC-positive trait may offer 
pre-infection is lost in chronic infection. DARC-null associated neutropenia is considered a 
mild condition and thus our findings support reports that the effect of ethnic neutropenia is not 
as pronounced as exhibited in severe neutropenia. Overall the data presented here provides 
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1.1 HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 
Since its identification over thirty years ago, Human Immunodeficiency Virus (HIV)-1 has 
become the defining public health concern of our time. HIV-1 targets cluster of differentiation 
(CD)4+ T cells of the immune system and infection leads to progressive immune dysfunction 
and deterioration. This allows opportunistic infections and cancers to thrive, resulting in 
Acquired Immunodeficiency Syndrome (AIDS) (Fauci and Lane, 2005). 
 
1.1.1 HIV-1 Epidemiology 
According to UNAIDS an estimated 36.9 million people were living with HIV in 2017 (Figure 
1.1), with 1.8 million new infections in that year alone. Sub-Saharan Africa remains the worst 
affected region, accounting for almost 70% of infected people worldwide. South Africa is one 
of the top ranking countries in the world in terms of HIV prevalence, estimated at 18.8% in 
2017 (UNAIDS, 2017b). Of the 7.9 million people infected with HIV in South Africa, the 
number of infections is disproportionately skewed towards the black South African population 
with an HIV prevalence of 16.6%, compared to other racial groups of 1.1%, 5.3% and 0.8% in 
the Caucasian, Coloured and Indian/Asian ethnic groups respectively (HRSC, 2017).    
 
 
Figure 1.1 Estimated Number of People Living with HIV-1 in 2017 (UNAIDS, 2017a). 
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1.1.2 HIV-1 Genome Organisation and Structure 
HIV-1 is a single-stranded, positive-sense, enveloped retrovirus that belongs to the Lentivirus 
genus of the Retroviridae family (Fauci and Lane, 2005). The HIV-1 retroviral genome, coded 
by an approximately 9kb Ribo Nucleic Acid (RNA), comprises nine overlapping genes that are 
flanked by identical long terminal repeat (LTR) regions at the 5’ and 3’ ends of the genome. 
These nine genes, namely group specific antigen (gag), polymerase (pol), envelope 
glycoprotein (env), viral infectivity factor (vif), viral protein R (vpr), viral protein U (vpu), 
negative regulation factor (nef), transactivator of transcription factor (tat) and regulator of 
virion protein (rev) encode for structural, accessory and gene regulatory proteins as depicted 
in Figure 1.2a (Freed, 2001, Fanales-Belasio et al., 2010). 
Mature HIV-1 virions are encapsulated by a lipoprotein membrane derived from host plasma 
membrane. The viral Env components glycoprotein (gp) 41 and gp120 are inserted into this 
lipid membrane. Bound to the lipid layer are matrix (MA) molecules composed of viral protein 
p17 which surrounds the conical capsid (CA) and protects the inner molecules of the virus 
particle. Enclosed within the CA are nucleocapsid (NC) molecules that are in tight conjunction 
with the single-stranded viral RNA, reverse transcriptase (RT), protease (PR) and integrase 
(IN) molecules (Fanales-Belasio et al., 2010). The structure of the HIV-1 virion is illustrated 
in Figure 1.2.b.    
The three structural proteins Gag, Env and Pol, which are common to all retroviruses, are 
initially synthesised as polyproteins and later cleaved by either viral PR or host cellular 
enzymes during or after the budding phase of the replicative cycle (described in section 1.1.3) 
into mature structural and enzymatic proteins. The accessory proteins Vif, Vpr, Vpu and Nef 
are thought to impede host defences and enhance viral pathogenicity, while the regulatory 
proteins Tat and Rev direct viral gene expression and nuclear export (Frankel and Young, 1998, 













Figure 1.2 HIV-1 Genome Organisation and Virion Structure 
(A) The HIV-1 genome is flanked by two long terminal repeat (LTR) regions. The structural genes gag, 
pol, and env encode for the proteins: matrix (MA), capsid (CA), nucleic-acid binding (NB), 
nucleocapsid core proteins (NC), protease (PR), reverse transcriptase (RT), integrase (IN) surface 
subunit glycoprotein (SU, gp120), and a smaller transmembrane protein (TM, gp41). Tat, rev, vif, nef, 
vpr and vpu encode for regulatory and accessory proteins. (B) Structure of the HIV-1 virion with 









1.1.3 HIV-1 Replication Cycle 
The replicative cycle of HIV-1 bears considerable similarity to that of other retroviruses, 
although there are select aspects that are exclusive to HIV-1 replication (Freed, 2001). The 
cycle can be described in several sequential steps and are referred to as 1) binding and entry; 
2) uncoating; 3) reverse transcription of RNA to Deoxyribo Nucleic Acid (DNA); 4) nuclear 
import; 5) provirus integration; 6) viral protein synthesis and assembly; 7) budding and cell 
exit and 8) maturation (Freed, 2001, Fanales-Belasio et al., 2010) as depicted in Figure 1.3. 
Virus particle entry into the target cell is facilitated by interaction of the viral Env with various 
host cellular membrane factors. Attachment to any of these factors brings Env into close 
proximity and enables adhesion with the primary HIV host receptor CD4 (Ugolini et al., 1999, 
Wilen et al., 2012). This high affinity interaction promotes the rearrangement of the variable 
loops V1/V2 and subsequently the V3 variable loop of gp120. In addition, a “bridging sheet” 
made up of four-stranded β sheets is formed (Kwong et al., 1998, Chen et al., 2005). Both these 
events are thought to be critical for co-receptor engagement with either the C-C chemokine 
receptor 5 (CCR5) or the CXC chemokine receptor 4 (CXCR4) proteins (Wilen et al., 2012). 
Co-receptor binding results in the formation of a ternary complex composed of gp120, CD4 
and the co-receptor, which in turn prompts the exposure of the highly hydrophobic N-terminus 
of gp41, known as the “fusion peptide” that inserts directly into the target membrane. Tethering 
of the viral and target membranes permits folding of the fusion peptide of each gp41 creating 
a six-helix bundle structure which aligns viral and host membranes and instigates the formation 
of the fusion pore and delivery of the virus into the host cell cytoplasm (Freed, 2001, Melikyan, 
2008, Wilen et al., 2012). 
Once the viral particle gains access to the cytoplasm, several events, collectively described as 
“uncoating” occur and seem essential to the success of the proceeding step of reverse 
transcription. Here, the CA destabilises and is lost, while some of the structural and enzymatic 
components, including MA, NC, RT, IN and Vpr remain intact as part of a high molecular 
weight reverse transcription complex (Freed, 1998, Freed, 2001). 
 
Next the viral genome undergoes reverse transcription where the single-stranded viral RNA is 
converted to a linear double stranded DNA (Hu and Hughes, 2012). Although the mechanism 
by which the viral complex  is transported to the nucleus is debatable, it is widely believed that 
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Vpr, and the DNA “flap” synthesised during reverse transcription, are required for nuclear 





Figure 1.3 HIV-1 Replication Cycle 
The diagram highlights the major sequential steps of the HIV-1 replication cycle, namely: binding and 
entry; uncoating; reverse transcription; nuclear import; provirus integration; viral protein synthesis and 
assembly; budding and maturation (Peterlin and Trono, 2003). 
 
 
Insertion of the linear, double-stranded viral DNA into the host cell chromosome is catalysed 
by the virus-encoded IN protein. The integrated viral DNA termed the “provirus” serves as the 
transcriptional template for viral RNA synthesis (Freed, 2001, Craigie and Bushman, 2012). 
The viral LTR region comprises various DNA regulatory elements and is the site of 
transcriptional initiation (Lee et al., 2009). Soon after infection only short, fully spliced 
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messenger (m) RNAs which encode for Tat and Rev are produced. Tat triggers the transcription 
and synthesis of lengthened transcripts, so that as infection progresses, there is accelerated 
transcription of partially sliced mRNAs that encode Env, Vif, Vpr and Vpu; and full-length 
transcripts which serve as the mRNA for the Gag-Pol polyproteins (Fanales-Belasio et al., 
2010, Karn and Stoltzfus, 2012). 
Most viral mRNAs are fully sliced before export to the cytoplasm. However transport of certain 
longer transcripts, such as those that encode Gag, Pol and Env, are facilitated by Rev (Fanales-
Belasio et al., 2010). Following export from the nucleus to the cytoplasm, RNA translation 
occurs on either free ribosomes or ribosomes attached to the endoplasmic reticulum to produce 
Gag and GagPol polyprotein precursors and Env glycoproteins (Freed, 2015).   
Virion assembly occurs in dedicated micro-domains, the formation of which is induced by Gag 
at the cell plasma membrane. Single-stranded genomic viral RNA directs RNA “packaging 
signal” which interacts with the NC domain of Gag and “captures” the viral RNA into virus 
particles (Sundquist and Krausslich, 2012, Freed, 2015). The central Gag domain, CA, 
facilitates protein-protein interactions that are required for virion assembly. Gag molecules are 
aligned and radially packed, MA domain binds to the inner surface of the viral membrane and 
the C terminus forms a conical shell layer that is positioned towards the particle core. MA 
trimers and the gp41 cytoplasmic tail of Env are central to the recruitment and incorporation 
of the Env glycoproteins into the forming virions, although the mechanism is not clearly 
understood (Freed, 2015). 
In events that remain unclear, the  virus interacts with cellular machinery, thus catalysing 
membrane scission and virion particle release or budding (Freed, 2015). During or soon after 
budding, viral PR cleaves Gag and GagPol polyprotein precursors, generating mature Gag and 
Pol proteins and sets into motion a series of morphological rearrangements that lead to virus 
maturation. The maturation period is viewed as a phase when the immature virion particle 
transforms into virus particle that can enter and replicate in a new target cell (Sundquist and 





1.2 HIV-1 PATHOGENESIS 
The main routes of HIV-1 transmission occurs through exposure of a mucosal surface to the 
virus, although other modes include intravenous drug use, by blood transfusion and mother-to-
child transmission. The initial phase before the detection of viral RNA is termed the eclipse 
phase (McMichael et al., 2010, Mogensen et al., 2010). Data collected from Simian 
Immunodeficiency Virus (SIV) infected rhesus macaques and acutely infected subjects alike 
suggest that resident memory CD4+ CCR5+ T cells are the first mucosal cell type to be infected 
(Li et al., 2005, Salazar-Gonzalez et al., 2009), and that productive infection emerges from a 
specific infectious founder virus. Local replication and expansion of the genetically restricted 
viral population is supported by signalling mucosal epithelial cells that recruit cytokine 
secreting dendritic cells, which subsequently attract additional activated CD4+ T cells that are 
susceptible to infection (Haase, 2010, Sagar, 2010), Figure 1.4.  
Primary or acute HIV-1 infection is distinguished as the period of infection when HIV-1 RNA 
first becomes detectable in the blood plasma until the formation of HIV-1-specific antibodies 
that are produced 3-4 weeks following infection (McMichael et al., 2010, Mogensen et al., 
2010). Within a week of infection, cell-free virus and infected cells disseminate and are able to 
infect HIV-specific CD4+ T cells in the draining lymph node. It is during this time that HIV-1 
RNA first becomes detectable in the blood plasma (10-17 days post-infection), followed by 






Figure 1.4 HIV-1 Transmission and the Early Events of HIV-1 Infection 
Key interactions between virus and host in the early stages of HIV-1 infection, from crossing the 
cervicovaginal mucosal barrier and infection of ‘resting’ CD4+ T cells in the lamina propria, through 
to expansion in the draining lymph nodes and subsequently the lymphoid tissues within weeks of 
infection (Haase, 2010). 
 
Consequently, entry by the virus into the general circulation and secondary lymph nodes allows 
efficient infection of the main target cell of choice i.e. CD4+ T cells, which are found in 
abundance at these sites (Haase, 2010, McMichael et al., 2010). Documented studies in SIV 
models and HIV-infected individuals provide evidence that acute infection is characterised by 
substantial memory CD4+ T cell depletion predominantly in mucosal tissues, particularly the 
gut associated lymphoid tissue (GALT) (Veazey et al., 1998, Brenchley et al., 2004). 
Interestingly, it has been documented that SIV infects up to 60% of the infected organism’s 
memory CD4+ T cells and that the majority of these cells undergo apoptosis within days 
(Mattapallil et al., 2005). Importantly, acute infection does not efficiently target CCR5 devoid 
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T cell subsets, including naïve and resting central memory T cells, thus allowing the 
regenerative potential of these subsets to remain intact (Grossman et al., 2006).  
Peak plasma viremia (>1 million HIV-1 RNA copies/ml) is reached 21-28 days post-infection 
and is accompanied by diminished peripheral CD4+ T cell counts. While circulating T cell 
numbers subsequently rebound close to pre-infection levels, CD4+ T cell levels in the GALT 
remain severely suppressed. It is at this stage that host HIV-specific, albeit non-neutralising, 
antibodies first become measureable (Fiebig et al., 2003, Lee et al., 2009, Mogensen et al., 
2010), Figure 1.5. Establishment of viral reservoirs of primarily latently infected resting 
memory CD4+ T cells occurs during this acute stage of infection and cannot be eliminated by 
highly active antiretroviral therapy (HAART) (Dinoso et al., 2009). At this stage of infection, 
individuals may present with acute retroviral syndrome symptoms that include influenza-like 
signs with fever, sore throat and lymphadenopathy (Kahn and Walker, 1998, McMichael et al., 
2010). Eventually, at approximately 25-31 days post-infection, plasma viremia starts to 
decrease over 12-20 weeks to reach a stable plateau termed viral set point which is viewed as 
a predictor of rate of disease progression (Fiebig et al., 2003, Lee et al., 2009).  Adaptive 
immune responses in the form of cytotoxic CD8+ T cells emerge as viral loads peak and it is 
widely recognised that these cells are predominantly responsible for the consequent decline in 
viremia (Borrow et al., 1994). 
Chronic infection ensues and is characterised by a gradual decline in circulating CD4+ T cells, 
rapid cell turnover and immune dysfunction. Central to HIV-1 pathogenesis is the heightened 
immune activation which is evidenced by the increased expression of immune activation 
markers including CD38 which is considered a reliable marker for immune activation, 
progression to AIDS and death (Liu et al., 1997). Prolonged activation is disadvantageous to 
the host and leads to immune exhaustion. Several factors have been implicated in chronic 
immune activation; these include increased activation of T cells, translocation of bacterial 
products across the damaged mucosal barrier and subsequent heightened pro-inflammatory 
cytokine production leading to the activation of latently infected cells (Ko et al., 2010, 
Mogensen et al., 2010).  
Progressive activation results in the loss of cytotoxic and cytokine-secreting abilities of 
immune cells, leading to their dysfunction. Thus, the capacity to control HIV-1 replication is 
further compromised and CD4+ T cell decline continues. At this time the host becomes highly 
susceptible to opportunistic infections and certain cancers, and an infected individual with 
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presentation of these clinical features is considered to have AIDS. The period between HIV-1 
acquisition and progression to AIDS is 8-10 years without antiretroviral treatment, although 
this can vary substantially amongst individuals where several factors such as immunological 
factors, genetic factors, infecting strain virulence and co-infections may influence disease 




Figure 1.5 Representation of the Clinical Course of HIV-1 Infection 
Schematic showing the markers of disease progression (CD4 count and viral load) and well as immune 
responses in the acute, chronic and AIDS phases of HIV-1 infection (The dashed line indicates that 
broad Nab have been found in only a portion of HIV-1 infected persons.) Abbreviations: Nab, 








1.3 THE HOST IMMUNE RESPONSE TO HIV-1 
The human immune system is multifaceted; consisting of innate and adaptive cell-mediated 
responses, humoral components and host restriction factors that provide protection against 
foreign, and often harmful microorganisms. Even from the earliest stages of HIV-1 infection, 
the host elicits a strong, although only partially successful, response to eradicate the virus.   
Innate immune cells, including dendritic cells (DCs), macrophages and natural killer (NK) 
cells, are the first line of defence which the HIV-1 virus encounters upon crossing the mucosal 
barrier. Epidermal DCs are probably the first immune cells to encounter the virus, and are 
activated via cytokines secreted by mucosal epithelial cells or through direct Toll-like receptor-
mediated recognition of viral RNA (Gonzalez et al., 2010). Activated DCs produce type 1 
interferons which trigger various antiviral pathways (Chang and Altfeld, 2010) and upregulate 
host restriction factors including APOBEC3G, TRIM5α and tetherin (Chakrabarti and Simon, 
2010). Follicular DCs are principally involved in the presentation of antigen to T cell 
lymphocytes and also provide signals for the activation of B cell lymphocytes. Macrophages 
also participate in cytokine secretion and antigen presentation which result in the activation of 
innate and adaptive immune responses (Collman et al., 2003).  
Natural killer (NK) cells proliferate in response to type 1 interferon production by DCs. 
Stimulated NK cells produce cytokines and chemokines that activate T cell lymphocyte 
proliferation; NK cell IFN-γ secretion also inhibits viral replication. Further to this, NK cells 
directly target HIV-1 infected cells that exhibit diminished expression of major 
histocompatibility complex (MHC) class I through cytolytic activity. Since MHC class I 
expression is crucial for peptide presentation to T cells, NK cells are essential when HIV 
escapes T cell responses (Fauci et al., 2005). The relationship between NK cells and HIV-1 is 
further explored in section 1.3.2.3. 
The adaptive immune system consists of T and B cell lymphocytes and humoral factors. MHC 
class I on infected CD4+ T cells display intracellularly degraded HIV peptide fragments for 
recognition by CD8+ T lymphocytes (Paranjape, 2005). CD8+ T cells are able to lyse these 
infected cells and secrete cytokines, i.e. IFN-γ, TNF-α, and chemokines, i.e. MIP-1 α, MIP β 
and RANTES, that inhibit virus replication and block viral entry into CD4+ T cells (Benito et 
al., 2004). The humoral immune response occurs later in infection. Non-neutralising antibodies 
against HIV-1 structural proteins appear approximately 20 days post infection and generally 
do not persist. Several months post infection, neutralising antibodies that are specific to viral 
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proteins involved in target cell entry are generated. Potent neutralizing antibodies have been 
shown to play a major role in HIV-1 controllers (Alter and Moody, 2010).  
There is mounting evidence that suggests a pivotal role for the earlier and quicker responses of 
innate immunity in HIV-1 infection, long before the induction of adaptive immune responses. 
The sections below describe two innate immune cell types that are of interest in this study, 
namely neutrophils and NK cells. 
 
1.3.1 Neutrophils 
Polymorphonuclear neutrophils (PMNs) are innate immune cells that are typically recognised 
as part of the first line of defence against invading pathogens through direct antimicrobial 
activity. They are formed in the bone marrow and continuously differentiate from myeloid 
precursor cells through regulation by hematopoietic cytokines, mainly granulocyte colony 
stimulating factor (G-CSF) and enter the circulation as terminally mature cells (Richards et al., 
2003, Summers et al., 2010). Daily neutrophil turnover is exceedingly rapid with 
approximately 109 cells per kilogram of body weight exiting the bone marrow in healthy 
individuals, making them the most abundant white blood cells in the periphery, constituting 
50-70% of circulating leukocytes (von Vietinghoff and Ley, 2008, Summers et al., 2010).  
Neutrophils are considered short-lived cells with a half-life of approximately 6-8 hours in 
circulation under basal conditions, although recent findings challenge this long perceived 
notion of a shortened lifespan. Experimental data from an in vivo study using 2H2O labelling 
now estimates an extended lifespan of 5.4 days under homeostatic conditions in humans (Pillay 
et al., 2010). During inflammation, neutrophil lifespan is increased several fold through 
activation by microbial products, endogenous cytokines and other pro-inflammatory mediators 
which results in the inhibition of cellular apoptosis. Prolonged lifespan during chronic 
inflammation often contributes to deteriorating disease prognosis. (Summers et al., 2010, 
Kolaczkowska and Kubes, 2013, Silvestre-Roig et al., 2016). Aged circulatory neutrophils 
exhibit increased expression of CXCR4 and CCR5; and reduced expression of CXCR2 and 
CD62L (Rankin, 2010). The altered surface marker profile ensures homing of senescent 
neutrophils to the bone marrow where they either die spontaneously by necrosis or apoptosis 
or are destroyed through phagocytosis by bone marrow macrophages (Kolaczkowska and 
Kubes, 2013, Hong, 2017). 
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Mature neutrophils are characterised by a lobulated or segmented nucleus and are enriched by 
cytoplasmic granules and secretory vesicles. The proposition of heterogeneous neutrophil 
phenotypes is a fairly recent concept. Although there is compelling evidence that suggests the 
presence of distinct neutrophil subsets, whether these subsets develop from a single precursor 
cell and represent different stages of maturity or reflect distinct neutrophil lineages remains 
unclear (Borregaard, 2010, Kolaczkowska and Kubes, 2013). Classical neutrophils or normal 
density neutrophils (NDNs) are primarily terminally differentiated and are thought to be in a 
resting state phase. Throughout systemic inflammation, ‘emergency granulopoiesis’ leads to 
enhanced production and mobilisation of neutrophils into the circulation. A portion these of 
mobilised neutrophils are immature; without the development of granules which are typically 
acquired during differentiation. These neutrophils are less granular and as such termed low 
density neutrophils (LDNs) (Hong, 2017).  
Different LDN subsets have been suggested, namely immunosuppressive and pro-
inflammatory LDNs. The pro-inflammatory LDN subset is highly exhibited in various 
autoimmune diseases and displays intensified type I interferon production and diminished 
phagocytic activity. However, since they share similar phenotypic and functional 
characteristics to that of activated NDNs, it is probable that these cells represent pre-exhausted 
activated NDNs rather than a separate LDN subset. Immunosuppressive LDNs have been found 
in individuals with haematological malignancies, sepsis and HIV-1 infection. Contrary to 
NDNs, these cells are linked to suppression of T cell responses including proliferation and IFN-
ɣ production. Phenotypic characterisation of these cells, however, remains to be determined 
(Silvestre-Roig et al., 2016, Hong, 2017).                 
During steady state conditions, neutrophils transverse the circulation as quiescent cells, 
continuously and randomly probing the endothelium. Recruitment of neutrophils into inflamed 
tissues is initiated by surface changes of local endothelial cells. Through several sequential 
steps, neutrophils are recruited from the vasculature to the tissue. Once in the interstitial space, 
neutrophil behaviour is dictated by chemotactic gradients toward invading pathogens. Chemo-
attractants also bind membrane receptors, initiating signalling pathways (Amulic et al., 2012, 




1.3.1.1 Neutrophil Effector Mechanisms 
The most well-known neutrophil effector processes include phagocytosis, degranulation, and 
production of reactive oxygen species (ROS). In subsequent years, an active form of cell death 
resulting in the release of neutrophil extracellular traps (NETs) has been described (Brinkmann 




Figure 1.6 Neutrophil Killing Mechanisms 
Neutrophils eliminate pathogens by multiple means, both intra- and extracellular. The most well-known 
mechanisms, phagocytosis, degranulation and production of neutrophil extracellular traps (NETs) are 
represented in the diagram (Kolaczkowska and Kubes, 2013). 
Phagocytosis is the principal process to clear pathogens and cell debris. It is an active, receptor-
mediated mechanism where foreign particles or microbes are internalised by the neutrophil 
cellular membrane into a vacuole known as a phagosome (Amulic et al., 2012). Internalisation 
is dependent on the interaction between the neutrophil and the pathogen and can be directly 
through recognition of pathogen-associated molecular patterns (PAMPs) or may be opsonin 
mediated. The well-characterised opsonin mediated phagocytosis can occur via two 
mechanisms, either fragment crystallisable gamma receptor (FcɣR)-mediated or complement 
receptor-mediated phagocytosis, the former of which requires the formation of membrane 
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extensions for the engulfment of Immunoglobulin (Ig)G opsonised particles (Underhill and 
Ozinsky, 2002, Lee et al., 2003).  
Engulfment alone is insufficient for pathogen elimination. Neutrophil cytoplasmic granules are 
unique organelles that store a plethora of antimicrobial proteins, metalloproteases and plasma-
derived proteins. Upon complete cell activation, granules fuse with the phagosomal membrane 
and release their contents into the vacuole lumen, thus creating an antimicrobial environment 
that is lethal to invading pathogens (Amulic et al., 2012). However, certain pathogens have 
adapted strategies to evade engulfment, modify phagosome maturation and create hospitable 
phagosomal conditions (Staali et al., 2006, McCaffrey et al., 2010). 
In parallel to fusion of granules with the phagosome, nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase assembles on the phagosome membrane and the reactive oxygen 
cascade commences by reducing oxygen to superoxide, which readily forms several reactive 
oxygen intermediates, and this collectively creates an uninhabitable environment to most 
pathogens. Despite the continuing fusion of acidic granules to the phagosome, NADPH oxidase 
activity sustains the maintenance of an alkaline pH within the phagosomal lumen, which is 
essential to the activation of serine proteases (Amulic et al., 2012).  
First described by Brinkmann and colleagues (2004), NETosis is an active form of cell death 
which results in the release of fibrous structures referred to as NETs into the extracellular space 
in response to surplus chemical or biological stimulus. The released NETs comprise 
decondensed chromatin, to which histones and antimicrobial proteins are attached and are 
thought to directly eliminate microbes through exposure to high concentrations of 
antimicrobials (Brinkmann et al., 2004, Papayannopoulos and Zychlinsky, 2009). The 
mechanisms involved in NET formation are not completely known, although formation is 
dependent on NADPH, myeloperoxidase and neutrophil elastase (Fuchs et al., 2007, Patel et 
al., 2010, Metzler et al., 2011).  
 
1.3.1.2 Neutrophil Regulatory Mechanisms 
Historically, neutrophils were viewed as no more than “professional killers”. However, recent 
research has highlighted their role in forming the foundation of the inflammatory response. As 
one of the earliest immune cellular components to arrive at the site of inflammation, neutrophils 
not only secrete cytokines and chemokines for the recruitment of other cell types, but they are 
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also responsible for creating adequate micro-milieu conditions to promote adaptive immune 
responses.  
In comparison to other cells types, neutrophils characteristically produce reduced volumes of 
cytokines per cell, but since they are abundant in frequency, their contribution to overall 
cytokine levels at the site of inflammation is quite substantial (Nathan, 2006). Initially cytokine 
release is principally Interleukin (IL)-8 and is directed toward the recruitment of cellular 
support, in particular other neutrophils (Scapini et al., 2000). Additionally, neutrophil-derived 
IL-1β and Tumour Necrosis Factor (TNF)-α promote the secretion of neutrophil chemo-
attractants by other cell types (Sica et al., 1990, Kasama et al., 2005). 
Neutrophils also shape the immune response by communicating with other cell types including 
monocytes/macrophages, dendritic cells (DCs), NK cells and T and B cell lymphocytes through 
cell-cell contact (Figure 1.7) (Mantovani et al., 2011). Neutrophils can induce monocyte 
recruitment either directly through production of conventional monocyte chemo-attractants or 
indirectly through the upregulation of adhesion molecules on the endothelium and encourage 
monocyte extravasation through secretion of granule proteins. Moreover, neutrophils can 
directly moderate monocyte/macrophage cytokine production, strengthening their effector 
activities (Soehnlein et al., 2008a, Soehnlein et al., 2008b, Amulic et al., 2012). Neutrophils 
also contribute to the recruitment, activation and programming of DCs. Neutrophils have been 
found to modulate maturation of DCs via contact-dependent communications. In contrast, 
neutrophil-derived elastase can diminish the allo-stimulatory capacity of monocyte-derived 
DCs and neutrophil secreted ectosomes have been shown to inhibit monocyte-derived DC 
maturation (Mantovani et al., 2011).        
Neutrophils also crosstalk with T and B cell lymphocytes. The production of various 
chemokines by neutrophils can attract two helper (Th)1 and Th17 cells to the site of 
inflammation through chemotaxis (Scapini et al., 2000, Pelletier et al., 2010). Neutrophils can 
also directly modulate T cell function by secreting IL-12 which is essential for Th1 cell 
differentiation, and are also known to express B cell development and maturation factors 
(Huard et al., 2008, Scapini et al., 2008). Recently it has been demonstrated that antigen-pulsed 
neutrophils can cross-present exogenous antigens and promote the differentiation of cytotoxic 
CD8+ T cells (Beauvillain et al., 2007). The regulatory interactions between neutrophils and 





Figure 1.7 Neutrophils interact with immune and non-immune cells in tissues and lymph nodes 
Circulating neutrophils are activated by systemic pathogens and crosstalk with platelets and endothelial 
cells. Activated neutrophils leave the circulation and crosstalk with resident and recruited immune cells, 
including macrophages, dendritic cells (DCs), natural killer (NK) cells and B and T cells. Neutrophils 
can also migrate to the lymph nodes and interact with DCs (Mantovani et al., 2011).  
 
1.3.1.3 Neutrophils and HIV-1 Infection 
Various studies have demonstrated that neutrophils and their associated factors are linked to 
increased HIV acquisition. Toll-like receptor and HIV-1 stimulated neutrophils from highly 
exposed seronegative (HESN) individuals were found to have reduced cytokine production 
compared to HIV-1 infected patients (Hernandez et al., 2015). Interestingly, high levels of 
human neutrophil peptides and cathelicidin from cervicovaginal samples in Kenyan sex 
workers pre-infection were associated with subsequent HIV acquisition (Levinson et al., 2009), 
and neutrophil pro-inflammatory cytokine IL-8 was increased in the cervicovaginal lavages 
(CVLs) of women that seroconverted compared to women that remained uninfected in the 
CAPRISA 004 microbicide trial in South Africa (Masson et al., 2015). Importantly, further 
analysis of the CAPRISA 004 cohort revealed increased CVL neutrophil proteases positively 
associated with IL-17 expression. This neutrophil/Th17 axis could represent an increased 
capacity of neutrophils to preferentially recruit Th17 target cells to the female genital tract 
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which could result in higher risk of HIV acquisition (Arnold et al., 2016, Hensley-McBain and 
Klatt, 2018).         
Various studies have suggested that neutrophils have an important role in controlling viral 
infections (Bastian and Schafer, 2001, Fujisawa, 2001, Yasin et al., 2004). The majority of 
studies investigating the role of neutrophils in HIV-1 infection have focused on the 
susceptibility of infected individuals to opportunistic bacterial and fungal co-infections (Casulli 
and Elbim, 2014). It has now become clear that the association between neutrophils and HIV-
1 is far more complex. 
Despite neutrophil-derived mediators such as ROS, TNF-α and IL-8 having been implicated in 
augmenting HIV-1 replication (Ho et al., 1995, Yoshida et al., 2007), recent literature suggests 
an active role of granule-derived proteins in controlling replication. Numerous studies have 
reported the inhibitory effect of α-defensins on several steps of the HIV-1 replicative cycle. It 
has been demonstrated that α-defensins can broadly block viral infectious particles at an early 
stage by specifically binding both CD4 on target cells and viral gp120 envelope glycoprotein, 
thereby inhibiting fusion of gp120 to CD4 and preventing viral entry regardless of co-receptor 
specificity or genetic subtype (Chang et al., 2005, Furci et al., 2007, Demirkhanyan et al., 
2012).  
Defensins have also been shown to downregulate both CD4 and CXCR4 expression and inhibit 
replication at the nuclear import, reverse transcription and integration phase (Furci et al., 2007, 
Seidel et al., 2010, Demirkhanyan et al., 2012). Defensins may also act indirectly by 
upregulating CC-chemokine expression and secretion (Macrophage Inflammatory Protein 
(MIP)-1α and MIP-1β) which in turn inhibits HIV-1 infection of macrophages (Guo et al., 
2004) or encourage HIV-specific lymphocyte proliferation responses and amplify interferon 
(IFN)-ɣ and perforin production by CD4+ and CD8+ T cells (Mohan et al., 2013). 
In comparison to negative controls, HIV-infected individuals were shown to have increased α-
defensin expression and production which was unaffected by antiretroviral therapy and may be 
associated with chronic immune activation (D'Agostino et al., 2009). Interestingly, in breastfed 
infants it was found that milk concentration of α-defensins significantly associated with 
decreased intrapartum and postnatal HIV transmission risk (Kuhn et al., 2005). Other granule 
stored antimicrobial peptides, specifically indolicidin (Robinson et al., 1998) and lactoferrin 
(Carthagena et al., 2011) also exhibit effective inhibitory actions against HIV-1. 
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Neutrophils are able to detect HIV-1 through surface expressed Toll-like receptor (TLR)-7 and 
TLR-8 (Kawai and Akira, 2008). Engagement of viral nuclei acids with TLRs triggers ROS 
production and promotes α-defensin and myeloperoxidase action (Klebanoff and Coombs, 
1992, Moguilevsky et al., 1992). In a study conducted by Saitoh et al. (2012) it was shown that 
via NET formation, neutrophils can capture HIV-1 and through α-defensin and 
myeloperoxidase action were able to promote HIV-1 elimination. However, in response, HIV-
1 was able to induce DC-derived IL-10 production which consequently suppresses TLR-
mediated NET release (Saitoh et al., 2012). 
HIV-1 does not actively establish infection in neutrophils but rather leads to weakened effector 
responses and an escalated rate of apoptosis. Despite a handful of contradicting reports 
(Bandres et al., 1993, Schwartz et al., 2010), the general consensus is that neutrophils from 
HIV-1 individuals, particularly those in the advanced stage of disease, display variable 
functional irregularities resulting in defective bacterial and fungal killing. HIV-1 alters 
phagocytosis of extracellular pathogens (Michailidis et al., 2012) presumably by 
downregulation of FcɣR (Kedzierska et al., 2002) and also modifies ROS production by 
disturbing the distribution of the NADPH oxidase complex within the neutrophil (Salmen et 
al., 2012), although the mechanism remains undefined. Continued exposure of neutrophils to 
HIV-1 or its products may reduce chemotactic receptor expression and thereby negatively 
impacting chemotaxis and the recruitment of the neutrophils (Casulli and Elbim, 2014). 
Additionally, a changed plasma cytokine environment, as seen in HIV-infected persons, may 
play a part in neutrophil dysfunction (Casulli and Elbim, 2014). Administration of IL-15 has 
been shown to augment neutrophil function and induce production of monocytic IL-8, which 
is the main neutrophil chemo-attractant (Mastroianni et al., 2000, d'Ettorre et al., 2002). It has 
also been established that resting neutrophils from treatment naïve HIV-infected individuals 
displayed elevated basal activation as measured by CD11b and L-selectin expression (Elbim et 
al., 1994).   
Neutrophil apoptosis accelerates considerably from the very early stages of HIV-1 infection 
and this shortened survival contributes to the observed neutropenia observed in advanced 
stages of infection (Casulli and Elbim, 2014). Several factors may be responsible for the 
increased rate of cell death including heightened basal ROS production (Salmen et al., 2007), 
increased activity of calpains, which are non-caspase cysteine proteases involved in apoptosis 
(Lichtner et al., 2006) or a decline of pro-inflammatory cytokines such as G-CSF and 
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granulocyte-macrophage-colony stimulating factor (GM-CSF) that are critical to neutrophil 
survival (Casulli and Elbim, 2014).     
 
1.3.2 Natural Killer (NK) Cells 
NK cells are an integral component of the innate immune system. They are a unique class of 
large, granular lymphocytes with the capacity to directly recognise and rapidly respond to non-
self, damaged, tumour and virally-infected cells without prior sensitisation (Lodoen and Lanier, 
2006, Ward and Barker, 2008). Derived primarily from the bone marrow micro-environment, 
they differentiate and mature from common lymphoid progenitors that are also known to 
generate T and B lymphocytes. In the periphery, NK cells range from 2 to 18% of total 
circulating lymphocytes with a predicted turnover of approximately 2 weeks (Lanier, 2005, 
Vivier et al., 2008).  
NK cells are distinguished from their lymphoid counterparts by the absence of T and B cell 
receptors such as CD3, T-cell receptor (TCR) or surface Ig B cell receptors and were thus 
initially termed “null” cells (Strauss-Albee and Blish, 2016). Presently they are defined as cells 
that lack CD3 and express neural cell adhesion molecule (NCAM, CD56), with the majority 
also expressing CD16. NK cells can be phenotypically classified according to the cell density 
of surface CD56 into two subsets specifically CD56 bright (expressing high levels of CD56) 
and CD56 dim (expressing low levels of CD56) cells (Cooper et al., 2001). There is sufficient 
evidence that these subsets have unique functional characteristics implying their distinct 
assigned roles in immunity. Constituting about 90% of NK cells in the periphery, CD56 dim 
cells are fully mature NK cells that primarily mediate cytotoxic responses. In contrast, CD56 
bright cells, representing approximately 10% of NK cells in circulation, express little or no 
CD16 and it is highly debatable as to whether these cells symbolise an immature, precursor 
subset of CD56 dim NK cells. They are responsible for abundant cytokine production and are 
limited in their cytolytic activity (Cooper et al., 2001). 
 
1.3.2.1 Natural Killer Cell Recognition and Activation 
NK cells are dissimilar to T and B cells in that they lack the ability to undergo somatic 
recombination, and thus cannot generate antigen specific receptors. Rather they respond via a 
multitude of sophisticated germline-encoded receptors that regulate their activation, 
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proliferation and effector mechanisms through a contemporary modification of a process 
referred to as the “missing-self hypothesis” (Karre et al., 1986, Ljunggren and Karre, 1990, 
Karre, 2002, Lanier, 2005) as illustrated in Figure 1.8. 
Proposed by Kärre and colleagues (Karre et al., 1986, Ljunggren and Karre, 1990), the missing-
self hypothesis works on the concept that NK cells are repressed from responding to self-cells 
that actively express major histocompatibility complex (MHC) class I molecules through 
interaction with NK inhibitory receptors.  In the absence or downregulation of MHC class I 
expression on hematopoietic cells, as is the circumstance with cellular transformation and 
certain viral infections, there is dampening of this inhibitory effect, rendering the cell 
susceptible to NK cytotoxicity (Karre et al., 1986, Ljunggren and Karre, 1990, Karre, 2002). 
To a large extent the presumptions of this concept still holds true, although subsequent research 
has revealed the complexity of NK cell activation. Upon adhesion to a potential target cell, 
interactions between NK cell receptors and target cell ligands determines whether the NK cell 
detaches and moves to the next potential target cell or remains bound and responds. It is now 
widely recognised that the outcome of NK cell activity relies on a counterbalance of signals 
from both activating and inhibitory receptors, such that unengaged inhibitory receptors results 
in unsuppressed activating signals from interaction with stress induced ligands and subsequent 
response initiation. 
Three major natural killer receptor (NKR) “superfamilies” have been described; the killer cell 
immunoglobulin-like receptors (KIRs) superfamily, the C-type lectin superfamily and the 
natural cytotoxicity receptors (NCRs). Receptor signalling is mediated either by conserved 
sequences within the cytoplasmic domains of these receptors or by their associated adaptor 
proteins. Cytoplasmic domains of all well-defined inhibitory receptors contain copies of the 
consensus sequence immunoreceptor tyrosine-based inhibitory motif (ITIM), whereas 
numerous activating receptors signal through adaptor proteins that possess the immunoreceptor 
tyrosine-based activation motif (ITAM) (Lanier, 2005). In the instance of inhibitory receptors 
binding to target cell ligand, the ITIM is phosphorylated and there is recruitment of 
phosphatases which work at the membrane to either dampen or completely arrest NK cell 
effector functions. Whereas in the case of activating receptors, tyrosine phosphorylation of 
ITAMs results in calcium influx, degranulation, and cytokine and chemokine gene transcription 
(Lanier, 2005).   




Figure 1.8 Natural killer cell Recognition and Activation 
(a) In the case of healthy cells, when the strength of the activating signals are dampened by the 
engagement of inhibitory receptors, NK cells are tolerant to host cells. (b) Tumour/transformed cells 
may lose expression of MHC class I molecules, termed as 'missing-self'. NK cells become activated and 
are no longer held in check by the inhibitory signal delivered by MHC class I molecule engagement. 
(c) Additionally, NK cells are selectively activated by 'stressed' cells, which upregulate activating 
ligands for NK cells and thereby overcome the inhibitory signalling delivered by MHC class I molecules 





1.3.2.2 Natural Killer Cell Functions 
NK cells are predominantly cytolytic and there are a number of mechanisms employed to 
mediate this activity. These include the release of cytoplasmic granules such as perforin and 
granzymes (degranulation) which are released when the NK cell is in close proximity to the 
cell targeted for killing. Additionally, in a process termed antibody-dependent cellular 
cytotoxicity (ADCC), NK cells can actively lyse target cells expressing surface antigen that are 
bound by specific antibodies produced as part of the humoral immune response. NK cells are 
equipped to recognise IgG-opsonised infected cells through expression of CD16, and upon 
interaction commences NK cell activation and release of cytotoxic granules (Cooper et al., 
2001, Caligiuri, 2008). 
Apart from their ability to mediate spontaneous cytotoxicity, NK cells are also a major source 
of several pro-inflammatory cytokines and chemokines including IFN-ɣ, TNF-α and GM-CSF, 
and are thus viewed as immune-regulatory cells able to “bridge” innate and adaptive immunity. 
They are also capable of directly modulating immune responses through interactions with 
macrophages, DCs and T cell lymphocytes. NK cells, in combination with cell receptors and 
cytokines, are able to enhance macrophage and DC maturation and activation (Vivier et al., 
2008). Furthermore, NK cells can directly influence adaptive immune responses by acting on 
T cells. NK cell-derived IFN-ɣ can promote CD4+ Th1 priming (Martin-Fontecha et al., 2004, 
Morandi et al., 2006). NK cells are also capable, in the case of insufficient expression of MHC 
class I molecules, of killing activated T cells by dampening CD94-NKG2A inhibitory 
signalling in NK cells (Lu et al., 2007).  
 
1.3.2.3 Natural Killer Cells and HIV-1 Infection 
The role of NK cells in viral infection has been repeatedly highlighted in individuals with NK 
cell deficiencies (Orange, 2006, Orange and Ballas, 2006). There is presently a wide consensus 
that in addition to adaptive immune responses, NK cells may be critical to early HIV-1 
containment well before the development of T and B cell responses, and may influence disease 
progression as discussed below.     
Several studies have suggested a significant role of NK cells in resistance to HIV-1 infection.  
In a group of Vietnamese intravenous drug users who were continually exposed to HIV-1 but 
remained uninfected, it was found that their apparent resistance to infection coincided with a 
repertoire of predominantly activating NKRs that endowed these individuals with higher 
25 
 
cytokine production and enhanced degranulation activity when compared to HIV-1 infected 
and healthy uninfected individuals (Scott-Algara et al., 2003, Ravet et al., 2007). This data has 
been repeatedly confirmed in other highly exposed, uninfected populations including Canadian 
adults (Boulet et al., 2008), exposed uninfected Colombian adults (Montoya et al., 2006) and 
African sex workers (Jennes et al., 2006).       
There is mounting evidence that NK cells have a direct role in the containment of HIV-1 
infection and therefore influences disease progression. This has been attributed to specific KIR 
genotypes in combination with their MHC class I ligand genotypes in certain individuals. Most 
convincing was a study conducted by Martin and colleagues (2002) which suggested a pivotal 
role for NK cells in controlling viral replication. The presence of KIR3DS1 in combination 
with the ligand human leukocyte antigen (HLA)-Bw4 was strongly associated with slower 
progression to advanced disease (Martin et al., 2002). Further study of this KIR3DS1/HLA-
Bw4 relationship demonstrated early containment of HIV-1 viremia and protection against 
opportunistic infections (Qi et al., 2006). In addition, in an in vitro study, Alter et al. (2007) 
demonstrated that KIR3DS1 expressing NK cells derived from healthy donors displayed 
enhanced NK cell-mediated killing in the presence of HIV-1 infected target cells expressing 
HLA Bw4 80lle (Alter et al., 2007).        
NK cells have been implicated in directly mediating antiviral immune pressure and thereby 
contributing to viral evolution. In examining HIV-1 subtype B chronically infected individuals, 
Alter and colleagues (2011) provided evidence that KIR-associated polymorphisms of the HIV-
1 sequence allowed for improved binding of NK cell inhibitory KIRs to HIV-1 infected CD4+ 
T cells, resulting in reduced antiviral activity of these KIR+ NK cells (Alter et al., 2011). 
Further to this, the presence of specific KIR/HLA combinations associated with p24 Gag 
sequence mutations were identified in a HIV-1 subtype C South African cohort, suggestive of 
viral evasion from NK cell activity through selection of HLA-presented epitope mutations  
(Holzemer et al., 2015). 
Primary HIV-1 infection results in activation and expansion of NK cells before the 
development of antibody responses. However, similar to other cell types, persistent HIV-1 
replication during chronic infection is associated with NK impairment, and this is seen most 
notably in an early loss of CD56 bright cells, secondary loss of CD56 dim cells and in the 
accumulation of a NK CD56 low cell type that are unable to respond to stimulation (Alter and 
Altfeld, 2006). Conflicting data surrounds NK cell activity in HIV-1 infection. While earlier 
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studies documented reduced NK cell activity in terms of declined IL-2, defective IFN-α 
secretion and impaired cytolysis (Alter and Altfeld, 2006), more recent reports have suggested 
elevated NK cell activity with raised cytokine production in viremic individuals (Ironson et al., 
2001, Parato et al., 2002, Alter et al., 2005). Infection also leads to altered NK cell receptor 
profiles, particularly an increase of inhibitory KIR expression. Expression of CD94 has been 
shown to fluctuate throughout infection, and even more striking is the diminished expression 
of NKG2A in chronic infection, both of which are likely due to the stepwise loss of CD56 
bright cells during infection (Alter and Altfeld, 2006, Altfeld et al., 2011, Jost and Altfeld, 
2012). 
 
1.3.3 Neutrophil / NK cell Interaction 
As previously mentioned, neutrophils have emerged as important regulators, capable of 
interacting with both the innate and adaptive arms of the immune system, including NK cells. 
The bi-directional interactions between neutrophils and NK cells have gained considerable 
appreciation in recent years and a number of studies have examined the interplay between these 
two cell types as described below. 
Early studies investigating possible regulatory mechanisms reported that NK responses could 
be modulated by neutrophil-derived ROS and granule proteins. Although initial studies were 
conducted before the identification of NK cells as a specific cell type, subsequent reports using 
NK-enriched lymphocytes and purified NK cell populations confirm that neutrophils were able 
to inhibit NK cell cytotoxicity and accelerate NK cell apoptosis in a ROS-dependent manner 
(Mellqvist et al., 2000, Bellner et al., 2005, Costantini and Cassatella, 2011). Specifically, it 
was established that modulation of NK cells was subset specific, where natural cytotoxicity 
receptor NKp46, important for inducing lysis of tumour cells, was down-regulated on NK 
CD56 low cells (Romero et al., 2006) which were highly sensitive to cell death (Thoren et al., 
2007, Harlin et al., 2007).  
Additional studies have revealed the modulatory effects of antimicrobial and signalling 
molecules contained within neutrophil granules. Arginase-1 depletes the micro-milieu of the 
amino acid arginine which consequently results in diminished NK proliferation and supressed 
IL-12/IL-18-stimulated production of IFN-ɣ by NK cells (Oberlies et al., 2009). In contrast, 
neutrophil elastase (Aoki et al., 1982) and lactoferrin (Shau et al., 1992) have been shown to 
increase NK cell-mediated cytotoxic activity. Azurophil granule proteins have also been 
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reported to amplify NK cell killing activity (Lala et al., 1992, Lindemann et al., 1994, 
Yamazaki and Aoki, 1998).  
More recently, neutrophils have been shown to directly, or in cooperation with other cell types, 
regulate NK cell development and function (Sporri et al., 2008, Costantini et al., 2011a, 
Costantini et al., 2011b, Jaeger et al., 2012). Neutrophils were found to be critical in the 
resolution of Legionella pneumophila infection in mice. In the case of depleted neutrophils, 
NK cells were unable to produce sufficient IFN-ɣ and clear infection. The authors proposed 
that together with dendritic cell derived IL-12, neutrophil activation of caspase-1 and IL-18 
production were essential in the activation of NK cells (Sporri et al., 2008).  
Similarly, the interactive network between human neutrophils, NK cells and 6-sulfo Lac+NAc+ 
dendritic cells (SLAN+ DCs) was described in vitro and is illustrated in Figure 1.9. Stimulated 
neutrophils were found to directly induce IFN-γ production by NK cells through cell-cell 
interaction via intercellular adhesion molecule 3 (ICAM-3) and the CD18/CD11d complex 
expressed on neutrophils and NK cells respectively. Neutrophils could likewise, through 
cellular contact via ICAM-1 and the SLAN+ DC CD18/CD11a complex, promote the release 
of IL-12p70 by SLAN+ DCs, which in turn potentiated the production of IFN-γ by NK cells. 
By a positive feedback loop, the release of IFN-γ by NK cells subsequently augmented the 
cross talk between neutrophils and SLAN+ DCs and the release of IL-12p70 (Costantini et al., 
2011a, Costantini et al., 2011b), Figure 1.9. 
Using an N-ethyl N-nitrosourea mutagenesis strategy, Jaeger and colleagues (2012) identified 
the mouse pedigree, Genista, with diminished NK cell reactivity. Further examination of this 
mutant phenotype revealed that mature neutrophils were essential in both the bone marrow and 
in circulation to allow for proper NK cell maturation and function. Neutrophil-deficient mice 
had NK cells that were impeded at an immature stage of development and were hypo-
responsive. In addition, their NK cells exhibited hyper-proliferation and reduced survival.  
These findings, demonstrating the fundamental role of neutrophils as mediators of NK cell 
function, were verified in individuals with established severe congenital neutropenia and 






Figure 1.9 Crosstalk between neutrophils, NK cells and SLAN+ DCs 
During inflammation cell–cell interactions between activated neutrophils and SLAN+ DCs (mediated 
by CD18 and ICAM1) induces release of IL-12p70 by SLAN+ DCs, which in turn enhances the 
production IFN-γ by activated NK cells. Activated neutrophils can also directly stimulate the production 
of IFN-γ by NK cells through engagement of CD11d–CD18 on NK cells by ICAM3 (Mantovani et al., 
2011). 
 
Historically, the extent to which NK cells influence neutrophils has received little 
consideration. Activated NK cells produce various CC chemokines including CCL3, CCL4, 
CCL5 and CCL8 (Robertson, 2002). The release of CCL8, an effective neutrophil 
chemoattractant, may affect neutrophil migration to the site of infection, whilst CCL3, CCL4 
and CCL5 could activate neutrophils and thus modulate effector mechanisms including 
respiratory burst and microbial killing under certain inflammatory conditions (Hartl et al., 
2008).  
Researchers have recently established that neutrophil activation and survival are moderated by 
NK cells. The release of soluble factors such as IFN-γ, TNF-α and GM-CSF by cytokine-
activated NK cells facilitated the activation and the prolonged survival of neutrophils under co-
culture conditions.  Depending on the cytokines to which the NK cells were exposed, NK cells 
were further able to enhance the expression patterns of certain neutrophil activation markers 
including CD11b and CD64. These neutrophils also exhibited sustained phagocytic 





1.4 THE DUFFY ANTIGEN SYSTEM AND HIV-1 IN SUB-SAHARAN AFRICA 
As previously mentioned, sub-Saharan Africa carries a disproportionate burden of the HIV-1 
epidemic. Though sub-Saharan Africa is home to about 12% of the global population, 70% of 
HIV-1 infected people live in this region. Several factors have been implicated to explain the 
alarmingly high HIV-1 incidence rate in this region. Of these, high risk sexual behavioural 
patterns has been perceived as the major factor contributing to the spread of infection (Velayati 
et al., 2007, Kenyon et al., 2013), although other factors including political factors, poor 
healthcare and access to antiretroviral therapy, to name a few, have been cited.  
However, the impact of various biological factors cannot be dismissed. There is substantial 
evidence linking sexually transmitted infections (STIs) and HIV transmission, although the 
varying influence on HIV susceptibility is microorganism dependent. Reviewed data of 22 
studies indicate herpes simplex virus type 2 (HSV-2) sero-positivity as the highest STI risk 
factor (Braunstein et al., 2009, Ward and Ronn, 2010). Furthermore, bacterial vaginosis which 
is highly prevalent amongst African women has been associated with increased risk of STI 
acquisition, including HIV infection. The increased presence of strict anaerobic species in 
bacterial vaginosis causes disruption of the mucosal epithelial barrier through production of 
pro-inflammatory metabolites and enzymes (Bayigga et al., 2019). Of recent interest is a 
variation of the Duffy antigen receptor for chemokines (DARC) that influences HIV-1 
infection as discussed in the following section.  
 
1.4.1 Duffy Antigen System 
The first description of the Duffy Antigen System was reported by Cutbush and colleagues 
(1950) in Nature following the detection of agglutinin in the serum of a haemophilic patient 
who had received multiple blood transfusions (Cutbush et al., 1950). To date six Duffy antigens 
have been described, although only three, specifically Fya, Fyb and Fy3, are considered to be 
clinically relevant. The Duffy antigen receptor for chemokines (DARC), also referred to as Fy 
glycoprotein (FY), is a glycosylated cell membrane receptor that in humans is encoded by the 
DARC gene located on the long arm of chromosome 1 (q21-q25) (Donahue et al., 1968). Two 
main, codominant alleles exist namely FYA and FYB which are differentiated by a single-
nucleotide polymorphism (SNP) (125G→A) with the corresponding antigens, Fya and Fyb, 
differing by a single amino acid (Gly42Asp) (Langhi and Bordin, 2006). Genotypes give rise 
to four phenotypes: Fy(a+b+), Fy(a+b-), Fy(a-b+) and Fy(a-b-), the last of which results from 
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a point mutation in the FYB allele with a single T to C substitution in the gene promoter region 
at nucleotide position -33. This prevents transcription, causing a disruption of Duffy antigen 
expression and results in the “erythrocyte silent” (ES) phenotype (Howes et al., 2011)  
Distribution of these phenotypes vary globally according to racial heredity, with the Fya and 
Fyb antigens relatively common in Caucasians and Asians. Frequencies of these antigens are 
far less in individuals of African descent and the Fy(a-b-) phenotype prevails in these 
populations (Reid and Lomas-Francis, 2004), Figure 1.10.  
The receptor is expressed primarily on the surface of erythrocytes, and to some extent is also 
located on endothelial cells of blood vessels, epithelial cells of lung alveoli, collecting ducts of 
kidneys and Purkinje cells of the cerebellum. Functionally, the receptor is multi-specific and 
binds several circulating chemokines including CXR and CC chemokines, as well as IL-8 and 
CCL5, thus acting as a chemokine sink and reservoir. However, no pathway signalling has been 
attributed to this receptor (Mohandas and Narla, 2005). Interestingly, point mutation in the 
FYB allele as exhibited in the Fy(a-b-) or DARC-null phenotype, only results in disruption of 
Duffy antigen expression on the surface of RBCs, while expression on non-erythroid cells is 
preserved (Duchene et al., 2017) This disruption may contribute to lower absolute neutrophil 
counts as discussed below.   
 
 
Figure 1.10 Distribution of the Duffy negativity phenotype 
Global prevalence of the Duffy negative phenotype (Howes et al., 2011). 
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Clinically, the presence of Duffy antigen on RBCs has been implicated in the acquisition of 
malarial parasite infection. Experimental data has demonstrated the dependency of 
Plasmodium vivax on the Duffy antigen system to establish erythrocyte infection (Howes et 
al., 2011). The absence of these antigens on erythrocytes, as is common in populations in sub-
Saharan Africa, has long been thought to confer relative resistance to certain malarial parasites 
in these individuals. In fact the variation in phenotype distribution among different racial 
groups seems to be the result of positive selection pressure in regions where Plasmodium vivax 
has historically been endemic, and may explain the relatively low prevalence of P. vivax 
malaria in the region (Howes et al., 2011).  
 
Recent literature identifies the DARC-null variant as the principal determinant of benign ethnic 
neutropenia. Using admixture mapping of African Americans and European Americans, a 
polymorphism within the Duffy gene on chromosome 1 was found to have a strong association 
with lower white blood cell (WBC) counts, specifically neutrophils in persons of African 
ancestry (Reich et al., 2009). It has been postulated that the DARC-null trait could account for 
up to 20% of the variation in WBCs between African Americans and European Americans 
(Reich et al., 2009). However, the mechanisms involved in this association are not fully 
understood. As mentioned earlier, DARC is a multi-specific receptor and may regulate 
peripheral chemokine levels that consequently affect neutrophil chemotaxis, migration and 
localisation. It is plausible that through DARC antigen disruption on RBCs and subsequent 
changes to circulatory chemokines, neutrophil recruitment from the bone marrow is diminished 
thus leading to lower circulating neutrophils (Paz et al., 2011).          
 
1.4.2 Benign Ethnic Neutropenia 
Ethnic neutropenia is a condition characterised by significantly reduced numbers of circulating 
neutrophils and has been shown to be exceedingly prevalent in individuals of African descent 
(25-50%) (Haddy et al., 1999, Grann et al., 2008). High prevalence of lower neutrophil counts 
has been repeatedly confirmed, not only in persons of African descent (Bain et al., 1984, 
Kourtis et al., 2005, Wells et al., 2006), but also in a few ethnic groups of Middle Eastern origin 
(Weingarten et al., 1993, Denic et al., 2009) and has been termed benign ethnic neutropenia 
(Haddy et al., 1999). Although the ailment was considered to have seemingly no adverse 
32 
 
clinical consequences, recent reports have associated DARC-linked neutropenia to HIV-1 
acquisition.  
 
1.4.3 DARC-null Genotype, Ethnic Neutropenia and HIV-1 Infection 
Interestingly, even before the connection between the DARC-null variant and ethnic 
neutropenia was established, He et al. (2008) suggested that the DARC-null genotype played a 
role in HIV-1 acquisition and disease progression. It was reported that in African Americans, 
individuals in possession of the null genotype had a 40% increased odds in HIV-1 acquisition 
and may even account for up to 11% of the epidemic in Africa (He et al., 2008). Conversely, 
the authors suggested that absence of the DARC trait associated with delayed development to 
AIDS related dementia, delayed loss of CD4+ T cells and prolonged survival (He et al., 2008). 
A few mechanisms were proposed to explain these findings. Firstly, before onset of infection, 
HIV-suppressive chemokines that are associated with DARC-expressing red blood cells 
(RBCs) may act as a protective shield, preventing HIV attachment to RBCs and averting 
subsequent transfer of HIV-1 to target cells. However, following HIV-1 acquisition, HIV-1 
binds to DARC on the surface of RBCs and transfers virus to target cells, indicating that 
DARC-expressing RBCs might act as carriers of infectious HIV-1 particles to susceptible cells 
(such as CD4+ T lymphocytes). Additionally, DARC-positive individuals may be predisposed 
to a more pro-inflammatory state that promotes HIV replication and spread (He et al., 2008, 
Kulkarni et al., 2009).   
 
However, it is important to note the considerable controversy generated by the He et al. (2008) 
paper. Subsequent data generated by four independent groups demonstrated contrasting 
outcomes. Two groups found no association between the DARC-null variant and HIV 
acquisition, whilst all four groups found unaltered disease progression in the absence of DARC.   
(Horne et al., 2009, Julg et al., 2009, Walley et al., 2009, Winkler et al., 2009).  
 
In correspondence to the He et al. (2008), Winkler and colleagues considered population 
substructure. It was stated that since DARC −46C is a marker for African ancestry, population 
substructure is a major confounding factor. Their analysis using ancestry-informative markers 
revealed minimal population substructure stratification between HIV negative and HIV 
positive subjects in a cohort of injecting drug users in Baltimore, USA. After taking these 
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considerations into account, the results indicated no association between the DARC-null 
genotype and HIV acquisition. Further to this, there were no significant associations between 
DARC-null and CD4 decline or progression to AIDS. Overall, the authors concluded that the 
infection signal observed in the He et al. (2008) study was the result of inadequate correction 
of population substructure between cases and control which led to false-positive associations 
(Winkler et al., 2009).  
Similarly, no associations between the DARC-null polymorphism and HIV acquisition and 
progression were found in a report by Walley et al. (2009). Using logistic regression models, 
the study found no effect of the DARC-null genotype on risk of HIV acquisition in African 
Americans. Furthermore, the authors noted no correlation between DARC and viral load set 
point, CD4+ T cell decline or progression to AIDS, thus indicating no associations with faster 
disease progression (Walley et al., 2009). Two studies further reiterated that the DARC-null 
polymorphism was not linked to HIV disease progression in African Americans (Horne et al., 
2009) or black South Africans (Julg et al., 2009) when assessed for clinical outcomes including 
rate of CD4+ T cell decline, plasma viral load burden and progression to AIDS and death.       
 
In correspondence that followed, He and colleagues highlighted several inconsistencies 
between their study and the other groups. These included subject selection and controls, sample 
size, route of HIV infection and end-point analysis (He et al., 2009). Overall, it should be noted 
that direct comparison between the He et al. (2008) and these latter reports is problematic due 
to the differences in cohort designs and study end-points. 
     
A subsequent study investigating high risk South African women identified the DARC-null 
trait as a predictor of low neutrophil counts with increased risk of HIV-1 infection. It was 
demonstrated that women with a pre-seroconversion neutrophil count of less than 2500 
cells/mm3 had an approximate 3 fold greater risk of HIV infection acquisition (Ramsuran et 
al., 2011). Consistent with this finding, it has also been established that low neutrophil counts, 
independent of lymphocyte and monocyte counts, are associated with an increased risk of 





1.5 STUDY RATIONALE, HYPOTHESIS AND OBJECTIVES 
Taken together, the current literature suggests a role for DARC-null linked neutropenia in HIV-
1 acquisition, while the impact of the polymorphism on HIV disease progression remains 
unclear. Thobakgale and Ndung’u (2014) hypothesised the manner in which DARC-null linked 
neutropenia in African populations may be associated with increased susceptibility or inability 
to control HIV-1 infection. They reasoned that in the context of ethnic neutropenia, neutrophils 
may be unable to clear initial infection due to either reduced circulating numbers or altered 
functional capacity. In addition, neutrophils were incapable of priming innate and adaptive 
immune cells, thus leading to an increased risk of infection and pathogen spread (Figure 1.11) 
(Thobakgale and Ndung'u, 2014).  
 
The influence of DARC-null linked neutropenia on neutrophil effector functions and the effect 
of the condition on downstream interaction with NK cells are unknown. In a previous study 
conducted in the highly HIV prevalent Umlazi region in Durban, South Africa, it was 
determined that of the 247 participants enrolled, 64.8% individuals were homozygous for the 
DARC-null allele, 31.2% were heterozygous and 3.9% were homozygous wildtype (Julg et al., 
2009), making this community setting ideal to assess the influence of the DARC-null trait in 




Figure 1.11 Association of DARC-null Genotype with Disease Susceptibility and Progression 
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Proposed mechanism of how DARC-null linked neutropenia may affect susceptibility or ability to 
control diseases. (a) In the context of low ANCs in DARC-null individuals, neutrophils are unable to 
clear infection and there may be an inability to prime immune cells, leading to increased risk of infection 
and pathogen spread. (b) When neutrophils counts and functions are optimal there is enhanced pathogen 
clearance, and neutrophil priming and cross-talk with other immune cells results in desired clinical 
outcome. (Thobakgale and Ndung'u, 2014). 
 
This study aimed to establish the consequences of DARC-null linked neutropenia in HIV 
negative and HIV-1 chronically infected individuals. We hypothesised that in the context of 
DARC-null and lower ANCs in our cohort participants, neutrophils would be impaired in their 
key antimicrobial functions and would be unable to efficiently prime NK cells, affecting NK 
cell maturation and function, and altering NK cell homeostatic activities such as survival and 
proliferation. We further hypothesised that the impaired cellular responses would be more 
prominent in HIV-1 infected individuals as compared to HIV negative individuals.    
In this cross sectional pilot study, we recruited HIV negative and HIV-1 chronically infected 
individuals from DARC-null prevalent Zulu/Xhosa African individuals from a high incidence 
HIV-1 setting in Durban, South Africa to address the following objectives: 
Objective 1: To assess the impact of the DARC-null trait on key neutrophil effector 
functions, specifically Fc-mediated phagocytosis, ROS and NET production. 
 
Objective 2: To assess the role of DARC-null trait on NK phenotypic profiles and 
functionality. 
Objective 3: To assess HIV-specific NK cell mediated activation in individuals with 
and without ethnic neutropenia. 
Objective 4: To assess the impact of the DARC-null trait on the NK cell homeostatic 
activities (survival and proliferation).  
The knowledge generated from this study will be beneficial in establishing the biological 
consequences of DARC-null associated ethnic neutropenia in HIV-1 infection for improved 
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Neutrophils constitute the earliest and most dominant innate immune response to invading 
pathogens. Their role in microbial clearance such as fungal and extracellular bacterial 
infections is well documented (Mocsai, 2013, Nauseef and Borregaard, 2014), and there is 
evidence of the key role of neutrophils in viral immunity (Bastian and Schafer, 2001, Fujisawa, 
2001, Yasin et al., 2004). Investigations of neutrophil responses in Human Immunodeficiency 
Virus (HIV)-1 infection have largely focused on susceptibility to bacterial and fungal co-
infections. Only recently have the direct interactions between neutrophils and HIV-1 been fully 
appreciated (Casulli and Elbim, 2014).   
Disorders of neutrophil counts (neutropenia) and function are usually associated with recurrent 
infection complications, particularly in severe cases where the absolute neutrophil count 
(ANC) drops to below 500 cells/mm3 (Hsieh et al., 2010, Thobakgale and Ndung'u, 2014). 
Congenital disorders driven by diminished neutrophil production and release from the bone 
marrow exhibit a higher risk of microbial infections in comparison to peripheral acquired 
neutropenia (Boxer, 2012). Ethnic neutropenia is the most frequent form of congenital 
neutropenia globally, commonest in persons of African descent. Clinically, the condition is 
considered moderate and is not associated with obvious increased oral and systemic infection 
incidence as observed in other forms of neutropenia (Hsieh et al., 2010). It is unclear whether 
ethnic neutropenia is associated with any mechanistic defects in neutrophil functions.  
Absence of the Duffy Antigen Receptor for Chemokines (DARC), a glycosylated cell 
membrane receptor encoded by the DARC gene located on chromosome 1, has been identified 
as the principal genetic determinant of ethnic neutropenia (Reich et al., 2009). A single 
nucleotide polymorphism (-46T>C) in the DARC promoter region abolishes gene expression 
and results in selective loss of DARC expression on erythrocytes (Howes et al., 2011). 
However, the mechanism through which the DARC-null polymorphism induces neutropenia 
remains poorly understood. Previous studies have established an association between lower 
circulating neutrophils exhibited in the absence of DARC and increased risk of HIV acquisition 
and mother-to-child transmission (He et al., 2008, Ramsuran et al., 2011, Kourtis et al., 2012). 
Following HIV infection, it has been suggested that the DARC-null state is accompanied with 
slower disease progression and that the polymorphism may impart a survival advantage in 
leukopenic HIV infected individuals (He et al., 2008, Kulkarni et al., 2009). Conversely, other 
reports contesting these findings demonstrated that DARC status did not impact the rate of 
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disease progression based on viral load set points, CD4+ T cell decline or progression to AIDS 
(Horne et al., 2009, Julg et al., 2009, Walley et al., 2009).  
Overall, the evidence appears stronger for an association between DARC-null-linked ethnic 
neutropenia and HIV acquisition than it does for its role in HIV disease progression. However, 
it is plausible that the influence of the DARC-null trait is complex, with many of its underlying 
unknown components contributing to HIV pathogenesis. While the absence of DARC is well 
associated with low circulating neutrophils, the effect of the polymorphism on neutrophil 
effector functions has not been investigated. Here we aimed to determine the influence of the 
DARC genotype on neutrophil effector functions in HIV-1 negative versus  HIV-1 chronically 
infected Zulu/Xhosa black African individuals in Durban, South Africa. We hypothesised that 
neutrophil effector mechanisms including phagocytosis, production of reactive oxygen species 
(ROS) or formation of neutrophil extracellular traps (NETs) would be impaired in the absence 
of DARC and that this dysfunction would be more distinct in HIV infected persons compared 















2.2.1 Participant Recruitment 
HIV negative participants were recruited from the Females Rising through Education, Support 
and Health (FRESH) cohort, an acute HIV infection monitoring cohort that targets high risk 
women, whilst HIV-1 subtype C chronically infected treatment naïve participants were 
recruited from the HIV Pathogenesis Programme (HPP) Acute Infection Cohort, an acute-
chronic HIV infection cohort. Both of these cohorts are located in the Umlazi region in Durban, 
KwaZulu-Natal (KZN), South Africa. Ethical approval for the maintenance of the cohorts have 
been attained from the University of KwaZulu-Natal (UKZN) Biomedical Research Ethical 
Council (BREC) (FRESH BREC Reference Number: BF131/11 and HPP Acute Infection 
Cohort BREC Reference Number: E036/06). All participants gave written informed consent 
to voluntarily participate in these cohorts. This particular study obtained further ethical 
clearance as a subsidiary of the above studies (BREC Reference Number: BE229/15). A total 
of 42 individuals sub-divided into HIV negative donors (n=20) and HIV-1 chronically infected 
individuals (n=22) were assessed. These individuals were further stratified by DARC status.  
 
2.2.2 ANCs, CD4 Counts and Viral Load 
Blood for full blood counts, CD4+ T cell count measurement and viral load quantification was 
collected in Ethylenediaminetetraacetic acid (EDTA) anticoagulated vacutainer tubes (Becton 
Dickinson (BD), Franklin Lakes, New Jersey, USA). ANCs were enumerated by full blood 
count using the automated XN 1000 Haematology Analyser (Sysmex, Kobe, Hyōgo, Japan). 
CD4 counts were measured using BD Trucount and analysed on a four-parameter FACS 
Calibur flow cytometer (BD). Viral loads were determined using the NucliSENS EasyQ HIV-
1 v2.0 kit with a detection limit of 20 copies/ml (BioMérieux, Marcy-l'Étoile, France).   
 
2.2.3 Quantification of Antiretroviral (ARV) Drugs in Plasma  
This study aimed to recruit HIV-1 chronically infected, treatment naïve individuals. ARV 
therapy usage in chronically infected patients was self-reported. Certain subjects maintained 
viral loads below 1000 RNA copies/ml at the time of assessment. To rule out ARV drug use, 
plasma samples were collected from these study participants and screened for ARV drugs using 
a quantitative liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) 
method. The method screened for nine ARVs, namely Emtracitabine, Tenofovir, Lopinavir, 
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Ritonavir, Nevirapine, Abacavir, Lamivudine, Zidovudine and Efavirenz. A plasma sample 
volume of 50 µl was processed using a protein precipitation method, ARV drug analytes were 
chromatographically separated on a Agilent Zorbax Eclipse Plus C18 (2.1 x 50mm, 3.5 µm) 
HPLC column (Agilent Technologies, Santa Clara, California, USA), detected using an AB 
Sciex 5500 triple quadrupole mass spectrometer (Sciex, Framingham, Massachusetts, USA) 
and quantitated using Analyst® 1.6.2 software (Sciex). 
 
2.2.4 DARC Genotyping 
DARC -46T   C (rs2814778) single-nucleotide polymorphism (SNP) genotyping was 
performed by TaqMan allelic discrimination assays which has been previously verified by 
direct sequence analysis by Julg et al. (2009). Briefly, genomic DNA was isolated from stored 
buffy coats using the QIAamp DNA Blood Midi kit (Qiagen, Hilden, Germany) according to 
manufacturer’s instructions. DNA concentration was standardised at 50ng/µl with polymerase 
chain reaction (PCR) grade water. A cocktail containing TaqMan Genotyping master mix (Life 
Technologies, Carlsbad, California, USA) and predesigned probes for the DARC gene (SNP 
ID: rs2814778, Applied Biosystems, Foster City, California, USA) was used to amplify target 
sequence in 50ng genomic DNA by real time PCR (RT-PCR) in the Light Cycler 480 (Roche, 
Basel, Switzerland) according to the manufacturer’s protocol.    
 
2.2.5 Neutrophil Isolation 
Blood was collected in sodium heparin BD Vacutainers (BD) from each participant and was 
processed within 4 hours of collection. Granulocyte fraction was prepared by layering an equal 
volume of whole blood over a Histopaque-1119 cushion (Sigma-Aldrich, St. Louis, Missouri, 
USA) and centrifugation at 800 x g for 20 minutes at room temperature, low brakes as 
previously described (Brinkmann et al., 2010). Centrifugation with the Histopaque-1119 poly-
sucrose solution allows for the rapid separation of cellular components based on density. 
Erythrocytes aggregate and sediment resulting in pellet formation. Polymorphonuclear 
leukocytes (PMNs) form a band in the histopaque-1119 solution above the pelleted 
erythrocytes, whereas peripheral blood mononuclear cells (PBMCs), which are lower in 
density form a band higher in the histopaque-1119 solution between the plasma layer and the 
PMN band (Figure 2.1).  
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The PMN band was collected, washed with Dulbecco's phosphate-buffered saline (dPBS) and 
centrifuged at 300 x g for 10 minutes at room temperature, followed by a second wash with 
chilled wash buffer (Dulbecco's phosphate-buffered saline (dPBS) containing 0.5% bovine 
albumin serum (BSA)) and centrifugation at 300 x g for 10 minutes at 4°C. Pelleted cells were 
then incubated with magnetically labelled CD15 Microbeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany) for 15 minutes at 4°C. Cells were again washed with chilled wash buffer 
and centrifuged at 300 x g for 10 minutes at 4°C. Pelleted cells were resuspended in 500µl 
chilled wash buffer and loaded into a MACS column placed in the magnetic field of a MACS 
Separator. Chilled wash buffer was added to the column 3 times, allowing the unlabelled cells 
to run through the column. The magnetically labelled CD15+ cells were retained within the 
column. The column was then removed from the magnetic field and the retained cells eluted 
as the CD15+ selected cell fraction, washed once in wash buffer and resuspended at 1million 
cells/ml in Roswell Park Memorial Institute (RPMI) 1640 Medium without phenol red 
indicator and containing 0.05% human serum albumin (HSA). Post purification cell counts 
were determined by 1:5 dilution with Trypan Blue Stain (Gibco) using a haemocytometer 
under a light microscope. The median neutrophil count was 15.2 million cells (IQR: 10-22 







Figure 2.1 Schematic of Neutrophil Isolation 
Whole blood layered over equal volumes of Histopaque-1119. Following density centrifugation, the 
PMN layer was removed, washed twice and incubated with CD15 microbeads. Cell suspension was 
passed through a column within a magnetic field. Positively labelled cells were retained within the 
column whilst unlabelled cells ran through the column as the “negative” flow through and was 
discarded. Removal of the column from the magnetic separator allowed for the positively labelled cells 








2.2.6 Neutrophil Purity 
Neutrophil purity was measured by assessing the expression of CD66b and CD15 surface 
markers on the isolated cell suspension. CD66b is a glycosylphosphatidylinositol (GPI)-linked 
protein that is exclusively expressed on two granulocyte populations; i.e. neutrophil and 
eosinophil cells (Lakschevitz et al., 2016). CD15 is a carbohydrate adhesion molecule that is 
expressed on glycoproteins, glycolipids and proteoglycans on the surface of all myeloid lineage 
cells (granulocytes and monocytes), except basophils (Gadhoum and Sackstein, 2008). By 
assessing the expression of CD66b and CD15 in the isolated cell suspension, the level of 
neutrophil purity can be estimated (neutrophils will express both markers), with only minimal 
eosinophil contamination. Any eosinophil contamination is considered negligible since 
neutrophils comprise over 90% of circulating granulocytes, whilst eosinophils contribute to 
less than 5% of the population (Geering et al., 2013).  
To determine the purity of the isolated cell suspension, half a million cells were centrifuged at 
13000 x g for 1 minute, supernatant removed and the pelleted cells stained with monoclonal 
antibodies anti-CD66b Fluorescein isothiocyanate (FITC, BD Biosciences) and anti-CD15 
Brilliant Violet (BV) 605 (Biolegend, San Diego, California, USA) for 20 minutes at room 
temperature in the dark. Cells were then washed with dPBS, centrifuged at 13000 x g for 1 
minute and supernatant removed before addition of fixation Medium A (Invitrogen, Carlsbad, 
California, USA) to ensure that morphological characteristics of the cells remained intact. 
Fluorescence minus one (FMOs) for CD66b and CD15 were prepared for each experiment to 
exclude background fluorescence in the gating strategies. Samples were acquired on an LSR 
II flow cytometer (BD) and at least 10000 events per sample were recorded. FlowJo Software 
Version 9 (TreeStar, Inc., Ashland, Oregon, USA) was used for sample analysis. Only 





Figure 2.2 Representative gating strategy for neutrophil purity 
All events from the side scatter area (SSC-A) vs forward scatter area (FSC-A) plot were included 
to determine neutrophil purity of each subject sample using flow cytometry. Fluorescence minus 
one (FMOs) for CD66b and CD15 were used to exclude cells that did not stain positive for CD66b 
and/or CD15. Neutrophils were identified as CD66b+CD15+.   
 
2.2.7 Phagosome Maturation 
Phagosome maturation refers to a series of sequential events that occur within the phagosome 
following internalisation. Delivery of antimicrobial molecules through secretory vesicle and 
granule fusion is central to this dynamic process and confers the phagosome the ability to 
degrade internalised pathogens (Lee et al., 2003). To evaluate the phagocytic capacity of 
neutrophils we employed a strategy developed by Podinovskaia et al. (2013) which measures 
the extent of bulk proteolysis that occurs within the phagosome. Immunoglobulin G (IgG) 
opsonised particles are modified to carry a reporter fluorochrome and DQ Green-BSA 
complex. Binding of IgG to the neutrophil Fc receptor (FcR) mediates the extension of 
pseudopods and engulfment of the opsonised particle. Thereafter, delivery of antimicrobial 
molecules to the phagosome results in degradation of the Green-BSA complex and emission 
of fluorescence that is used as an indicator of phagosome progression.    
DQ Green-BSA reporter beads were prepared as previously described (Podinovskaia et al., 
2013). Briefly, 5mg of 3.0µm carboxylate-modified silica particles (Kisker Biotech GmbH & 
Co., Steinfurt, Germany) were washed three times with 1ml of dPBS and centrifuged at 2000 
x g for 60 seconds at room temperature. Particles were resuspended in 1ml PBS containing 
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20mg cyanamide (Sigma-Aldrich) and incubated on a shaker for 20 minutes at room 
temperature. Particles were then washed three times in dPBS before resuspending in 1ml 
coupling buffer (0.1M boric acid in double distilled water (ddH20), adjusted to pH 8.0 with 
10M sodium hydroxide) containing 3mg DQ Green-BSA (Life Technologies, Carlsbad, 
California, USA) and 100µg IgG (Sigma-Aldrich) and incubated on a shaker overnight at room 
temperature. Particles were washed twice in coupling buffer and once in dPBS before 
resuspending in 500µl dPBS containing 0.02% sodium azide (Sigma-Aldrich). Particles were 
stored at -20°C in aliquots protected from light.    
One million isolated neutrophils in RPMI-1640 medium without phenol red indicator and 
containing 0.05% HSA was used to measure phagosome maturation after addition of 5µl 
prepared DQ Green-BSA reporter beads and incubation at 37°C for either 10 minutes, 60 
minutes or 120 minutes. Samples were fixed with paraformaldehyde (1% final concentration, 
Sigma-Aldrich) and acquired on an LSRII Flow Cytometer (BD), recording at least 50000 
events. For each experiment, a tube containing neutrophils incubated for 120 minutes without 
DQ Green BSA was acquired for gating strategies and a tube containing DQ Green-BSA 
reporter beads alone was acquired to determine background fluorescence. Flow Cytometry 
Standard files were analysed using FlowJo Software Version 9 (TreeStar, Inc., Ashland, 
Oregon, USA).  
 
2.2.8 ROS production 
In parallel to phagosome maturation, assemblage of the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase complex on the phagosome membrane results in the production 
of ROS intermediates. Accumulation of ROS within the phagosome creates a toxic 
environment to most microbes. ROS production by neutrophils was measured by chemi-
luminescence as previously described (Fuchs et al., 2007).  
Briefly, 1x105 isolated neutrophils in RPMI-1640 medium without phenol red indicator (0.05% 
HSA) and containing 50µM luminol (Sigma-Aldrich) and Horseradish peroxidase (Sigma-
Aldrich) at a final concentration of 1.2 units/ml were seeded per well in a 96 well plate and 
allowed to rest at 37°C 5% CO2 for 30 minutes. Thereafter, cells were cultured with either 
RPMI-1640 medium alone as a negative control or with 10nM phorbol 12-myristate 13-acetate 
(PMA, Sigma-Aldrich) in triplicate and luminescence was read every 2 minutes for a period 
of 120 minutes in a Glomax Multi Detection System (Promega, Madison, Wisconsin, USA). 
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Triplicate readings for unstimulated and PMA stimulated conditions were averaged. 
Unstimulated readings were used to subtract background luminescence from PMA stimulated 
readings.         
 
2.2.9 NET Quantification 
A form of programmed cell death that is distinct from apoptosis and necrosis, leads to the 
generation of NETs (Brinkmann et al., 2004). The process involves the release of nuclear 
material studded with antimicrobial factors from the cell. These extracellular fibres are able to 
bind pathogens and thus aid to eliminate invading microbes.  Here we adapted a fluorescent 
microscopy based technique to quantify NET production following neutrophil activation with 
PMA stimulus as previously described (Brinkmann et al., 2010).   
Fifty thousand isolated neutrophils in 400µl RPMI supplemented with 0.05% HSA were 
seeded on 14mm coverslips placed in 24 well plates. Neutrophils were either left untreated as 
a negative control (100µl RPMI) or activated with 50nM PMA and incubated at 37°C 5% CO2 
for 10 minutes, 60 minutes or 120 minutes before addition of paraformaldehyde fixative 
solution (2% final concentration) to halt further NET formation. Plates were stored at 4°C 
overnight until coverslip staining.     
Coverslips with the attached cells were removed from the 24 well plate with fine forceps and 
washed three times for 5 minutes by floating coverslips with the fixed cells facing downwards 
on dPBS drops placed on hydrophobic parafilm. Cells were permeabilised with 0.5% Triton 
X-100 (Sigma-Aldrich) in dPBS for 5 minutes, and thereafter blocked in blocking buffer (3% 
donkey serum, 3% fish gelatine, 0.5% Tween (all from Sigma-Aldrich), 1% BSA (Biowest, 
Nuaillé, France) in dPBS) for 30 minutes at room temperature. Thereafter solutions containing 
antibody directed against the subnucleosomal complex of Histone 2A, Histone 2B, and 
chromatin (mouse anti-PL2-3, Zychlinsky Lab, Max Planck Institute for Infection Biology, 
Berlin, Germany) and rabbit anti-neutrophil elastase (Calbiochem, San Diego, California, 
USA) diluted in blocking buffer were applied to the coverslips and placed in a humid chamber 
for 1 hour in the dark. After washing with dPBS three times for 5 minutes, solution containing 
Hoechst 33342, dye-conjugated goat anti-mouse Alexa Flour 568 and goat anti-rabbit Alexa 
Flour 488 (all from Life Technologies) diluted in blocking buffer was applied to the coverslips 
and placed in a humid chamber for 45 minutes in the dark. Coverslips were then washed twice 
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with dPBS and once with distilled water before mounting with mowiol solution (Calbiochem) 
to glass slides, allowed to dry overnight and subsequently stored at 4°C. 
To quantify NET production, images were taken from five randomly selected regions of each 
coverslip using the 10× lens on a Zeiss upright fluorescence microscope equipped with an 
AxioCam MRC microscope camera (Oberkochen, Germany). The exposure times for each 
channel were kept constant over the course of an experiment after using a bright representative 
region for calibration. Images were loaded separately for each channel onto ImageJ/FIJI 
software. The Hoechst 33342 fluorescent channel image was used to collect data of total cell 
number in a selected region. The image was converted to an 8-bit image and binarised using 
Bernsen’s thresholding method with the parameter 1 contrast threshold value set at 15. 
Particles were analysed with the size set to a minimum of 20 pixels. The PL2-3 fluorescent 
channel image was used to collect data of NET production in the selected region. The threshold 
was applied manually to an image fixed with cells that were activated for 10 minutes with 
PMA. The threshold was adjusted to the minimum value that allowed only objects larger than 
75 pixels (spontaneous NETs > 75 pixels) to be visible. This minimum threshold value was 
then applied to coverslip regions stimulated for different time intervals for the same specimen. 
The summarised output was exported to a spreadsheet programme for further processing. NET 
production was calculated as follows:  
NET-rate (%) = 100 × Objects counted (PL2-3 channel) / Objects counted (Hoechst channel). 
The NET production on each coverslip was calculated as an average of the five randomly 
selected regions. RGB-merged images of the three channels Hoechst, PL2-3 and neutrophil 
elastase were compiled and used as control images to manually assess and exclude non-
neutrophil cells and artefacts from the results.  
 
2.2.10 Statistical Analysis 
GraphPad Prism Version 5 software (GraphPad software Inc., La Jolla, California, USA) was 
used for statistical data analysis. Differences between two studied groups was examined by 
Mann-Whitney U test. Differences between more than two groups was examined by 1 way 
ANOVA followed by Bonferonni’s Multiple Comparison Test. Differences with a p value 
<0.05 were considered statistically significant. For ROS production, area under curve was 





To assess the possible influence of the DARC-null trait and ethnic neutropenia on neutrophil 
effector functions, 42 participants of Zulu/Xhosa ethnicity were enrolled into our study cohort. 
The cohort comprised 20 HIV negative donors and 22 HIV infected subjects that were therapy 
naïve. The majority of the subjects (40 out of 42) were female with a median age of 20, 
interquartile range (IQR) (19-22) and 22 years, IQR (20-25) in HIV negative and HIV infected 
individuals respectively.  
Assessment of our participant cohort by HIV status indicated that CD4 counts were 
significantly lower in HIV infected persons compared to HIV negative individuals (median 
CD4 count of 653 and 892 cells/mm3 respectively, p=0.002, data not shown). Further analysis 
by DARC status showed no significant differences in CD4 counts in HIV negative subjects 
(DARC-null median CD4 count of 824 cells/mm3; DARC-positive median CD4 count of 1198 
cells/mm3, p=0.08) or infected individuals (DARC-null median CD4 count of 582 cells/mm3; 
DARC-positive median CD4 count of 618 cells/mm3, p=0.53, Table 2.1). Furthermore viral 
loads were not statistically different by DARC genotype in HIV-infected individuals (DARC-
null median viral load of 4150 RNA copies/ml; DARC-positive median viral load of 12250 
RNA copies/ml, p=0.48 Table 2.1). 
  
Table 2.1 Clinical Characteristics of Study Participants used to assess Neutrophil Function 
 
Data is represented as median (IQR). * Full range CD4 counts are indicated in brackets instead of IQR. 
Abbreviations: DARC, Duffy Antigen Receptor for Chemokines; CC, DARC-null; TC/TT, DARC-
positive; ANC, Absolute Neutrophil Count; IQR, Interquartile range; n, number; na, not applicable. 
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2.3.1 High Prevalence of the DARC-null trait in the Zulu/Xhosa Population 
The DARC-null trait is exceedingly prevalent on the African continent (Howes et al., 2011). 
High prevalence of this polymorphism has previously been reported in persons of Zulu/Xhosa 
ethnicity where 64.8% of HIV-infected individuals and 64.7% of high risk South African 
women displayed the DARC-null allele (Julg et al., 2009, Ramsuran et al., 2011). Here we 
used allelic discrimination assays for SNP genotyping in order to distinguish DARC-null and 
DARC-positive individuals.   
Twenty nine (69%) of the participants were negative for the DARC trait irrespective of HIV 
status. In HIV negative individuals, 13 of 20 participants (65%) were DARC-null, whilst 7 of 
20 (35%) were DARC-positive. In HIV-infected subjects, the presence of the polymorphism 
was even higher, 16 of 22 participants (73%) were DARC-null and 6 of 22 subjects (27%) 
were DARC-positive (Table 2.1). 
Thus, despite the comparatively smaller sample size used here, our data is in agreement with 
past studies (Julg et al., 2009, Ramsuran et al., 2011) that indicate high prevalence of the 
DARC-null allele in populations within this region.     
 
2.3.2 DARC-null trait is associated with reduced ANCs 
Neutrophils constitute 50-70% of circulating leukocytes with typical counts ranging from 
2.0x103 to 7.5x103 cells/mm3 of whole blood. Previous reports have indicated a strong 
association of the DARC variant with ANCs. The DARC-null polymorphism is accompanied 
with persistently low concentrations of circulating neutrophils and is a predictor of ethnic 
neutropenia where ANCs are repeatedly less than 1.5x10 cells/mm3 (Hsieh et al., 2010). To 
ascertain whether our studied cohort displayed similar associations, we compared ANCs 
according to DARC trait in both HIV negative and HIV-1 infected individuals.  
Among our study participants we found no differences in ANCs by HIV status where median 
ANCs were 3.17x103 and 2.56x103 cells/mm3 in HIV negative and HIV-infected individuals 
respectively (data not shown). We did, however, observe that median ANCs were significantly 
lower in DARC-null compared to DARC-positive individuals in both HIV negative (p=0.0007) 
and HIV infected (p=0.03) persons (median ANC of 2.64x103 cells/mm3 in HIV negative and 
2.22x103 cells/mm3 in infected DARC-null compared to 5.07x103 cell/mm3 in HIV negative 
and 4.08x103 cells/mm3 in infected DARC-positive subjects, Table 2.1). Significantly reduced 
ANCs were observed when comparing DARC-null and DARC-positive individuals, 
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irrespective of HIV status, although this finding was more prominent in HIV negative 
individuals (p=0.0007 in HIV negative individuals, Figure 2.3A and p=0.03 in HIV infection, 
Figure 2.3B). As an indication of ethnic neutropenia in our cohort of African individuals, only 
13.8% (4 of 29) of our recruited DARC-null subjects had ANCs of 1.5x103 cells/mm3 or less 
at the time of sampling (data not shown).  
In line with current literature (Reich et al., 2009), our data suggested that DARC-null 
individuals exhibited significantly lower circulating neutrophil counts, although only a 




Figure 2.3 ANCs stratified by DARC variant 
Comparison of ANCs measured by full blood count according to DARC genotype in HIV negative (A) 
and HIV positive (B) individuals. Bar graphs indicate medians extended to interquartile range (IQR) 
with whiskers. The p-values refer to differences in ANC between DARC-null and DARC-positive 
participants at the time of sampling. Abbreviations: ANC, Absolute Neutrophil Count; DARC, Duffy 






2.3.3 Phagocytic activity enhanced in the absence of DARC  
Recognition, internalisation and phagosome maturation are the hallmarks of the neutrophil 
response to effectively clear invading pathogens (Mayadas et al., 2014). We thus sought to 
measure the phagocytic capacity of neutrophils in DARC-null individuals and whether this 
phagocytic ability is altered by DARC status or ANCs in HIV negative and HIV-1 infected 
individuals. Phagocytosis is routinely quantified by measurement of bacterial or opsonised 
bead internalisation. Here we measured phagosome maturation by flow cytometry after 10 
minutes, 60 minutes and 120 minutes of introducing IgG opsonised beads to isolated 
neutrophils (Figure 2.4A). Phagosome maturation exhibited a steady increase over all time 
intervals in the 120 minute period in all studied subjects (p<0.0001, Figure 2.4B), and this 
increase was irrespective HIV status (Figure 2.4C and Figure 2.4D).  
HIV infection reduces neutrophil phagocytosis capacity, although the mechanisms underlying 
this altered activity are not fully understood (Casulli and Elbim, 2014). Here a trend of lower 
phagocytic ability in HIV chronically infected compared to HIV negative persons was 
observed at all measured time intervals over a 120 minute period (Figure 2.4E, p=0.08 at 10 
minutes; p=0.24 at 60 minutes; p=0.06 at 120 minutes). Subsequent analysis by DARC status 
revealed that DARC-null individuals (irrespective of HIV status) had a higher proportion of 
neutrophils able to phagocytose opsonised beads at 10 minutes and 60 minutes (Figure 2.4F, 
p=0.05 at 10 minutes and p=0.05 at 60 minutes in HIV negative individuals; and Figure 2.4G, 
p=0.009 at 10 minutes and p=0.07 at 60 minutes in HIV infected individuals). The median 
frequency of phagocytosing neutrophils was still higher in DARC-null compared to DARC-
positive individuals at 120 minutes post bead incubation (74.5% versus 64.3% in HIV negative 
and 67.9% versus 55.4% in HIV infection in DARC-null and DARC-positive individuals 
respectively). However, overall no statistical differences were observed in the phagocytic 
potential between DARC-null and DARC-positive individuals in HIV negative or HIV infected 
persons at 120 minutes post bead incubation (Figures 2.4F and 2.4G).  
In HIV negative individuals, the frequency of phagocytosing neutrophils did not correlate with 
ANCs, whilst, in contrast, the number of phagocytosing neutrophils inversely correlated with 
ANCs in chronically infected individuals at 10 minutes (a trend was observed) and 60 minutes 
following bead incubation (Figure 2.4H).   
Taken together our data suggests that the DARC genotype may play a role in the phagocytosing 
potential of neutrophils irrespective of HIV status. In the absence of the DARC phenotype a 
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higher proportion of neutrophils are able to phagocytose in an FcR dependent manner soon 













Figure 2.4 Neutrophil Phagocytosis (NP) in HIV negative and HIV infected individuals 
(A) Representative gating strategy employed for measuring phagosome maturation by flow cytometry. 
Background fluorescence was determined by acquisition of DQ Green-Bovine Serum Albumin (BSA) 
reporter beads alone. The gating strategy for neutrophils was determined by acquisition of neutrophils 
without DQ Green-BSA reporter beads. The gating strategy was applied to neutrophil samples 
incubated with DQ Green-BSA reporter beads for 10 minutes, 60 minutes and 120 minutes. Neutrophil 
phagocytosis (NP) was measured as DQ Green-BSA (Alexa Flour 488-A) positive. NP is shown for all 
(B), HIV negative (C) and HIV-infected (D) subjects over all timed intervals. Dots indicate data points 
for each participant joined by lines over the 120 minute time interval. 1 way ANOVA was used to 
examine differences in neutrophil phagocytosis (NP) over time. The p-values refer to the differences in 
median NP across all timed intervals (i.e. 10, 60 and 120 minutes). (E) Comparison of NP by HIV 
status. The p-values refer to differences in NP between HIV negative and HIV-infected subjects. NP 
was further assessed by DARC status in HIV negative (F) and HIV-infected (G) individuals 
respectively. The p-values indicate differences in NP between DARC-null and DARC positive 
participants. Boxes extend from the 25th to 75th percentile and medians are indicated by the horizontal 
line. Whiskers indicate minimum and maximum values. (H) Correlations between NP and ANCs in 
HIV negative and HIV-infected individuals at 10 minutes, 60 minutes and 120 minutes. Data was 
examined by Spearman correlation analysis. Lines of best fit are indicated in correlation graphs. Dots 
indicate individual data points. Abbreviations: NP, Neutrophil Phagocytosis; CC, DARC-null; TC/TT, 




2.3.4 ROS Production is unaffected by DARC status 
During the phagocytic process several enzymatic mechanisms are involved in microbial 
killing. Superoxide burst leads to the release of toxic compounds within the phagosome and is 
crucial to these processes. We next assessed the superoxide producing potential of neutrophils 
from study participants following in vitro PMA stimulation. Luminol oxidation measured by 
chemi-luminescence was used as an indicator of ROS production. Similar to other effector 
mechanisms, the ability of neutrophils to generate ROS has been shown to be compromised 
during HIV infection (Casulli and Elbim, 2014). Here, ROS release was observed within 10 
minutes of PMA stimulation and reached peak secretion within 60 minutes irrespective of HIV 
status (Figures 2.5A, 2.5B and 2.5C, see Supplementary Figure 1 for averaged data). ROS 
production was higher in HIV negative compared to infected persons at 60 and 120 minutes 
(median luminol oxidation was measured at 9.04 x 106 at 60 minutes and 1.91 x 107 Relative 
Light Units (RLU) at 120 minutes compared to 8.59 x 106 at 60 minutes and 1.70 x 107 RLU 
at 120 minutes in HIV negative and infected individuals respectively). However statistical 
analysis showed no significant differences between HIV uninfected and infected individuals 
at 10, 60 or 120 minutes following stimulation (Figure 2.5D).  
ROS production was further assessed in DARC-null compared to DARC-positive participants 
in HIV negative and HIV positive individuals respectively. In HIV uninfected individuals, 
median luminol oxidation was measured at 9.53 x 106 and 1.92 x 107 RLU in DARC-null 
compared to 8.74 x 106 and 1.91 x 107 RLU in DARC-positive persons at 60 and 120 minutes 
respectively. In infected individuals, median luminol oxidation was measured at 8.62 x 106 and 
1.84 x 107 RLU in DARC-null compared to 7.26 x 106 and 1.50 x 107 RLU in DARC-positive 
persons at 60 and 120 minutes respectively. Statistical analysis displayed no significant 
disparities in overall superoxide release according to DARC status (Figures 2.5E and 2.5F) or 
by ANCs (Figure 2.5G) in uninfected or infected persons.  
Taken together our data suggests that the potential of neutrophils to produce ROS is unaffected 
by HIV infection in this study population. This was unexpected as it was in contrast to previous 
reports of diminished ROS production in HIV infected individuals. Furthermore our results 
indicate that neither the absence of DARC nor lower ANCs (when neutrophil numbers are 












Figure 2.5 Neutrophil reactive oxygen species (ROS) release in HIV negative and HIV infected 
individuals 
Neutrophil reactive oxygen species (ROS) production in all (A), HIV negative (B) and infected (C) 
subjects as measured by chemi-luminescence every 2 minutes over a 120 minute time interval. Dots 
indicate data points for each participant joined by lines over the 120 minute time interval. Black dots 
indicate unstimulated samples. Stimulated samples are indicated by grey (HIV negative) and orange 
(HIV positive) dots. (D) Comparison of Neutrophil ROS production by HIV status. Neutrophil ROS 
production was further assessed by DARC status in HIV negative (E) and infected (F) individuals 
respectively. Dots indicate individual data points. Medians are indicated and extended to interquartile 
range (IQR) with whiskers. The p-values as indicated by ns refer to no significant differences by HIV 
or DARC status. (G) Correlations between Neutrophil ROS production and ANCs in HIV negative and 
infected individuals at 10 minutes, 60 minutes and 120 minutes. Dots indicate individual data points. 
Abbreviations: ROS, reactive oxygen species; DARC, Duffy antigen receptor for chemokines; CC, 
DARC-null; TC/TT, DARC-positive; ANC, Absolute Neutrophil Count; IQR, interquartile range; ns, 






2.3.5 Prolonged exposure to stimulus leads to lower NET formation in DARC-null 
persons during HIV infection 
The ability of neutrophils to form NETs in a process called NETosis is a relatively recent 
discovery (Brinkmann et al., 2004). It involves the release of genomic material together with 
antimicrobial factors in an effort to counter larger pathogens that evade phagocytosis (Branzk 
et al., 2014). Here we measured NETosis following neutrophil stimulation with PMA over a 
120 minute period using fluorescent microscopy (Figure 2.6A). Data demonstrating NET 
quantification during HIV infection is lacking and also it is unknown whether DARC state 
impacts NET production.  To address this gap, we hypothesised that NET production upon 
neutrophil activation would be altered in the absence of DARC and that this impairment would 
be more marked during HIV infection. 
No significant differences in frequency of NET producing neutrophils were observed by HIV 
status in our study (Figure 2.6B). The median frequency of NET producing neutrophils was 
27% at 60 minutes and 76% at 120 minutes in HIV negative individuals compared to 18% at 
60 minutes and 71% at 120 minutes in HIV infected persons (Figure 2.6B).   
Further assessment by DARC genotype showed that the median frequency of NET producing 
neutrophils was 0.3% and 42% in DARC-null compared to 0.2% and 7% in DARC-positive 
persons at 10 minutes and 60 minutes post stimulation in HIV negative individuals 
respectively. In chronically infected persons, the median frequency of NET producing 
neutrophils was 1% and 20% in DARC-null compared to 0.03% and 11% in DARC-positive 
subjects at 10 minutes and 60 minutes post stimulation respectively. However, statistical 
analysis did not show any significant differences in NET production between DARC-null and 
DARC-positive individuals at 10 minutes or 60 minutes post stimulation irrespective of HIV 
status (Figures 2.6C and 2.6D).  
In contrast, following prolonged exposure to stimulus (120 minutes), DARC-null individuals 
had lower NET production medians compared to DARC-positive persons. Median frequencies 
of NET producing neutrophils was 73% in DARC-null compared to 78% in DARC-positive 
subjects in HIV negative individuals. During HIV infection, median NET production was 65% 
in DARC-null compared to 84% in DARC-positive individuals (Figures 2.6C and 2.6D). 
Moreover, overall examination by DARC status revealed significantly lower NET release in 
DARC-null chronically infected persons compared to their DARC-positive counterparts 
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(Figure 2.6D, p=0.04). Further analyses revealed no association between the frequency of NET 
producing neutrophils and ANCs regardless of HIV or DARC status (Figure 2.6E).   
Taken together this data suggests that neutrophils are not significantly impaired in their ability 
to produce NETs during HIV infection. Neutrophils from DARC-null individuals are rapidly 
activated within the first hour and produce NETs in response to stimulus. However, during 
chronic HIV infection, prolonged activation of neutrophils may lead to impairment of NETosis 










Figure 2.6 Neutrophil extracellular trap (NET) production in HIV negative and HIV infected 
individuals 
(A) Representative microscopy images showing Hoechst (blue) and PL2-3 (red) staining at 10x and 
20x magnification after 60 minutes post PMA activation. (B) Comparison of NET production by HIV 
status. The p-values refer to differences in NET production between HIV negative and HIV-infected 
subjects. Net production was further assessed by DARC status in HIV negative (C) and HIV-infected 
(D) individuals respectively. The p-values refer to differences in NET production between DARC-null 
and DARC-positive subjects. Boxes indicate the 10-90% data spread and whiskers extend to the 
interquartile range (IQR). Medians are indicated by the horizontal line inside the box. Dots indicate 
outliers. (E) Correlations between NET production and ANCs in HIV negative and infected individuals 
at 10 minutes, 60 minutes and 120 minutes. Abbreviations: NET, Neutrophil extracellular trap; CC, 
DARC-null; TC/TT, DARC-positive; ANC, Absolute Neutrophil Count; IQR, interquartile range; ns, 








DARC-null linked neutropenia is associated with increased susceptibility to HIV acquisition. 
Interestingly, subsequent to infection, reports suggest a survival advantage imparted on 
leukopenic DARC-null persons in comparison to non-leukopenic DARC-null and DARC-
positive individuals. However, the mechanisms involved in these associations are not fully 
elucidated. Here we investigated the influence of DARC on neutrophil functionality in HIV 
negative and therapy naïve HIV infected individuals in a DARC-null prevalent population 
from Durban, KwaZulu-Natal, South Africa.  
 The DARC-null polymorphism was highly prevalent in our studied cohort and we observed 
that ANCs were reduced in individuals with the DARC-null trait regardless of the HIV status. 
The functional capacity of neutrophils as assessed by three key effector functions, i.e. the 
ability to phagocytose, produce ROS and NETs demonstrated differential results. A trend of 
lower phagocytic capacity was observed in HIV infected individuals compared to HIV 
negative subjects; however, neither production of ROS or NETs were altered in HIV infection. 
Assessment of the neutrophil functions by DARC status, revealed higher phagocytosis activity 
in DARC-null compared to DARC-positive individuals, which was more pronounced in HIV 
infected than in HIV negative subjects. In contrast, a reduction in NET production was noted 
in HIV infected individuals with the DARC-null trait following 2 hours of in vitro stimulation. 
The DARC-null trait is predominantly displayed in persons of African ancestry, and the 
absence of DARC has been associated with lower neutrophil counts in circulation (He et al., 
2008, Reich et al., 2009). Assessment of HIV-1 chronically infected African individuals based 
in Durban indicated that 64.8% (247 of 381) of the patients were homozygous for the DARC-
null allele (Julg et al., 2009), whilst a longitudinal study of high risk South African woman 
described that 64.7% (92 of 142) of their study subjects possessed the DARC-null trait 
(Ramsuran et al., 2011). We here observed comparable frequencies of the DARC-null variant 
(69%) within a similar population group of Zulu/Xhosa individuals from the Durban area. 
Furthermore, in accordance with previous reports, the DARC-null genotype was significantly 
associated with reduced neutrophil counts in studied individuals irrespective of HIV status, 
although this finding was substantially less prominent in chronic HIV infection. Accelerated 
neutrophil apoptosis is generally observed in HIV infection (Casulli and Elbim, 2014). 
Whether the effect of the DARC-null variant on neutrophil count is overshadowed by this 
accelerated apoptosis is unclear and requires further investigation.      
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There are conflicting reports of neutrophil responses in HIV-1 disease. While few studies have 
described an increase of key responses such as phagocytosis, oxidative burst and intracellular 
bacterial killing in HIV-1 infected patients compared to their HIV negative counterparts 
(Bandres et al., 1993, Schwartz et al., 2010), the general consensus suggests that infection leads 
to defective neutrophil responses and a higher rate of neutrophil apoptosis (Casulli and Elbim, 
2014). Past studies have reported significantly impaired neutrophil phagocytosis and reduced 
superoxide burst in HIV-1 infected individuals (Casulli and Elbim, 2014). In addition, previous 
investigations have demonstrated the adverse effects of HIV infection on neutrophil 
phagocytosis of extracellular bacteria (Pos et al., 1992, Michailidis et al., 2012). Ingestion of 
Staphylococcus aureus was compromised in AIDS patients with CD4 counts below 200 
cells/mm3 compared to controls following 60 minutes incubation with opsonised bacteria (Pos 
et al., 1992). Furthermore, superior neutrophil functional responses were detected in patients 
with better immunological status and lower viral loads (Michailidis et al., 2012). While the 
mechanism for this altered activity remains unclear, reports of monocyte function suggest that 
HIV proteins  impede phagocytosis through downregulation of the gamma signalling chain of 
the FcR (Kedzierska et al., 2002) and inhibit phagosome formation in a Nef-dependent manner 
(Mazzolini et al., 2010). In agreement with these reports, we observed lower FcR-mediated 
phagocytosis of opsonised beads in HIV infected persons compared to HIV negative subjects, 
although this difference was not significant (p=0.08 at 10 minutes and p=0.06 at 120 minutes). 
We also found that HIV-infected individuals studied here did not display lower ROS 
production in comparison to uninfected individuals. Plasma RNA levels have been shown to 
be associated with reduced ROS production. Individuals with less than 1000 viral copies/ml 
have been shown to display no differences in oxidative metabolism to HIV negative persons. 
Reduced ROS release was detected in patients with more than 1000 viral copies/ml, while 
extreme ROS dysfunction was observed in patients with more than 10,000 viral copies/ml (Diz 
Dios et al., 2000). Interestingly, neutrophils from HIV negative subjects exhibited supressed 
release of ROS following priming with synthetic HIV-1 envelope peptide, signifying the direct 
role of HIV virions in the alteration of neutrophil functional responses (Munoz et al., 1999). 
Moreover, no significant modification of neutrophil ROS production was described in HIV-1 
asymptomatic individuals with a CD4 count above 200 cells/mm3 following neutrophil 
activation with PMA (Munoz et al., 1999).  
Importantly, these previous reports noted that the severity of neutrophil impairment is 
dependent on the stage of HIV disease. Neutrophil dysfunction is more evident in the later 
66 
 
stages of infection in patients with high HIV-1 plasma concentrations and lower CD4 
lymphocyte counts (Campbell, 1990, Mastroianni et al., 1999). Moreover, the prevalence of 
coinfection with opportunistic pathogens during advanced disease contributes to diminished 
neutrophil response (Shi et al., 2014). Chronically infected subjects that were studied here 
presented with low viral loads at the time of sample collection, 59% (13 of 22) had a viral load 
lower than 10,000 copies/ml and all HIV infected persons studied had a CD4 count above 300 
cells/mm3. Clinically, these data indicate that none of these individuals were in the later stages 
of disease, and could partly explain our observation of no significant differences in FcR-
mediated phagocytic capacity or levels of ROS production between HIV negative and infected 
individuals. 
Furthermore, our data suggests that NET release following PMA exposure was unaffected in 
HIV infection; it is plausible that variations in NET production due to HIV may not have been 
detected due to lower viral loads in our studied cohort. In contrast to other neutrophil functions, 
data on NET formation is lacking with regard to HIV infection. The role mediated by NET 
formation in preventing HIV transmission has been described (Jenne et al., 2013, Barr et al., 
2018), however, whether this mechanism is modified following infection remains unclear.  
Various genetic mutations have been associated with neutrophil disorders either in count 
and/or function including phagocytosis and superoxide release (Lakshman and Finn, 2001). It 
is well established that the absence of the DARC phenotype is associated with lower circulating 
ANCs characteristic of ethnic neutropenia. Yet the influence of this polymorphism on 
neutrophil function has been virtually unexplored. A recent study reported similar neutrophil 
gene expression in subjects with and without ethnic neutropenia, suggesting intact neutrophil 
function in individuals with low DARC expression (Charles et al., 2018).    
We thus assessed the impact of the DARC-null polymorphism on neutrophil effector functions 
in our study cohort. We noted enhanced FcR-mediated phagocytosis in neutrophils from 
DARC-null individuals and this activity was not affected by HIV infection. Higher phagocytic 
activity was exhibited within the first hour following incubation with beads and thereafter no 
differences in bead uptake was exhibited between DARC-null and DARC-positive persons. 
Neutrophil phagocytosis through FcR engagement is characteristically very rapid. Uptake of 
IgG opsonised particles has been measured within minutes, and the rate at which neutrophils 
can efficiently phagocytose is a clear advantage in terms of host immunity (Herant et al., 2006, 
Mayadas et al., 2014). A recent report indicated that DARC knockout murine models exhibited 
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phenotypically distinct neutrophils. Notably, neutrophils from DARC-deficient mice displayed 
a higher expression of FcɣR and CD45, which is known to enhance FcɣR function (Duchene 
et al., 2017). Similarly, neutrophils characterised from HIV negative DARC-negative 
individuals were found to selectively upregulate FcɣRIIIb (CD16) and CD45 expression in 
comparison to DARC-positive individuals (Duchene et al., 2017). Here we show higher FcR-
mediated phagocytosing potential in neutrophils from DARC-null individuals, specifically at 
the earlier timed intervals. This is a probable consequence of augmented FcR expression and 
may be beneficial in the faster clearance of pathogens in DARC-null individuals.  
Furthermore, we observed higher (although not significant) frequencies of neutrophils able to 
produce ROS and NETs in DARC-null individuals within the first hour following stimulation 
regardless of HIV status. Neutrophil activation progresses through multiple steps, and 
neutrophils are considered to be fully activated when they are able to fully function (i.e. induce 
phagocytosis, produce ROS and release NETs). Responsiveness to stimuli priming allows for 
rapid and efficient neutrophil activation (Mayadas et al., 2014). Higher frequencies of ROS 
and NET production in DARC-null individuals within the first hour could indicate a more rapid 
response to stimulus in DARC-null persons. The data may suggest that neutrophil activation 
is more easily induced in DARC-null persons, resulting in a higher frequency of cells with 
earlier responses to stimulus compared to DARC-positive individuals. Interestingly, in the 
absence of DARC, murine models displayed modified hematopoietic stem cell (HSC) 
differentiation and exhibited higher proportions of committed myeloid progenitor cells in the 
bone marrow (Duchene et al., 2017). Furthermore, genome expression indicated marginally 
activated neutrophil profiles in DARC-null individuals with benign ethnic neutropenia 
(Charles et al., 2018). Whilst leukocyte migration and HSC mobilisation pathways were most 
affected (Charles et al., 2018), this slightly activated state of neutrophils from DARC-null 
persons could contribute to rapid induction of neutrophil defence mechanisms.        
While earlier functional responses (within the first hour) to stimulus were seemingly slower in 
neutrophils from DARC-positive individuals, prolonged stimulation (2 hours) resulted in 
neutrophil activity that was comparable to neutrophils from DARC-null neutrophils. An 
exception to this observation was a more robust NET response following prolonged stimulation 
in neutrophils from DARC-positive HIV infected individuals compared to their DARC-
negative counterparts. Interestingly, this variation in NET release was not exhibited in HIV 
negative individuals by DARC state, suggesting that chronic inflammation during HIV 
infection may contribute to lower NET production in DARC-null HIV infected persons. It is 
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possible that the slightly activated neutrophil profile exhibited in the absence of DARC coupled 
with continued inflammatory signals displayed in HIV infection could induce faster neutrophil 
cell exhaustion and death in DARC-null persons. While diminished NET production would be 
unfavourable in clearing pathogens, it has been noted that disproportionate NET formation 
occurring in chronic activation elicits antibody-mediated autoimmune activity and organ 
damage (Chen and Nunez, 2010, Barnado et al., 2016). Thus lower NET formation in DARC-
null chronically infected persons may be beneficial in averting excessive tissue damage in these 
individuals. 
While the data presented here provides evidence of variation in neutrophil function in the 
absence of the DARC allele, we were limited by numerous factors. Neutrophils are a fragile 
cell subset and the four hour period between blood collection and processing was longer than 
the ideal conditions when assessing neutrophil activity; however, this time period was 
consistent for all samples. Furthermore, positive selection separation for the enrichment of 
neutrophils using the CD15+ MACS beads was not ideal and could have resulted in activation 
and altered phenotypic characteristics of the isolated neutrophils. However, this technique 
provided the best neutrophil purity levels compared to other approaches that were tested. The 
limitation was taken into account and all assays included a control sample to subtract 
background from possible activation during the isolation procedure. Other limitations included 
a small sample size and chronically infected patients with relatively lower viral loads than that 
typical of untreated HIV infected patients. Our observations may therefore not be 
representative of typical disease progression in the absence of antiretroviral therapy. 
Furthermore, many of our DARC-null subjects were not neutropenic as defined by the ANC 
threshold of <1500 cells/mm3, and since these patients were not followed longitudinally we 
cannot determine which patients possessed neutropenic characteristics. Additional sample 
collection from chronically infected treatment naïve individuals became challenging during 
the study due to the global implementation of the HIV test and treat policy. Despite these 
limitations, we were able to identify variation in the neutrophil response, particularly with 
regard to phagocytosis. We noted differences in neutrophil phagocytosis as either an effect of 
HIV infection or lack of DARC. Although participants with identified ethnic neutropenia were 
scarce, we were able to provide evidence of the influence of the DARC-null polymorphism 
rather than lower ANCs on neutrophil effector functions irrespective of HIV status.  
In summary, we addressed the impact of the DARC-null allele on three key neutrophil 
responses in persons recruited from an HIV-1 prevalent population. We focused on these three 
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functions as they are primary to the killing efficiency of neutrophils as a first line of host 
immunity. Beyond these effector functions, neutrophils have emerged as immunomodulatory 
cells that contribute to ongoing immune responses through either soluble protein secretion or 
direct interaction with other immune cells (Mayadas et al., 2014), and these mechanisms in the 
context of DARC require future attention.              
To our knowledge this is the first study to assess the influence of the DARC-null polymorphism 
on neutrophil function in an HIV-1 setting. Our findings opposed our hypothesis of impaired 
neutrophil responses in the absence of DARC. Neutrophils from DARC-null individuals with 
lower ANCs were not functionally impaired. Interestingly, our data suggested that neutrophils 
displayed higher phagocytic activity in the absence of DARC which could suggest a 
compensatory mechanism for lower ANCs in these individuals. Higher neutrophil activity 
could explain the asymptomatic characteristics associated with ethnic neutropenia as 
demonstrated by higher neutrophil activity in individuals with DARC null trait regardless of 
HIV status. Furthermore, higher neutrophil phagocytosis detected in DARC-null individuals 
may serve as an advantage in chronic HIV infection, where a higher proportion of neutrophils 
able to rapidly phagocytose foreign pathogens could benefit DARC-null individuals in immune 
defence against opportunistic infection in stages of advanced disease. Overall, our data provide 














CHAPTER 3: NATURAL KILLER (NK) CELL PROFILES IN 
HIV-1 INFECTED INDIVIDUALS WITH DUFFY ANTIGEN 
















Natural killer (NK) cells represent a distinct class of innate lymphoid cells that are able to 
rapidly respond to tumour and virally infected cells without prior sensitisation (Lanier, 2005). 
NK cell responses are governed by counterbalance of signals from a diverse array of germline 
encoded activating and inhibitory receptors. Activation of NK cells leads to the initiation of 
effector mechanisms that include direct cytotoxicity through release of cytoplasmic granules, 
antibody dependent cellular cytotoxicity (ADCC) and production of soluble proteins that are 
involved in immune response modulation (Lanier, 2005, Vivier et al., 2008).  
Substantial evidence suggests the imperative role of NK cells in HIV-1 protection (Lederman 
et al., 2010, Hens et al., 2016), and previous studies have highlighted the significance of these 
cells in the early containment and control of HIV-1 infection subsequent to transmission 
(Carrington and Alter, 2012). Furthermore, the impact of NK cells in HIV infection is 
supported by the evolution of viral strategies to evade NK cell mechanisms (Lisnic et al., 2010, 
Jost and Altfeld, 2012). Prolonged HIV-1 infection without antiretroviral therapy intervention 
is associated with several NK cell defects and impaired immune responses. Together these 
factors can influence the course of HIV-1 infection and disease outcome. 
Neutrophils have emerged as immune-regulatory cells in recent years; amongst their functions 
is their ability to either directly or in cooperation with other cell types ensure terminal 
maturation and attainment of complete effector functionality in NK cells (Costantini et al., 
2011a, Costantini et al., 2011b, Jaeger et al., 2012). Specifically, one such study demonstrated 
that neutrophil-deficient mice had NK cells that were impeded at an immature stage of 
development and were hypo-responsive. This key role of neutrophils as mediators of NK cell 
function was subsequently verified in severe congenital neutropenia (SCN) and autoimmune 
neutropenia (AIN) patients (Jaeger et al., 2012) where NK cell maturation and function were 
impaired in neutropenic patients. 
Disorders that result in low neutrophil counts (below 500 cells/mm3) are usually rare and 
contribute to severe immune complications (Hsieh et al., 2010). Contrary to this, a type of 
neutropenia – termed benign ethnic neutropenia – is common in the African population, 
occurring in 25-50% of persons of African ethnicity (Thobakgale and Ndung'u, 2014). The 
condition is characterised by repeatedly low absolute neutrophils counts (ANCs) below 1500 
cells/mm3, but is not associated with increased oral and systemic infections (Hsieh et al., 2010). 
The Duffy antigen receptor for chemokines (DARC)-null polymorphism is the principal 
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genetic determinant of benign ethnic neutropenia (Thobakgale and Ndung'u, 2014). The 
ailment was initially considered to have no adverse clinical consequences (Haddy et al., 1999). 
However, recent data has implicated the DARC-null trait and its linked neutropenia to several 
health issues including asthma, rheumatoid arthritis, cancer and transplant rejection (Ulvmar 
et al., 2011). 
Individuals in possession of the DARC-null genotype and its associated neutropenia are 
reported to have an increased HIV-1 acquisition risk (He et al., 2008, Ramsuran et al., 2011). 
Furthermore, low neutrophil counts, independent of lymphocyte and monocyte counts, have 
been associated with an increased risk of mother-to-child HIV transmission (Kourtis et al., 
2012). The effect of the DARC-null state on disease progression is less certain. Suggestions 
that the absence of DARC may predispose individuals to a survival advantage (Kulkarni et al., 
2009) is debatable. Contrasting studies in HIV-1 chronically infected persons of African 
descent showed no association between the DARC-null allele and markers of HIV disease 
progression (Horne et al., 2009, Hesslein et al., 2011, Sun and Lanier, 2011, Julg et al., 2009).  
Thus, while the implications of DARC-null linked neutropenia in HIV-1 acquisition and 
possibly disease progression have been described, the underlying mechanisms for this 
association remain unclear. Different mechanisms have been proposed; the low circulatory 
levels of neutrophils present in DARC-null neutropenic individuals could impact both the 
priming and functional capacity of NK cells, thus leading to an impaired ability of NK cells to 
mediate an effective response against HIV-1 resulting in adverse disease outcomes 
(Thobakgale and Ndung'u, 2014).   
In this chapter we hypothesised altered neutrophil priming of NK cell in the presence of the 
DARC-null polymorphism that would result in modified NK cell phenotypic patterns and 
impaired NK cell functionality. We assessed the impact of DARC-null genotype and lower 
ANCs on NK cell profiles from HIV negative and HIV-1 chronically infected treatment naïve 
black South African individuals from Durban, KwaZulu-Natal in South Africa. In particular, 
we assessed NK cell maturation/differentiation characteristics and functionality in whole blood 
and cryopreserved peripheral mononuclear cells (PBMCs) from these individuals. 
Overall we found that in HIV negative individuals, absence of DARC associated with lower 
NK cell numbers and higher frequencies of less differentiated NK cells. However, this 
immature phenotype did not amount to functional differences by DARC genotype. In contrast 
HIV-1 infected individuals displayed NK cell subset redistribution and higher activation which 
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was accompanied by lower cytolytic potential. However, these observed phenotypic and 




























3.2.1 Participant Recruitment 
HIV negative participants were recruited from the Females Rising through Education, Support 
and Health (FRESH) cohort, an acute HIV infection monitoring cohort that targets high risk 
women. HIV-1 subtype C chronically infected treatment naïve subjects were recruited from the 
HIV Pathogenesis Programme (HPP) Acute Infection Cohort, an acute-chronic HIV infection 
cohort. Both of these cohorts are located in the Umlazi region in Durban, KwaZulu-Natal 
(KZN), South Africa. Both studies attained ethical approval from the University of KwaZulu-
Natal (UKZN) Biomedical Research Ethical Committee (BREC) (FRESH BREC Reference 
Number: BF131/11 and HPP Acute Infection Cohort BREC Reference Number: E036/06). All 
participants gave written informed consent to voluntarily participate in these studies. This 
particular study obtained further ethical clearance as a subsidiary of the above mentioned 
studies (BREC Reference Number: BE229/15). A total of 39 individuals sub-divided into HIV 
negative donors (n=20) and HIV-1 chronically infected individuals (n=19) were assessed. 
These individuals were further stratified by DARC status as described below and summarized 
in Table 3.1.  
 
3.2.2 ANCs, CD4 Counts and Viral Load 
Blood for full blood counts, CD4+ T cell count measurement and viral load quantification was 
collected in Ethylenediaminetetraacetic acid (EDTA) anticoagulated vacutainer tubes (Becton 
Dickinson (BD), Franklin Lakes, New Jersey, USA). ANCs were enumerated by full blood 
count using the automated XN 1000 Haematology Analyser (Sysmex, Kobe, Hyōgo, Japan). 
CD4 counts were measured using BD Trucount and analysed on a four-parameter FACS 
Calibur flow cytometer (BD). Viral loads were determined using the NucliSENS EasyQ HIV-
1 v2.0 kit with a detection limit of 20 copies/ml (BioMérieux, Marcy-l'Étoile, France).   
 
3.2.3 Quantification of Antiretroviral (ARV) Drug in Plasma  
This study aimed to recruit HIV-1 chronically infected, treatment naïve individuals. ARV 
therapy usage in chronically infected patients was self-reported. Certain subjects maintained 
viral loads below 1000 RNA copies/ml at the time of assessment. To rule out ARV drug use, 
plasma samples were collected from these study participants and screened for ARV drugs using 
a quantitative liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) 
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method. The method screened for nine ARVs, namely Emtracitabine, Tenofovir, Lopinavir, 
Ritonavir, Nevirapine, Abacavir, Lamivudine, Zidovudine and Efavirenz. A plasma sample 
volume of 50 µl was processed using a protein precipitation method, ARV drug analytes were 
chromatographically separated on a Agilent Zorbax Eclipse Plus C18 (2.1 x 50mm, 3.5 µm) 
HPLC column (Agilent Technologies, Santa Clara, California, USA), detected using an AB 
Sciex 5500 triple quadrupole mass spectrometer (Sciex, Framingham, Massachusetts, USA) 
and quantitated using Analyst® 1.6.2 software (Sciex). 
 
3.2.4 DARC Genotyping 
DARC -46T   C (rs2814778) single-nucleotide polymorphism (SNP) genotyping was 
performed by TaqMan allelic discrimination assays which has been previously verified by 
direct sequence analysis by Julg et al. (2009). Briefly, genomic DNA was isolated from stored 
buffy coats using the QIAamp DNA Blood Midi kit (Qiagen, Hilden, Germany) according to 
manufacturer’s instructions. DNA concentration was standardised at 50ng/µl with polymerase 
chain reaction (PCR) grade water. A cocktail containing Taqman Genotyping master mix (Life 
Technologies, Carlsbad, California, USA) and predesigned probes for the DARC gene (SNP 
ID: rs2814778, Applied Biosystems, Foster City, California, USA) was used to amplify target 
sequence in 50ng genomic DNA by real time PCR (RT-PCR) in the LightCycler 480 (Roche, 
Basel, Switzerland) according to the manufacturer’s protocol.    
 
3.2.5 PBMC Isolation, Cryopreservation and Thawing  
Blood collected in sodium heparin BD Vacutainers (BD) from each participant was processed 
within 6 hours of collection. One millilitre (1ml) of blood was reserved for the whole blood 
assays, and the remainder was used for lymphocyte fraction preparation by density 
centrifugation on a Histopaque-1119 cushion (Sigma-Aldrich, St. Louis, Missouri, USA) at 
800 x g for 20 minutes, low brakes as previously described (Brinkmann et al., 2010).  
Cell counts were determined by 1:5 dilution with Trypan Blue Stain (Gibco) counted using a 
haemocytometer under a light microscope. Cells were prepared for cryopreservation by 
refrigerated centrifugation and re-suspended at a final concentration of 10 million cells/ml in 
ice cold freezing solution containing 1:10 Dimethyl Sulfoxide (DMSO) (Merck Millipore, 
Billerica, Massachusetts, USA) and Foetal Bovine Serum (FBS). The frozen samples were 
stored in 2ml cryogenic vials in a liquid nitrogen Biorack ultralow freezer for long term storage 
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and subsequently batched for phenotypic and intracellular staining (ICS) assays. Cell viability 
was not statistically different by HIV or DARC status. Median viability was 92% in HIV 
negative and 88% in HIV infected individuals (p=0.12). By DARC status, median viability in 
HIV negative individuals was 91% and 94% in DARC-null and DARC-positive individuals 
respectively (p=0.82), and in HIV infected individuals was 88% and 84% in DARC-null and 
DARC-positive individuals respectively (p=0.59). 
Cryopreserved cells were rapidly thawed, washed twice in pre-warmed R10 medium (RPMI 
Medium 1640 (Gibco) containing 10% gamma irradiated, heat inactivated FBS (Gibco), 1% 
L-Glutamine, 1% Penicillin Streptomycin and 1% Hepes buffer 1M (all from Lonza, Basel, 
Basel-Stadt, Switzerland) at 500 x g for 8 minutes at room temperature. Cells were rested in 
R10 medium in a 37°C, 5% CO2 incubator for at least 2 hours. Sample viability and cell counts 
were determined by trypan blue exclusion, and cells were re-suspended at 10 million cells/mL 
in R10 medium for subsequent assays. 
 
3.2.6 PBMC Ex vivo phenotyping and in vitro ICS staining 
All PBMC staining was performed in 96-well plates. Each staining / fixation incubation was 
for 20 minutes at room temperature in the dark, followed by washing with Dulbecco's 
phosphate-buffered saline (dPBS) and centrifuged at 850 x g for 6 minutes. For phenotype 
staining, one million cells were stained with LIVE/DEAD Fixable Aqua Dead Cell Stain 
(Invitrogen, Carlsbad, California, USA) to exclude dead cells, followed by cell surface staining 
with the following monoclonal antibodies: anti-CD3 PE-CF594 (clone:UCHT1), anti-CD14 
V500 (clone:M5E2), anti-CD19 V500 (clone:HIB19) (to exclude of T-cells, monocytes and B-
cells respectively), and NK cell markers Alexa-Fluor-700 conjugated anti-CD56 (clone:B159) 
and anti-CD16 APC-Cy7 (clone:3G8, all from BD Biosciences). In addition, to assess 
activation and differentiation, cells were stained with anti-CD69 fluorescein isothiocyanate 
(FITC (clone:FN50, BD Biosciences), anti-CD38 Phycoerythrin (PE), (clone:HB7 BD 
Biosciences) anti-HLA-DR Brilliant Violet (BV) 711 (clone:L243 Biolegend, San Diego, 
California, USA), anti-CD27 BV605 (clone:O323 Biolegend), anti-CD11b PE-Cy5 
(clone:ICRF44), anti-PD-1 BV421 (clone:EH12.2H7 Biolegend) and anti-CD57 APC 
(clone:NK-1, BD Biosciences), before addition of fixation Medium A (Invitrogen, Carlsbad, 




For in vitro functional assays: 1 million cells were assessed for cytokine production and 
degranulation capacity in the presence of degranulation marker anti-CD107a PE-Cy5 
(clone:H4A3, BD Biosciences), BD GolgiStop protein transport inhibitor (GolgiStop, BD 
Biosciences) and Brefaldin A (Sigma-Aldrich) at a final concentration of 10µg/ml with either 
R10 medium alone, Recombinant Human Interleukin (IL)-2, Recombinant Human IL-15 (both 
from R&D Systems, Minneapolis, Minnesota, USA), and Recombinant Human IL-18 (Medical 
& Biological Laboratories, Japan) all at a final concentration of 10ng/ml alone, K562 cell line 
alone (effector:target ratio of 10:1), or both for 18 hours at 37°C, 5% CO2.  
Following overnight culturing, samples were stained with LIVE/DEAD Fixable Aqua Dead 
Cell Stain followed by surface staining with anti-CD3 PE-CF594, anti-CD14 BV650 
(clone:M5E2), anti-CD19 BV650 (clone:HIB19, both from Biolegend), Alexa-Fluor-700 
conjugated anti-CD56 and anti-CD16 APC-Cy7 as described above and anti-CD158a PE 
(clone: HP-3E4), anti-CD158b PE (clone:CH-L, both from BD Biosciences), anti-CD158e1/e2 
PE (clone:) and anti-NKG2A APC (clone: Z199, both from Beckman Coulter), followed by 
fixation with Medium A and ICS staining with antibody cocktail containing cytokine markers 
anti-Tumor necrosis factor (TNF)-α PerCP-Cy5.5 (clone:Mab11) and anti-Interferon gamma 
(IFN-ɣ) PE-Cy7 (clone:B27, both from Biolegend) in the presence of permeabilisation buffer 
Medium B (Invitrogen). 
 
3.2.7 Whole Blood Cytokine and Degranulation Assay 
Simultaneous to PBMC isolation, the frequency of CD107a positive and IFN-ɣ producing NK 
cells in whole blood was determined following HIV-1 peptide stimulation as previously 
described (Thobakgale et al., 2012). The whole blood assay was used to assess antibody 
mediated NK cell activity following stimulation with HIV peptides and therefore requires the 
presence of plasma which would be absent in PMBCs. In brief, 200µl of whole blood was 
stimulated with either gp120 or gp41 HIV-1 peptides at a final concentration of 2µg/ml, in the 
presence of 1µg co-stimulatory anti-human CD28/CD49 antibodies (BD Biosciences, San Jose, 
California, USA). A negative control with whole blood alone and a positive control with whole 
blood stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin at a final 
concentration of 1µg/ml and 0.5µg/ml respectively were included for each participant sample. 
Brefaldin A at a final concentration of 10µg/ml, 1µl of a 1:10 dilution of GolgiStop to R10 and 
degranulation marker anti-CD107a PE-Cy5 were added to each sample before incubation at 
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37°C, 5% CO2 for 6 hours. After incubation, 20µl of EDTA was added to arrest activation and 
remove adherent cells, before lysis of erythrocytes with BD FACS lysing solution and 
permeabilisation of leucocytes was done with BD FACS permeabilising solution (all from BD 
BioSciences). Cells were washed and stained with an antibody cocktail containing anti-CD3 
PECy5.5 (clone:7D6), anti-CD14 Pacific Blue (clone:TuK4), anti-CD19 Pacific Blue 
(clone:SJ25-C1) (all from Invitrogen), anti-CD56 Alexa-Fluor-700, anti-CD16 APC-Cy7 and 
anti-IFN-ɣ PE-Cy7 for 1 hour and fixed with Medium A before data acquisition.     
 
3.2.8 Description of NK cell markers 
CD56 or Neural-Cell Adhesion Molecule (NCAM) is a homophilic binding glycoprotein. 
Although CD56 is typically used as an NK cell marker, the function of CD56 on NK cells is 
still unknown (Van Acker et al., 2017). 
CD16 or FcγRIII, is found on the surface of several leukocytes and participates in signal 
transduction. The CD16 molecule on NK cells is involved in triggering antibody-dependent 
cellular cytotoxicity (ADCC) (Vivier et al., 2008).  
NK cell subsets are defined by the relative expression of CD56. The fully mature CD56 dim 
subset (CD56+CD16+) is potently cytotoxic and generally comprises about 90% of total 
circulatory NK cells in healthy individuals. The CD56 bright cells (CD56+CD16-) are 
considered as an immature subset with cytokine secreting potential that account for <10% of 
the NK cell population (Cooper et al., 2001, Lanier, 2005). Chronic HIV infection is associated 
with an accumulation of the aberrant CD56 negative subset (CD56-CD16+) (Jost and Altfeld, 
2012). 
CD11b is an integrin family member that is expressed on the surface of many leukocytes. 
Functionally, CD11b mediates inflammatory responses through regulation of leukocyte 
adhesion and migration (Rosetti and Mayadas, 2016).  
CD27 is a costimulatory receptor belonging to the TNF family and is constitutively expressed 
on naive T and B cells and on NK cells (Grant et al., 2017). 
CD11b/CD27 NK cell maturation as proposed by Fu and colleagues (2011) suggests that four 
populations defined by CD11b and CD27 expression (CD11b-CD27-; CD11b-CD27+; 
CD11b+CD27+ and CD11b+CD27-) represents distinct development stages of NK cells with 
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varying functional capabilities. At the least mature stage, NK cells exhibits a CD11b-CD27- 
phenotype. Through stepwise acquisition of CD27 and CD11b, NK cells progress through 
intermediate development stages which are defined as CD11b-CD27+ and CD11b+CD27+. 
Finally loss of CD27 demarcates full maturation to the CD11b+CD27- phenotype. 
Development stages based on CD11b and CD27 expression have been suggested to 
functionally correspond to CD56 bright and CD56 dim subsets, where CD11b-CD27+ and 
CD11b+CD27+ intermediate phenotypes correspond to the cytokine producing CD56 bright 
subset and the fully mature CD11b+CD27- phenotype corresponds to the potently cytolytic 
CD56 dim subset (Fu et al., 2011). 
CD158a, CD158b and CD158e1/e2 are inhibitory killer-cell immunoglobulin-like receptors 
(KIRs) with long cytoplasmic domains. Recognition and binding of KIRs to HLA class I 
molecules on self-cells triggers inhibitory signals via immune tyrosine-based inhibitory motifs 
(ITIMs) which results in suppression of NK cell activity (Lanier, 2005). 
NKG2A belongs to the CD94/NKG2 family of C-type lectin receptors. NKG2A is an 
inhibitory receptor with long cytoplasmic domains. Recognition and binding of NKG2A to 
HLA-E on self-cells triggers inhibitory signals via ITIM which results in suppression of NK 
cell activity (Lanier, 2008).    
The KIR/NKG2A model described by Beziat et al. (2010) commences with the CD56 bright 
subset that highly express NKG2A and few KIRs, transitioning through intermediate phases to 
the terminally differentiated KIR+NKG2A- subset. Based on a stepwise loss of NKG2A and 
the correlated acquisition of KIRs, the model thus forms a basis to predict the functional fate 
of NK cells. Each phenotypic stage of differentiation is characterised by unique functional 
attributes where KIR-NKG2A+ cells respond by cytokine secretion, KIR+NKG2A+ and 
KIR+NKG2A- cells are dominantly cytotoxic, whilst KIR-NKG2A- are regarded as hypo-
responsive cells (Beziat et al., 2010).     
CD57 is expressed as a carbohydrate epitope on the surface of NK cells. Increased CD57 
expression defines terminal differentiation of peripheral NK cell maturation and is an indicator 
of potently cytotoxic NK cells with impaired sensitivity to cytokine stimulus and diminished 
replicative capacity (Nielsen et al., 2013). 
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CD69 is a human transmembrane C-Type lectin protein that acts as an immune regulator. It is 
induced shortly after NK cell activation with a potential role in triggering cell cytotoxicity 
(Fogel et al., 2013).  
HLA-DR is an MHC class II cell surface receptor. HLA-DR presents peptide antigens to 
immune cells. Increased HLA-DR expression is a marker of prolonged activation typically 
seen in chronic infection (Fogli et al., 2004).   
Upregulation of PD-1 antigen expression is commonly associated with NK cell dysfunction 
and is routinely used as a marker of cell exhaustion (Beldi-Ferchiou et al., 2016). 
CD107a is expressed primarily across lysosomal membranes. Cell surface expression of 
CD107 has been identified as a marker for granule release (i.e. degranulation) on NK cells 
(Alter et al., 2004a). 
IFN-ɣ is a dimerised soluble immune-stimulatory cytokine. It is produced predominantly by 
NK and cytolytic T cells and is an important activator of macrophages and inducer of class II 
MHC molecule expression. IFN-ɣ is also able to inhibit viral replication directly (Schoenborn 
and Wilson, 2007). 
TNF-α is a cell signalling cytokine produced by various immune cells and is involved in 
systemic inflammation. TNF-α is able to induce fever and cellular apoptosis; and inhibit 
tumorigenesis and viral replication (Pfeffer, 2003). 
     
3.2.9 Sample Acquisition and Statistical Analysis 
Samples were acquired on an LSR Fortessa flow cytometer (BD). Daily routine instrument QC 
was performed by the flow cytometry administrator using Cytometer Setup and Tracking beads 
(BD Biosciences). Compensation was performed for each experiment using the Anti-Mouse 
Ig, κ/Negative Control Compensation Particles Set (BD Biosciences). A compensation tube for 
each panel antibody was prepared as follows; one drop of anti-mouse Ig, κ and one drop of 
negative control beads were mixed in a 5ml round bottom polypropylene tube and stained with 
the antibody of interest for 20 minutes. Compensation tubes were stored in the dark at 4°C until 
acquisition. Compensation was calculated using FACS Diva Software (BD) on the experiment 
template used to acquire experimental samples. At least 250 000 events per sample were 
recorded. Fluorescence minus one (FMOs) were used in each experiment to exclude 
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background fluorescence in the gating strategies for each activation/differentiation marker. 
FMOs were prepared by staining a PBMC sample with a mastermix containing all the 
antibodies of the phenotype panel except the activation/differentiation marker of interest. For 
ICS assays, degranulation and cytokine frequencies were examined after background 
subtraction from unstimulated control. FlowJo Software Version 9 (TreeStar, Inc., Ashland, 
Oregon, USA) was used for sample analysis. Differences between studied groups was 
examined by Mann-Whitney U test using GraphPad Prism Version 5 software (GraphPad 






















3.3 RESULTS  
To determine whether the DARC-null trait and the associated ethnic neutropenia modifies NK 
cell phenotypic characteristics and functional responses, we examined frequencies, maturation 
and differentiation profiles, cytolytic activity and cytokine production of NK cells in 
Zulu/Xhosa individuals. A total of 39 individuals were assessed, of which 20 individuals were 
HIV-uninfected (DARC-null=12 and DARC-positive=8), and 19 individuals were HIV-1 
chronically infected (DARC-null=10 and DARC-positive=9) (Table: 3.1).  
All individuals but one were female, with a median age of 21, interquartile range (IQR) (19-
22) and 23 IQR (20-24) years in HIV negative and HIV infected patients respectively. Thirty 
nine individuals were assessed in this chapter, of which 22 (56%) were found to display the 
DARC-null trait. ANCs by HIV status did not differ significantly (p=0.08, data not shown). 
ANCs were significantly lower in DARC-null compared to DARC-positive individuals in both 
HIV negative (p=0.0004) and HIV-1 infected (p<0.0001) subjects. CD4 counts were 
significantly lower in HIV infected persons compared to HIV negative individuals (p=0.003, 
data not shown). Assessment by DARC status showed no differences in CD4 counts in HIV 
negative subjects (DARC-null = median CD4 count of 883 cells/mm3; DARC-positive = 
median CD4 count of 919 cells/mm3) or infected individuals (DARC-null = median CD4 count 
of 608 cells/mm3; DARC-positive = median CD4 count of 709 cells/mm3, Table 1). Further to 
this, no significant differences were observed in viral loads by DARC genotype in infected 
individuals (DARC-null = median viral load of 9300 RNA copies/ml; DARC-positive = 











Table 3.1 Clinical Characteristics of Study Participants used to assess NK cell Phenotype and 
Function 
 
Data is represented as median (IQR). *ANC median and IQR was calculated from 8 participants (ANC 
was not available for 1 participant). Abbreviations: DARC, Duffy Antigen Receptor for Chemokines; 
CC, DARC-null; TC/TT, DARC-positive; ANC, Absolute Neutrophil Count; IQR, Interquartile range; 
n, number; na, not applicable. Female participants: n=38, Male participants: n=1. Recruitment of HIV 
negative participants was from an all-female cohort, thus we had no male HIV negative participants. 
While both males and females were recruited in our HIV positive cohort, almost 83% of patients 
enrolled were females (183 of 221 patients). Samples were collected from individuals that were 
recruited / presented at the clinic during sample collection and met the criteria of not having initiated 
antiretroviral treatment. Thus while recruitment of HIV participants was unbiased, we did have unequal 













Viral Load, RNA copies/ml na na na 9300 (3275-23250) 7200 (750-70500) 0.9
HIV Negative HIV Positive
DARC CC (n=12) DARC TC/TT (n=8) p value DARC CC (n=10) DARC TC/TT (n=9) p value
Absolute Neutrophil Count, 10
3
 cells/mm
3 2.59 (2.13-3.39) 4.99 (4.48-5.73) 0.0004 1.75 (1.59-2.21) 4.34* (3.27-5.45)* <0.0001
CD4 count, cells/mm
3 883 (720-981) 919 (693-1066) 0.7 608 (487-759) 709 (533-845) 0.44
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3.3.1 Marked reduction of total NK cell counts in DARC-null HIV negative individuals   
To gain insight of the circulating NK cell population in the context of DARC-null persons, NK 
cell frequency and subset composition were assessed. NK cells were quantified based on the 
absence of CD3, CD14 and CD19 and the presence of CD56 and/or CD16 surface markers in 
total viable lymphocytes. NK cells were further defined by the relative expression of CD56 and 
CD16 into three subsets, namely CD56+CD16- (CD56 brights), CD56+CD16+ (CD56 dims) 
and CD56-CD16+ (CD56 negatives) subsets (Figure 3.1A).  
NK cells typically comprise 2-18% of total circulating lymphocytes (Vivier et al., 2008). As a 
proportion of lymphocytes, total NK cell frequencies observed here were comparable between 
HIV negative and HIV-1 chronically infected persons (median frequency of 4.76% and 3.39% 
respectively, Figure 3.1B). Subsequent analysis by DARC status indicated strikingly lower 
total NK cell frequencies in DARC-null HIV negative individuals compared to DARC-positive 
HIV negative individuals (p=0.006, Figure 3.1C). Total NK cell frequencies also strongly 
correlated with ANCs in HIV negative individuals (p=0.002, Figure 3.1E). Assessment of HIV-
infected individuals showed no differences in total NK cell frequencies when grouped by 
DARC status or ANCs (Figure 3.1D and Figure 3.1F).  
NK cells are phenotypically and functionally diverse and can be characterised as CD56 dim 
(CD56+CD16+), CD56 bright (CD56+CD16-) or CD56 negative cells (CD56-CD16+) 
(Caligiuri, 2008). In accordance with other studies our data indicated higher frequencies of the 
CD56 dim population in HIV negative individuals compared to HIV-infected donors (p=0.01, 
Figure 3.1G), and elevated CD56 negative NK cell subset counts were observed in the HIV-
infected group (p=0.005, Figure 3.1G). Although NK cell subset frequencies were not 
significantly different when stratified by DARC genotype irrespective of HIV status (Figure 
3.1H and Figure 3.1I), a weak trend was noted towards higher CD56 bright frequencies in 
DARC-null compared to DARC-positive HIV negative donors (p=0.08, Fig 3.1H).  In addition, 
a negative correlation was observed between CD56 bright frequencies and ANCs in HIV 
negative individuals (p=0.05, data no shown).  
Taken together, these data indicate that the DARC-null trait and lower ANCs are associated 
with reduced peripheral NK cell counts in HIV negative persons. Furthermore, higher CD56 
bright frequencies in HIV negative donors suggest that the NK cell subset composition in these 
DARC-null individuals may be skewed toward an immature profile. In contrast, the results 
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suggest that DARC-null neutropenia may have no effect on NK cell counts or subset 














Figure 3.1 Total NK cell and subset frequencies in HIV negative and HIV infected individuals 
(A) Representative gating strategy employed for the identification of total NK cells from lymphocytes 
using multi-parametric flow cytometry. Gating was on side scatter area (SSC-A) vs forward scatter area 
(FSC-A) to identify lymphocytes followed by exclusion of doublets by forward scatter height (FSC-H) 
vs FSC-A, and exclusion of non-viable cells, T-cells, B-cells and monocytes by use of viability dye and 
anti-CD3, anti-CD19 and anti-CD14 monoclonal antibodies. NK cells were identified as CD56 positive 
and/or CD16 positive cells. NK cells subsets were further identified from total NK cells as 
CD56+CD16- (CD56 brights), CD56+CD16+ (CD56 dims) or CD56-CD16+ (CD56 negatives). (B) 
NK cell frequency as a percentage of total viable lymphocytes in HIV negative and HIV infected 
individuals. NK cell frequency as a percentage of total viable lymphocytes in HIV negative (C) and 
HIV infected (D) individuals as grouped by DARC genotype. Bar graphs indicate medians extended to 
interquartile range (IQR) with whiskers. Correlations between NK cells as a percentage of total 
lymphocytes and absolute neutrophil counts (ANCs) are shown in HIV negative (E) and HIV infected 
(F) participants. (G) CD56 brights, CD56 dims and CD56 negatives subset frequencies as a percentage 
of total NK cells in HIV negative and HIV infected subjects. NK cell subset frequencies were further 
stratified by DARC genotype in HIV negative (H) and HIV-infected (I) donors. Dots indicate 
individual data points. Medians are indicated and extended to interquartile range (IQR) with whiskers. 
The p-values as indicated by ns refer to no significant differences.  Abbreviations: DARC, Duffy 
antigen receptor for chemokines; CC, DARC-null; TC/TT, DARC-positive; ANC, Absolute neutrophil 
count; IQR, interquartile range; ns, p-value not significant; r, Spearman rho.  
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3.3.2 Absence of DARC is associated with a less differentiated NK cell profile in HIV 
negative individuals 
NK cells are a heterogeneous population which proceed through several stages of development 
(Cooper et al., 2001). Our earlier finding showed that there was a trend of higher frequencies 
of the CD56 bright NK cell subset in HIV negative individuals with reduced ANCs. This result 
suggested a less mature NK cell phenotype in these individuals compared to persons with 
typical ANCs. We thus assessed the maturation/differentiation status of NK cells in these 
participants to determine whether distinct NK cell phenotypes were evident in HIV infection, 
and whether these varied by DARC genotype and ANCs in HIV negative and HIV-1 infected 
individuals. Two groups have proposed maturation/differentiation models for NK cells in 
previous reports (Beziat et al., 2010, Fu et al., 2011), while CD57 expression has been 
described as a marker for terminal differentiation (Nielsen et al., 2013).  
NK cells were assessed by the maturation model proposed by Fu and colleagues by measuring 
CD11b and CD27 expression (gating strategy depicted in Figure 3.2A) Assessment of HIV 
negative and HIV positive participants demonstrated comparable frequencies in three of the 
four subsets. The majority of NK cells were mature CD11b+CD27- irrespective of HIV status 
(median frequencies of 83.5% and 78.2% in HIV negative and infected individuals 
respectively, Figure 3.2B). HIV infected subjects demonstrated higher frequencies of the 
intermediate CD11b-CD27+ subset, although this subset comprised only a minor proportion of 
NK cells (median frequencies of 0.33% and 0.65% in HIV negative and HIV infected 
individuals respectively, Figure 3.2B).  
In HIV negative individuals, DARC-null individuals had lower (although not significant) 
frequencies of the mature CD11b+CD27- subset. Furthermore significantly higher proportions 
of intermediate CD11b+CD27+ and CD11b-CD27+ subsets (p=0.01 and p=0.05, respectively, 
Figure 3.2C) were observed in DARC-null individuals. These observations were not apparent 
in the HIV infected group where CD11b/CD27 subset frequencies were unaffected by DARC 
genotype or ANC (Figure 3.2D).  
Using both the relative expression of CD56 and the CD11b/CD27 model offers a more 
thorough assessment of NK cells in terms of maturation subsets. The data suggests that 
CD11/CD27 maturation subsets are not significantly altered during HIV infection. Assessment 
of CD11b/CD27 subsets by DARC genotype confirmed our previous result of higher 
frequencies of the immature CD56 bright NK cells in DARC-null HIV negative individuals. 
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The model used here also indicates higher levels of a less mature NK cell phenotype in the 
absence of DARC and may suggest that the DARC trait may contribute to full maturation of 
NK cells in HIV negative study subjects. Conversely, the data indicates that lack of DARC 






Figure 3.2 Frequency of CD11b/CD27 subsets in total NK cells 
(A) Representative gating strategy used to identify CD11b/CD27 subsets from total NK cells (as 
described in Figure 1A) using multi-parametric flow cytometry. FMO samples for CD11b and CD27 
were employed on total NK cells to adjust the quadrant gates to identify subpopulation combinations 
CD11b+CD27-; CD11b+CD27+; CD11b-CD27+ and CD11b-CD27- respectively. Here an example 
for both an HIV negative and HIV positive sample are shown after adjustment of the quadrant gating. 
(B) CD11b/CD27 subsets as a percentage of total NK cells in HIV negative and HIV infected 
participants. CD11b/CD27 subsets were further stratified by DARC genotype in HIV negative (C) and 
HIV infected (D) individuals. Dots indicate individual data points. Medians are indicated and extended 
to interquartile range (IQR) with whiskers. The p-values as indicated by ns refer to no significant 
differences. Abbreviations: DARC, Duffy antigen receptor for chemokines; CC, DARC-null; TC/TT, 
DARC-positive; ANC, Absolute neutrophil count; 11b+/27-, CD11b+CD27- NK cell subset; 
11b+/27+, CD11b+CD27+ NK cell subset; 11b-/27+, CD11b-CD27+ NK cell subset; 11b-/27-, 





Next to assess terminal differentiation, NK cells were evaluated using the KIR and NKG2A 
model described by Beziat et al. (2010). Frequency gating for KIR/NKG2A is shown in Figure 
3.3A. Lower frequencies of the cytolytic KIR+NKG2A+ subset were detected in HIV infected 
persons compared to uninfected individuals (p=0.05, Figure 3.3B). Moreover higher (although 
not significant) median frequencies of the hypo-responsive KIR-NKG2A- subset were noted 
in HIV infection (median frequencies of 13.3% and 36.8% in HIV negative and infected 
participants respectively, Figure 3.3B).  
HIV negative donors with the DARC-null trait displayed lower (although not significant) 
median frequencies of the cytotoxic KIR+NKG2A- subset (median frequencies 38.9% and 
48.3% in DARC-null and DARC-positive persons respectively, Figure 3.3C). Furthermore, a 
trend of higher frequencies of the hypo-responsive KIR-NKG2A- subset was observed in 
DARC-null individuals compared to DARC-positive individuals (p=0.06, Figure 3.3C) and 
ANCs were negatively associated with this KIR-NKG2A- subset (p=0.03, data not shown). No 
differences were indicated in any of the KIR/NKG2A subset frequencies in the HIV infected 
group when assessed by DARC genotype or ANC (Figure 3.3D). 
Taken together our data suggested a slightly less differentiated NK cell phenotype during HIV 
infection. In the context of DARC, absence of DARC was associated with higher proportions 
of less differentiated NK cells in HIV negative individuals, whilst this difference in NK cell 
phenotype by DARC genotype was lost in HIV infection.  
In summary, the two models used to assess NK cell phenotype together provide insight of the 
impact of HIV and DARC on NK cell maturation/differentiation. Both models confirm higher 
proportions of a less mature NK cell phenotype in HIV infected individuals. Assessment of 
HIV negative individuals indicated a less mature NK cell phenotype in those that lacked the 
DARC allele. In contrast, both models revealed no alteration in maturation/differentiation 












Figure 3.3 Expression of KIR/NKG2A subsets in total NK cells 
(A) Representative strategy employed for the identification of KIR and/or NKG2A expressing NK cells 
following ex vivo phenotype antibody staining using multi-parametric flow cytometry. Here an 
example HIV negative sample is shown after adjustment of the quadrant gating. (B) KIR/NKG2A 
subsets as a percentage of total NK cells in HIV negative and HIV infected individuals. KIR/NKG2A 
subsets further stratified by DARC genotype in HIV negative (C) and HIV infected (D) individuals. 
Dots indicate individual data points. Medians are indicated and extended to interquartile range (IQR) 
with whiskers. The p-values as indicated by ns refer to no significant differences. Abbreviations: 
DARC, Duffy antigen receptor for chemokines; CC, DARC-null; TC/TT, DARC-positive; ANC, 
Absolute neutrophil count; K+N-, KIR+NKG2A- NK cell subset; K+N+, KIR+NKG2A+ NK cell 
subset; K-N+, KIR-NKG2A+ NK cell subset; K-N-, KIR-NKG2A- NK cell subset; IQR, interquartile 






To further characterise differentiation status of NK cells, we quantified terminal differentiation 
using CD57 expression in these participants. HIV negative and HIV infected persons 
demonstrated comparable CD57 expression (Figure 3.4A). In HIV negative participants, CD57 
expression was considerably lower in DARC-null compared to DARC-positive individuals 
(p=0.02, Figure 3.4B), and CD57 expression strongly correlated with ANC (p=0.009, Figure 
3.4D). No differences in CD57 expression were observed in HIV-infected individuals based on 
DARC genotype or ANC (Figure 3.4C and Figure 3.4E). 
In summary, this data suggests similar frequencies of fully differentiated NK cells in HIV 
negative and infected persons. The results indicated lower proportions of fully differentiated 
NK cells in DARC-null compared to DARC-positive subjects that is mostly noted in HIV 
negative subjects and lost in chronic HIV-infection. Interestingly, these findings support our 
earlier maturation and differentiation data, showing that the DARC genotype may influence 





Figure 3.4 Expression of CD57 in total NK cells 
(A) CD57 expressing NK cells as a percentage of total NK cell count in HIV negative and HIV infected 
individuals. CD57 expressing NK cells as a percentage of total NK cells in HIV negative (B) and HIV 
infected (C) individuals grouped by DARC genotype. Boxes extend from the 25th to 75th percentile and 
medians are indicated by the horizontal line. Whiskers indicate minimum and maximum values. 
Correlations between CD57 expressing NK cells and absolute neutrophil counts (ANCs) are shown in 
HIV negative (D) and HIV infected (E) participants. Dots indicate individual data points. Medians are 
indicated and extended to interquartile range (IQR) with whiskers. The p-values as indicated by ns refer 
to no significant differences. Abbreviations: DARC, Duffy antigen receptor for chemokines; CC, 
DARC-null; TC/TT, DARC-positive; ANC, Absolute neutrophil count; IQR, interquartile range; ns, p-
value not significant.  
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3.3.3 DARC-null trait has no impact on NK cell activation status and functionality 
Next, we aimed to determine whether NK cell activation ex vivo differed in patients by HIV 
status and DARC genotype. We hypothesised that the absence of DARC would contribute to 
modified NK cell phenotype, specifically we expected higher NK cell activation status in 
DARC-null individuals independent of HIV status. To address this question, previously 
described markers of acute and chronic activation, CD69 and HLA-DR respectively, were 
quantified on NK cells. In addition, we examined cell exhaustion as quantified by the PD-1 
antigen which is commonly associated with NK cell dysfunction (Beldi-Ferchiou et al., 2016).  
HIV negative donors were found to have higher frequencies of CD69 expressing NK cells 
compared to HIV infected individuals (p=0.008, Figure 3.5A). Consistent with a previous 
report (Fogli et al., 2004), chronic NK cell activation as measured by HLA-DR was evident in 
HIV infected persons compared to HIV negative controls (p=0.02, Figure 3.5A). HIV-infected 
persons also showed a trend of higher expression of exhaustion marker PD-1 compared to 
uninfected individuals (p=0.09, Figure 3.5A). DARC-null HIV negative individuals displayed 
lower median frequencies of CD69 expressing NK cells compared to DARC-positive 
individuals (median frequencies of 10.8% and 17.78% respectively, Figure 3.5B). However, 
these differences in CD69 expression were not significant. Moreover, NK cell activation as 
measured by HLA-DR and PD-1 exhaustion marker was not affected by DARC genotype or 
ANCs in HIV negative persons (Figure 3.5B and Supplementary Figures 2A, 2C and 2E). 
Likewise, no differences in NK cell activation or exhaustion were displayed in HIV infected 
individuals by DARC status or ANCs (Figure 3.5C and Supplementary Figures 2B, 2D and 
2F). 
Taken together this data indicated variation in NK cell activation profiles during HIV infection. 
Furthermore, NK cells from HIV infected individuals exhibited a more exhausted phenotype 
in comparison to HIV negative individuals. Contrary to our hypothesis our data revealed that 
neither DARC genotype nor ANC had an impact on activation and exhaustion status of NK 
cells. 




Figure 3.5 Expression of CD69, HLA-DR and PD-1 in total NK cells 
(A) Expression of CD69, HLA-DR and PD-1 on total NK cells HIV negative and HIV infected 
individuals. Expression of CD69, HLA-DR and PD-1 on total NK cells in HIV negative (B) and HIV 
infected (C) individuals grouped by DARC genotype. Dots indicate individual data points. Medians are 
indicated and extended to interquartile range (IQR) with whiskers. The p-values as indicated by ns refer 
to no significant differences. Abbreviations: DARC, Duffy antigen receptor for chemokines; CC, 









The functional activity of NK cells is predominantly characterised by direct killing of 
infected/transformed cells through release of cytoplasmic granules. Cell surface expression of 
CD107 has been previously identified as a marker for granule release (degranulation) (Alter et 
al., 2004a). NK cells also produce various pro-inflammatory cytokines and chemokines that 
shape the adaptive immune response (Vivier et al., 2008). To investigate the impact of DARC 
genotype and ANC on NK cell functionality we assessed degranulation (CD107a) and cytokine 
production (TNF-α and IFN-ɣ) in PBMCs following overnight stimulation with MHC-devoid 
K562 target cell line and a combination of cytokines (IL-2, IL-15, IL-18).   
Our results indicated higher CD107a expression in total NK cells from HIV negative compared 
to HIV infected individuals (p=0.05, Figure 3.7A). Moreover, no differences in the proportion 
of TNF-α and IFN-ɣ secreting NK cells were evident in HIV infection (data not shown). Further 
assessment detected no differences in degranulation (Figures 3.7B-3.7D) or cytokine 






Figure 3. 6 Expression of CD107a in NK cells 
(A) CD107a expressing NK cells as a percentage of total NK cell count in HIV negative and HIV 
infected individuals. CD107a expressing NK cells as a percentage of total NK cells in HIV negative 
(B) and HIV infected (C) individuals grouped by DARC genotype. Boxes extend from the 25th to 75th 
percentile and medians are indicated by the horizontal line. Whiskers indicate minimum and maximum 
values. Correlations between percentage of NK cells expressing CD107a and absolute neutrophil count 
(ANC) in HIV negative (D) and HIV infected (E) individuals. Dots indicate individual data points. 
Medians are indicated and extended to interquartile range (IQR) with whiskers. The p-values as 
indicated by ns refer to no significant differences. Abbreviations: DARC, Duffy antigen receptor for 
chemokines; CC, DARC-null; TC/TT, DARC-positive; ANC, Absolute neutrophil count; IQR, 
interquartile range; ns, p-value not significant; r, Spearman rho.   
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Frequent and strong antibody mediated NK cell responses have been detected in chronic HIV-
1 infection following stimulation with HIV-1 peptides. These responses targeted Env antigens 
more than other HIV-1 proteins and were shown to be mediated by plasma (Thobakgale et al., 
2012). We thus sought to assess this HIV-specific NK cell activity in whole blood in our cohort 
following stimulation with HIV-1 gp120 and gp41 peptides, for gating strategies see 
Supplementary Figure 3.   
In line with previous findings we detected little or no response to HIV-1 antigens in uninfected 
individuals, whilst some (but not all) HIV-1 chronically infected individuals displayed 
measurable expression of CD107a and IFN-ɣ, particularly in response to gp120 (Figure 3.8A 
and Figure 3.9A). However, comparison of CD107a expression and IFN-ɣ production in HIV 
negative or HIV-1 chronically infected persons by DARC genotype showed no disparities 
(Figures 3.8B-3.8C and Figures 3.9B-3.9C), and further analyses exhibited no relationship 
between ANCs and CD107a (Supplementary Figure 4) or IFN-ɣ expression (Supplementary 
Figure 5) in response to gp120 or gp41 respectively. 
In summary, our data indicated lower degranulation activity in response to MHC devoid cell 
line during HIV infection. Plasma mediated NK cell degranulation was detected, particularly 
in response to HIV Env gp120 antigen in HIV infected individuals and this is consistent with 
previous data (Thobakgale et al., 2012). Investigation of NK cell activity in PBMCs and whole 
blood assays suggested that while the absence of DARC in HIV negative individuals may 
contribute to a less differentiated NK cell profile, this may not translate to measurable 
functional impairment of these cells. Similarly, DARC-null trait in HIV-1 infection did not 
affect functional activity.   
 
 





Figure 3. 7 CD107a expression following whole blood stimulation with HIV-1 peptides gp120 or 
gp41 
(A) Percentage of CD107a expressing NK cells in HIV negative and HIV infected individuals. 
Percentage of CD107a expressing NK cells further grouped by DARC genotype in HIV negative (B) 
and HIV infected (C) individuals. Dots indicate individual data points. Medians are indicated and 
extended to interquartile range (IQR) with whiskers. The p-values as indicated by ns refer to no 
significant differences. Abbreviations: DARC, Duffy antigen receptor for chemokines; CC, DARC-






Figure 3. 8 IFN-ɣ expression following whole blood stimulation with HIV-1 peptides gp120 or 
gp41 
(A) Percentage of IFN-ɣ expressing NK cells in HIV negative and HIV infected individuals. Percentage 
of IFN-ɣ expressing NK cells further grouped by DARC genotype in HIV negative (B) and HIV 
infected (C) individuals. Dots indicate individual data points. Medians are indicated and extended to 
interquartile range (IQR) with whiskers. The p-values as indicated by ns refer to no significant 
differences. Abbreviations: DARC, Duffy antigen receptor for chemokines; CC, DARC-null; TC/TT, 






DARC-null linked neutropenia is associated with increased HIV-1 infection risk in sub-
Saharan Africa, however its impact on HIV pathogenesis is unclear. Notably, NK cell priming 
and effector functionality are dependent on continual interactions with mature neutrophils in 
the bone marrow and peripheral compartments. Here we assessed possible modifications 
introduced by the absence of the DARC trait and low circulating neutrophils on peripheral NK 
cell differentiation, maturation and effector profiles in HIV negative and HIV-1 infected 
Zulu/Xhosa individuals from the Umlazi region in Durban, South Africa.  
The data presented here showed that 56% (22 out of 39) of our subjects possessed the DARC-
null polymorphism and these individuals exhibited reduced absolute ANCs independent of 
HIV status. Examination of NK cell dynamics in these individuals showed similar NK cell 
counts irrespective of HIV status. We also found that in HIV negative individuals, the DARC-
null trait was associated with reduced NK cell counts but elevated CD56 bright subset 
frequencies when compared to DARC-positive individuals. Determination of NK cell 
maturation and differentiation by CD11b/CD27, KIR/NKG2A and CD57 quantification 
revealed an immature phenotype with lower frequencies of terminally differentiated NK cells 
in DARC-null compared to DARC-positive HIV negative individuals. In contrast HIV-1 
infected individuals displayed NK cell subset redistribution marked by higher CD56 negative 
cells, marginally higher proportions of less mature NK cells, higher expression of markers of 
activation and exhaustion accompanied by lower cytolytic potential. However, these observed 
phenotypic and functional differences were lost upon stratification by DARC genotype.  
Numerous studies allude to the alteration of NK cell profiles associated with HIV infection, 
and there is general consensus that high viremic infection leads to reduction in total NK cell 
counts and CD56 subset redistribution (Alter et al., 2004b, Milush et al., 2013, Mikulak et al., 
2017). Here we did not detect a difference in NK cell counts between HIV negative and infected 
individuals. Many of our infected subjects had relatively low viral loads to those typically 
observed in chronic infection and could explain our observation of moderate reduction of NK 
cell counts. Nonetheless, in line with literature (Fauci et al., 2005, Mikulak et al., 2017), we 
observed diminished CD56 bright and CD56 dim subset proportions and substantially higher 
frequencies of the irregular CD56 negative subset in HIV infected individuals.  
NK cell differentiation is evaluated using receptor expression profiling models either alone or 
in combination (Bozzano et al., 2017). To gain a comprehensive understanding of the NK cell 
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maturation/differentiation profile in our study cohort, we assessed NK cells using two 
previously proposed NK cell models (CD11b/CD27 and KIR/NKG2A subset profiles) and 
CD57 expression. Previous reports suggest NK cell profile pattern variance in terms of 
differentiation status during HIV infection. HIV-infected individuals have been shown to 
exhibit a more mature/differentiated NK cell repertoire. Specifically, higher frequencies of 
terminally differentiated NK cells as measured by CD57 expression (Hong et al., 2010, 
Kaczmarek et al., 2017) and lower frequencies of NKG2A and CD27 expression (Kaczmarek 
et al., 2017), which are receptors associated with a less mature phenotype (Beziat et al., 2010, 
Fu et al., 2011). Overall, our data demonstrated comparable frequencies of fully differentiated 
NK cells in HIV negative and HIV infected subjects. This was indicated by similar proportions 
of CD57 positive NK cells irrespective of HIV status. Furthermore, assessment by 
maturation/differentiation models showed no differences in the frequencies of the fully mature 
CD11b+CD27+ and KIR+NKG2A- NK cell subsets. Although we did observe higher 
frequencies of the intermediate CD11b-CD27+ NK cell subset in HIV infected individuals, this 
CD11b/CD27 subset was only a minor subset in all participants (>5%) while the remaining 
CD11b/CD27 subsets showed no differences by HIV status. The only other difference noted 
during HIV infection was a reduction of the intermediate KIR+NKG2A+ NK cell subset. This 
observation of lower proportions of the KIR+NKG2A+ subset during HIV infection has been 
previously described (Peppa et al., 2018), but in contrast to a shift toward a mature or terminally 
differentiated NK cell phenotype (Peppa et al., 2018), we noted here that KIR+NKG2A+ 
reduction was accompanied with higher (although not significant) proportions of the hypo-
responsive KIR-NKG2A- NK cell subset. Dissimilarities between our and past observations 
could be due to variations in NK cell analysis. Most studies have reported on CD56 positive 
NK cells whilst our analyses comprised total NK cells including the dysfunctional CD56 
negative subset. We have previously described the phenotypic characteristics of the CD56 
negative subset, and we noted reduced CD57 expression on NK cells of this subset in 
chronically infected individuals (Zulu et al., 2017). Thus phenotypic alterations within this 
subset could account for differences observed between our observations in this cohort 
compared to previous reports.   
Consistent with previous reports (Kuri-Cervantes et al., 2014, Beldi-Ferchiou et al., 2016), we 
show here higher NK cell exhaustion and activation (HLA-DR expression) in chronic HIV-1 
infected subjects. Elevated frequencies of activated and exhausted NK cells have been 
associated with disease progression to AIDS (Kuri-Cervantes et al., 2014, Mikulak et al., 2017). 
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Although HIV infection is associated with NK cell activation, there are contrasting reports on 
the effect of HIV viremia on NK cell functional responses and these mechanisms seemingly 
depend on disease state (Mikulak et al., 2017). Previous studies have reported that NK cells 
exhibit higher levels of cytolytic potential (as measured by degranulation marker CD107a) and 
elevated secretion of antiviral cytokines during chronic disease (Alter et al., 2004b, Wong et 
al., 2010). Following in vitro culturing with MHC devoid cell line, NK cell degranulation 
tended to correlate with patient viral load (Wong et al., 2010). Inconsistent with these reports, 
chronic HIV-1 infection in our study setting was associated with lower degranulation capacity, 
and production of cytokines (TNF-α and IFN-ɣ) were not different between HIV negative and 
HIV-infected individuals. Possible reasons including lower viral loads in our study group and 
an accumulation of the irregular and dysfunctional CD56 negative subset in HIV infected 
individuals could drive inferior cytolytic NK cell activity (Fauci et al., 2005, Zulu et al., 2017) 
in this group compared to HIV negative donors.  
Various populations have been assessed for frequency of the DARC-null polymorphism 
(Grann et al., 2008, He et al., 2008, Hodgson et al., 2014). Noteworthy, are the reports of high 
risk South African woman and HIV-1 chronically infected individuals based in Durban where 
64.7% (92 of 142) and 64.8% (247 of 381) of patients were described to be homozygous for 
the DARC-null allele respectively (Julg et al., 2009, Ramsuran et al., 2011). Despite our small 
sample size in this pilot study, we also demonstrated a high DARC-null distribution of over 
50% in our African cohort. In addition, we also observed here that the DARC-null genotype 
significantly associated with reduced neutrophil counts in individuals regardless of HIV status, 
consistent with previous literature that reported the DARC-null polymorphism as the genetic 
determinant of ethnic neutropenia in persons of African descent (Reich et al., 2009). 
There are limited reports on the effect of neutrophil deficiency on NK cell phenotype and 
effector function (Sporri et al., 2008, Jaeger et al., 2012, Ueda et al., 2016) and to our 
knowledge this is the first to explore this mechanism in African individuals in a high HIV-1 
incidence setting. Interestingly, most of the observations made in the context of HIV infection 
above were not associated with absence of the DARC trait. Despite observations of lower NK 
cell frequencies with a less differentiated phenotype in DARC-null HIV negative individuals, 
the DARC-null trait was not associated with other NK cell profile modifications.  
Jaeger et al. (2012) previously described comparable peripheral NK cell counts in controls and 
patients with neutropenia, such as severe congenital neutropenia (SCN) and autoimmune 
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neutropenia (AIN). It was observed by the authors in parallel neutrophil deficient mouse 
models that increased cell death sensitivity was counterbalanced with hyper-proliferative 
capacity, resulting in unaltered NK cell frequencies (Jaeger et al., 2012). In contrast to this 
report, we observed reduced NK cell counts in HIV negative DARC-null individuals with 
lower ANCs. Our findings may suggest modified peripheral NK cell homeostasis in DARC-
null HIV negative individuals. Thus the important question of whether NK survival and/or 
proliferation is affected by the DARC-null allele is addressed in detail in Chapter 4.  
Furthermore, it has been shown that neutropenic individuals exhibit higher frequencies of less 
mature CD56 bright cells coupled with impaired cell reactivity in terms of IFN-ɣ release in 
response to the K562 cell line (Jaeger et al., 2012). Similarly, we observed that the DARC-null 
trait was associated with higher proportions of the CD56 bright subset and a less mature NK 
cell phenotype as measured by CD11b/CD27 profiling in HIV negative individuals. DARC 
Further, quantification of KIR/NKG2A and CD57 expression were indicative of fewer 
terminally differentiated NK cells in HIV negative DARC-null individuals with lower ANCs 
compared to DARC-positive subjects. These findings of a less matured/differentiated NK cell 
profile were suggestive of hypo-responsive NK cells in HIV negative DARC-null individuals.  
Surprisingly, despite our findings of a less differentiated NK cell profile in DARC-null HIV 
negative individuals, our functional data demonstrated that cytolytic potential and cytokine 
production were unaffected by the DARC-null trait and no differences were detected by 
activation and exhaustion status ex vivo. Hypo-responsive KIR-NKG2A- cells can be re-
educated and become fully functional following specific cytokine stimulation (Beziat et al., 
2010). This supports the notion that NK cells are not halted at a less differentiated state, and 
following appropriate stimulus are able to further differentiate and gain functional capabilities. 
While HIV negative DARC-null individuals exhibited a less differentiated NK cell phenotype 
ex vivo, it is possible that in vitro stimulation allowed for further differentiation and increased 
cytolytic activity in these cells, and may explain our observation of no differences in NK cell 
cytotoxic mechanisms by DARC status.     
NK cell variations that were detected between HIV negative DARC-null and DARC-positive 
individuals were not observed in HIV-1 infected individuals, implying that DARC-null trait 
does not influence NK cell responses in chronic infection. It is plausible that any advantage 
that DARC-positive individuals are predisposed to is masked by the general leukopenia 
commonly detected in chronic disease (De Santis et al., 2011). Alternatively, these advantages 
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could be lost in untreated chronic infection. We were unable to determine the time of infection 
in these individuals, and without longitudinal samples pre and post infection, we could not 
determine the stage during infection when such advantages are lost. Thus the current cohort 
could not fully assess the impact of DARC-null genotype on NK cells and whether this trait is 
beneficial or detrimental in chronic HIV-1 infection.  
Since this was intended to be a pilot study, limitations include a small sample size. Also, 
although testing negative for antiretroviral drugs, some of our chronically infected patients had 
relatively lower viral loads (<1000 RNA copies/ml) than previously described chronic patients. 
Many of our DARC-null subjects were not neutropenic as defined by the ANC threshold of 
<1500 cells/mm3 at the time of sampling, and since these patients were not followed 
longitudinally we cannot conclude which patients were neutropenic. Moreover, the HIV 
universal test and treat policy that was implemented during our study, made additional sample 
collection from chronically infected treatment naïve subjects increasingly challenging. 
To our knowledge no previous studies have assessed the impact of DARC-null polymorphism 
and low neutrophil counts on NK phenotypic characteristics and functionality in an HIV-1 
setting. Taken together, our findings suggest that in HIV negative individuals, DARC-null 
neutropenia results in reduced NK cell frequencies. Reduced cell counts may result in 
dampened NK cell responses and may indicate a greater risk to viral infections in these 
individuals (Orange, 2006, Orange and Ballas, 2006). Although NK cells in these individuals 
are seemingly less mature, it is encouraging that NK cells are not functionally impaired as seen 
in patients with severe neutropenia. The DARC-null trait and lower ANCs is considered a 
milder condition compared to other neutrophil deficiencies, and thus our findings support 
reports that the effect of DARC-null genotype is not as pronounced as that seen in severe 
neutropenia (Paz et al., 2011).  
In conclusion the mechanism proposed by Thobakgale and Ndung’u (2014) of differential NK 
cell priming and function in DARC-null populations does not fully elucidate the association of 
DARC-null neutropenia with HIV-1 risk or disease progression. Only disparities in NK cell 
count and priming was noted in HIV negative donors, whilst no NK cell functional impairment 
was observed by DARC status independent of HIV status, indicating that NK cell priming is 
not altered in the presence of the DARC-null polymorphism and lower ANCs. Nevertheless, 
the mechanism proposed by Thobakgale and Ndung’u includes impairment of several cell types 
that are known to interact with neutrophils (Thobakgale and Ndung'u, 2014). Here we only 
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assessed this model with respect to NK cell phenotype and function, thus evaluation of other 


























CHAPTER 4: NK CELL SURVIVAL AND PROLIFERATION 

















Natural Killer (NK) cells are bone marrow-derived leukocytes that differentiate from lymphoid 
progenitors. Cell development occurs primarily in the bone marrow, although NK cell 
maturation has been reported in secondary lymphoid organs, before eventual migration to the 
peripheral tissues (Andrews and Smyth, 2010, Bernardini et al., 2013). NK cells are critical to 
the early detection of infection, transformation or stress through continuous surveillance of 
host tissue well before the development of adaptive immune responses.  
The role of NK cells during infectious diseases is most notable in their defence against viral 
pathogens, particularly those viruses that are elusive to T-cell mediated activity. Interestingly, 
the impact of NK cells in such instances is highlighted by the evolution of certain viruses to 
employ strategies that evade specific NK cell mechanisms (Lisnic et al., 2010, Jost and Altfeld, 
2012). The importance of NK cells in health and disease is further emphasised in individuals 
that are lacking in NK cell number and/or function. Deficiency of peripheral NK cells are 
implicated in susceptibility to viral infections that result in severe clinical outcomes (Orange, 
2006, Orange, 2013). 
Alterations to NK cell homeostasis is key to understanding NK cell deficiency and hypo-
responsiveness. NK cells typically constitute 2-18% of the total circulating lymphocyte pool 
with a turnover of approximately 2 weeks. Homeostatic maintenance of circulating NK cell 
numbers is influenced by the generation of new cells within the bone marrow and the survival 
and proliferation of existing cells in circulation. Several factors tightly regulate these processes 
including cell-cell interactions and cytokine signals that are transmitted through cell surface 
receptors (Ranson et al., 2003, Sun and Lanier, 2011). Jaeger et al. (2012) described a 
regulatory role for neutrophils that ensures NK cell terminal maturation. Dissection of a 
neutrophil deficient mouse phenotype suggested impaired NK cell homeostasis, as displayed 
by poor survival and hyper-proliferation, which was associated with hypo-responsiveness in 
these cells. The essential role of neutrophils in NK cell dynamics are seemingly conserved 
across species (Jaeger et al., 2012) and thus necessitates the examination of NK cell biology in 
neutropenia-associated conditions in humans.     
Most human neutrophil disorders in cell count and function are rare (Hsieh et al., 2010). 
Dissimilarly, ethnic neutropenia is extremely common on the African continent. A single 
nucleotide polymorphism (SNP) in the Duffy Antigen Receptor for Chemokines (DARC) 
promoter region results in selective loss of DARC on erythrocytes. While this DARC-null 
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polymorphism coincides with a phenotype that serves as a resistant factor to invasion of certain 
malarial parasites, it is also the causative genetic factor of ethnic neutropenia (Reich et al., 
2009, Howes et al., 2011). DARC-null linked neutropenia overlaps strikingly with global HIV 
prevalence and has been associated with a 3-fold higher risk of HIV acquisition (Ramsuran et 
al., 2011).  
The implications of DARC-null neutropenia on the NK cell compartment have been 
hypothesised (Thobakgale and Ndung'u, 2014), where low neutrophils are proposed to have a 
detrimental effect on NK cell biological processes important in optimal clearance of pathogens. 
Here we examined NK cell homeostasis in DARC-null individuals in a population with high 
HIV prevalence. Specifically we assessed NK cell survival and proliferation in cryopreserved 
peripheral mononuclear cells (PBMCs) from these individuals. We hypothesised that NK 
survival and proliferation would be impaired in the presence of the DARC-null trait and lower 


















4.2.1 Participant Recruitment 
HIV negative participants were recruited from the Females Rising through Education, Support 
and Health (FRESH) cohort and HIV-1 subtype C chronically infected treatment naïve 
participants were recruited from the HIV Pathogenesis Programme (HPP) Acute Infection 
Cohort as previously described in Chapter 2. In this analysis, a total of 36 individuals sub-
divided into HIV negative donors (n=19) and HIV-1 chronically infected individuals (n=17) 
were assessed. These individuals were further stratified by DARC status.  
 
4.2.2 ANCs, CD4 Counts and Viral Load 
Blood for full blood counts, CD4+ T cell count measurement and viral load quantification was 
collected in Ethylenediaminetetraacetic acid (EDTA) anticoagulated vacutainer tubes (Becton 
Dickinson (BD), Franklin Lakes, New Jersey, USA). ANCs were enumerated by full blood 
count using the automated XN 1000 Haematology Analyser (Sysmex, Kobe, Hyōgo, Japan). 
CD4 counts were measured using BD Trucount and analysed on a four-parameter FACS 
Calibur flow cytometer (BD). Viral loads were determined using the NucliSENS EasyQ HIV-
1 v2.0 kit with a detection limit of 20 copies/ml (BioMérieux, Marcy-l'Étoile, France).   
 
4.2.3 Quantification of Antiretroviral (ARV) Drug in Plasma  
This study aimed to recruit HIV-1 chronically infected, treatment naïve individuals. ARV 
therapy usage in chronically infected patients was self-reported. Certain subjects maintained 
viral loads below 1000 RNA copies/ml at the time of assessment. To rule out ARV drug use, 
plasma samples were collected from these study participants and screened for ARV drugs using 
a quantitative liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) 
method. The method screened for nine ARVs, namely Emtracitabine, Tenofovir, Lopinavir, 
Ritonavir, Nevirapine, Abacavir, Lamivudine, Zidovudine and Efavirenz. A plasma sample 
volume of 50 µl was processed using a protein precipitation method, ARV drug analytes were 
chromatographically separated on a Agilent Zorbax Eclipse Plus C18 (2.1 x 50mm, 3.5 µm) 
HPLC column (Agilent Technologies, Santa Clara, California, USA), detected using an AB 
Sciex 5500 triple quadrupole mass spectrometer (Sciex, Framingham, Massachusetts, USA) 
and quantitated using Analyst® 1.6.2 software (Sciex). 
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4.2.4 DARC Genotyping 
DARC -46T   C  (rs2814778) SNP genotyping was performed by TaqMan allelic 
discrimination assays which has been previously verified by direct sequence analysis (Julg et 
al., 2009). Briefly, genomic DNA was isolated from stored buffy coats using the QIAamp DNA 
Blood Midi kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. DNA 
concentration was standardised at 50ng/µl with polymerase chain reaction (PCR) grade water. 
A cocktail containing Taqman Genotyping master mix (Life Technologies, Carlsbad, 
California, USA) and predesigned probes for the DARC gene (SNP ID: rs2814778, Applied 
Biosystems, Foster City, California, USA) was used to amplify target sequence in 50ng 
genomic DNA by real time PCR (RT-PCR) in the LightCycler 480 (Roche, Basel, Switzerland) 
according to the manufacturer’s protocol.    
 
4.2.5 PBMC Isolation, Cryopreservation and Thawing  
Blood collected in sodium heparin BD Vacutainers (BD) from each participant was processed 
within 4 hours of collection. Whole blood was used for lymphocyte fraction preparation by 
density centrifugation on a Histopaque-1119 cushion (Sigma-Aldrich, St. Louis, Missouri, 
USA) at 800 x g for 20 minutes, low brakes as previously described (Brinkmann et al., 2010).  
Cell counts were determined by 1:5 dilution with Trypan Blue Stain (Gibco) counted using a 
haemocytometer under a light microscope. Cells were prepared for cryopreservation by 
refrigerated centrifugation and re-suspended at a final concentration of 10 million cells/ml in 
ice cold freezing solution containing 1:10 Dimethyl Sulfoxide (DMSO) (Merck Millipore, 
Billerica, Massachusetts, USA) and heated inactivated Foetal Bovine Serum (FBS, Gibco). 
The frozen samples were stored in 2ml cryogenic vials in a liquid nitrogen Biorack ultralow 
freezer for long term storage and subsequently batched for NK cell survival and proliferation 
assays.  
Cryopreserved cells were rapidly thawed, washed twice in pre-warmed R10 medium (RPMI 
Medium 1640 (Gibco) containing 10% gamma irradiated, heat inactivated FBS, 1% L-
Glutamine, 1% Penicillin Streptomycin and 1% Hepes buffer 1M (all from Lonza, Basel, 
Basel-Stadt, Switzerland) at 500 x g for 8 minutes at room temperature. Cells were rested in 
R10 medium in a 37°C, 5% CO2 incubator for at least 2 hours. Sample viability and cell counts 
were determined by trypan blue exclusion, and cells were re-suspended at 10 million cells/mL 
in R10 medium for subsequent assays. 
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4.2.6 NK cell Survival 
NK cells were assessed for survival by plating one million PBMCs in 96-well plates with either 
R10 medium alone or in the presence K562 cell line (effector:target ratio of 10:1) and 10ng 
each of Recombinant Human Interleukin (IL)-2, Recombinant Human IL-15 (both from R&D 
Systems, Minneapolis, Minnesota, USA), and Recombinant Human IL-18 (Medical & 
Biological Laboratories, Japan) and incubated for 18 hours at 37°C, 5% CO2.  
Following overnight culture, cells were stained for surface markers with antibody cocktail 
containing anti-CD3 Allophycocyanin (APC, clone: UCHT1), anti-CD56 Alexa-Fluor-700 
(clone: B159), anti-CD16 APC-Cy7 (clone: 3G8), anti-CD14 V500 (clone: M5E2) and anti-
CD19 V500 (clone: HIB19, all from BD Biosciences). Fluorescein isothiocyanate (FITC) 
conjugated Annexin V and propidium iodide (PI) staining solution were included in the 
antibody cocktail in the presence Annexin V binding buffer (all from BD Biosciences) to detect 
for cell death via apoptosis and necrosis respectively. Cells were stained for 20 minutes at room 
temperature in the dark, washed in 2% FCS in Dulbecco's phosphate-buffered saline (dPBS) 
and centrifuged at 850 x g for 6 minutes. The supernatant was discarded and fixation Medium 
A (Invitrogen, Carlsbad, California, USA) added which ensured that the morphological 
characteristics of the cells remained intact. Cells were stored at 4°C until sample acquisition.  
  
4.2.7 NK cell Proliferation 
To assess for the replicative capacity of NK cells, PBMCs were washed once with DPBS to 
remove traces of FSC and centrifuged at 500 x g for 6 minutes. Pelleted PMBCs were stained 
with carboxyfluorescein succinimidyl ester (CFSE) dye (Invitrogen) for 7 minutes at 37°C with 
5% CO2. Cells were immediately washed with ice cold FSC to stop the reaction and centrifuged 
at 500 x g for 6 minutes. Cells were then washed once with R10 medium, centrifuged at 500 x 
g for 6 minutes and resuspended at 10 million cells/ml in R10 medium. One million PBMCs 
were plated in 96-well plates with either R10 medium alone or in the presence of cytokine 
mixture containing 10ng each of Recombinant Human Interleukin (IL)-2, Recombinant 
Human IL-15 (both from R&D Systems, Minneapolis, Minnesota, USA), and Recombinant 
Human IL-18 (Medical & Biological Laboratories, Japan) and incubated for 5 days at 37°C 
with 5% CO2. R10 medium was changed on day 3 by removing 100µl supernatant from each 
well without disturbing the cell pellet and replaced with fresh R10 medium.  
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 On day 5 cells were stained with LIVE/DEAD Fixable Aqua Dead Cell Stain (Invitrogen) to 
exclude dead cells, followed by cell surface staining with monoclonal antibodies: anti-CD3 
APC (clone:UCHT1), Alexa-Fluor-700 conjugated anti-CD56 (clone:B159) and anti-CD16 
APC-Cy7 (clone:3G8), anti-CD14 BV650 (clone: M5E2, Biolegend), anti-CD19 BV650 
(clone: HIB19, Biolegend) before fixing with Medium A. Staining / fixation incubations were 
for 20 minutes at room temperature in the dark, followed by washing with Dulbecco's 
phosphate-buffered saline (dPBS) and centrifugation at 850 x g for 6 minutes. Cells were stored 
at 4°C until sample acquisition.  
 
4.2.8 Sample Acquisition and Statistical Analysis 
Samples were acquired on an LSR II flow cytometer, recording at least 250 000 events per 
sample. FlowJo Software Version 9 (TreeStar, Inc., Ashland, Oregon, USA) was used for 
sample analysis. For survival assays, fluorescence minus one (FMOs) for Annexin V and PI 
were prepared with each experiment to exclude background fluorescence in the gating 
strategies. For proliferation assays, unstimulated cells were used to subtract background from 
the stimulated cells for each patient sample. Differences between studied groups was examined 
by Mann-Whitney U test using GraphPad Prism Version 5 software (GraphPad software Inc., 














To gain insight into the possible impact of the DARC-null trait on NK cell homeostasis, we 
examined the survival and proliferation of NK cells within our participant cohort. A total of 36 
individuals were assessed, of which 19 individuals were HIV-uninfected (DARC-null=11 and 
DARC-positive=8), and 17 subjects were HIV-1 chronically infected (DARC-null=9 and 
DARC-positive=8) (Table 4.1).  
Thirty five of thirty six subjects were female with a median age of 21 (IQR 19-22) and 23 (IQR 
20-24) years in HIV negative and HIV infected patients respectively. Twenty participants 
(55.6%) were negative for the DARC allele. DARC-null individuals had significantly lower 
absolute neutrophil counts (ANCs) compared to DARC-positive individuals in both HIV 
negative and HIV-1 infected (p=0.0006 and p=0.0003 respectively, data not shown) subjects. 
CD4 counts were significantly lower in HIV infected persons compared to HIV negative 
individuals (median CD4 count of 653 and 892 cells/mm3 respectively, p=0.003).  
Assessment by DARC status, showed no differences in CD4 counts in HIV negative subjects 
(DARC-null = median CD4 count of 892 cells/mm3; DARC-positive = median CD4 count of 
919 cells/mm3) or infected individuals (DARC-null = median CD4 count of 563 cells/mm3; 
DARC-positive = median CD4 count of 743 cells/mm3, Table 4.1). Further to this, no 
significant differences were observed in viral loads by DARC genotype in infected individuals 
(DARC-null = median viral load of 9500 RNA copies/ml; DARC-positive = median viral load 












Table 4.1 Clinical Characteristics of Study Participants used to assess NK cell Survival and 
Proliferation 
 
Data is represented as median (IQR). *ANC median and IQR was calculated from 7 participants (ANC 
was not available for 1 participant). Abbreviations: DARC, Duffy Antigen Receptor for Chemokines; 
CC, DARC-null; TC/TT, DARC-positive; ANC, Absolute Neutrophil Count; IQR, Interquartile range; 















3 892 (770-984) 919 (693-1066) 0.8 563 (487-729) 743 (607-848) 0.14
Viral Load, RNA copies/ml na na na 9500 (2650-30500) 11150 (700-95250) 0.96
HIV Negative HIV Positive
DARC CC (n=11) DARC TC/TT (n=8) p value DARC CC (n=9) DARC TC/TT (n=8) p value
Absolute Neutrophil Count, 10
3
 cells/mm
3 2.80 (2.11-3.52) 4.99 (4.48-5.73) 0.0006 1.77 (1.52-2.25) 4.03* (3.23-4.90)* p=0.0003
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4.3.1 Reduced survival of activated NK cells in HIV infected individuals with DARC-
null genotype 
Cell death can proceed either through the apoptotic or necrotic pathways. Cellular activation 
can increase cell sensitivity to apoptosis (programmed cell death) and activation-induced cell 
death (Childs and Berg, 2013). We used a combination of Annexin V and propidium iodide 
staining to detect NK cells undergoing either apoptosis or necrosis following activation with 
K562 cell line and cytokines. NK cells that survived overnight stimulation were negative for 
Annexin V and propidium iodide staining (Figure 4.1A).       
We observed similar median frequencies of NK cell survival of 96% in HIV negative and 95% 
in HIV-infected individuals when cells were left untreated (data not shown). Median 
frequencies of total NK cell survival were significantly higher in HIV negative (87%) 
compared to HIV infected individuals (80%) following cellular activation with K562 cell line 
and cytokines (p=0.02, Figure 4.1B). HIV negative individuals grouped by DARC trait showed 
no differences in the frequency of NK cell survival under untreated or stimulated conditions 
(Figure 4.1C). Ex vivo assessment of NK cell survival showed no differences by DARC status 
in HIV chronically infected persons. However, a trend of lower NK cell survival was noted in 
activated NK cells from DARC-null individuals after stimulation with K562 cell line and 
cytokines compared to DARC-positive participants (Figure 4.1D; p=0.09). Further 
examination showed no association between NK cell survival and ANCs or DARC genotype 
in either HIV negative or HIV infected individuals (Figure 4.1E).   
Together the data suggests that NK cell survival is unaffected by DARC status in HIV negative 
individuals. However, survival of activated NK cells is reduced during HIV infection, and this 
is more evident in DARC-null individuals where there tended to be lower NK cell survival 
compared to DARC-positive persons. 











Figure 4.1 Total NK cell survival in HIV negative and HIV infected donors 
Representative gating strategy employed to assess NK cell survival using multi-parametric flow 
cytometry. Initial gating was on side scatter area (SSC-A) vs forward scatter area (FSC-A) to identify 
lymphocytes followed by exclusion of doublets by forward scatter height (FSC-H) vs FSC-A, and 
exclusion of T-cells, B-cells and monocytes using anti-CD3, anti-CD19 and anti-CD14 monoclonal 
antibodies. Total NK cells were identified as CD56 positive and/or CD16 positive cells. Survival was 
assessed by staining with Annexin V (Ann) and Propidium Iodide (PI). FMO samples for Ann and PI 
were used to adjust the quadrant gates to identify staining combinations Ann+PI-; Ann+PI+; Ann-PI+ 
and Ann-PI- from total NK cells. The gating strategy was applied to unstimulated and K562+cytokine 
stimulated samples for each participant. NK cells that survived were identified as Ann-PI-. (B) 
Percentage of NK cell survival for unstimulated and K562+cytokine stimulated cells in HIV negative 
and HIV infected individuals. Participants were further stratified to show percentage of NK survival 
for unstimulated and K562+cytokine stimulated cells in HIV negative (C) and HIV infected (D) 
individuals by DARC trait. Dots indicate individual data points. Medians are indicated and extended to 
interquartile range (IQR) with whiskers. The p-values as indicated by ns refer to no significant 
differences by HIV or DARC status. (E) Correlations between absolute neutrophil counts (ANCs) and 
NK survival for unstimulated and K562+cytokine stimulated cells in HIV negative and HIV infected 
individuals. Dots indicate individual data points. Abbreviations: DARC, Duffy antigen receptor for 
chemokines; CC, DARC-null; TC/TT, DARC-positive; ANC, Absolute Neutrophil Count; Ann, 




4.3.2 No differences in NK cell proliferation by HIV or DARC status in studied 
individuals 
Peripheral NK cell proliferation levels are relatively low at physiological state. Upregulation 
of pro-proliferative cytokines that utilise the common gamma chain drives NK cell expansion. 
To investigate NK cell proliferation we employed CFSE labelling of PMBCs to track NK cell 
divisions in response to cytokines that are known facilitate NK cell activation and generation. 
Antigen-induced cellular proliferation is initiated during HIV infection. We thus hypothesised 
that HIV infected individuals in our cohort would have higher levels of dividing NK cells. 
NK cell proliferation due to activation was measured by subtracting CFSE divisions in 
unstimulated from CFSE divisions in cytokine stimulated NK cells (Figure 4.2A). In contrast 
to our hypothesis, we observed similar levels of NK cell expansion following cytokine 
induction in HIV negative and HIV infected subjects where median NK cell proliferation 
frequencies were 50% and 45% respectively (Figure 4.2B). As verification of our data we 
assessed NK cell CFSE divisions between HIV negative and HIV infected individuals in 
unstimulated cultures alone and stimulated cultures without subtraction of unstimulated 
divisions. Consistent with our initial observation, we did not detect differences between HIV 
negative and HIV infected individuals in either case. Median NK cell proliferation frequencies 
were 16% and 14% in HIV negative and HIV infected individuals for unstimulated cultures, 
and 69% and 58% in HIV negative and HIV infected individuals in stimulated cultures (data 
not shown). Furthermore, we detected no differences in NK cell proliferation by DARC trait 
or ANCs in both HIV negative (Figure 4.2C and Figure 4.2E) and chronically infected subjects 
(Figure 4.2D and Figure 4.2F).     
Together our results shows no difference in NK cell proliferation by HIV status. Furthermore 
the data indicates that DARC status and ANC levels do not impact on NK cell proliferation in 









Figure 4.2 Total NK cell proliferation in HIV negative and HIV infected donors 
Representative gating strategy employed to assess NK cell proliferation using multi-parametric flow 
cytometry. Gating on side scatter area (SSC-A) vs forward scatter area (FSC-A) to identify all cells was 
followed by exclusion of non-viable cells using viability dye. T-cells, B-cells and monocytes were 
excluded and total NK cells identified as described in Figure 1 above. Proliferation was assessed on 
CFSE stained NK cells where divided cells are identified as cells with lower CFSE fluorescence 
compared to undivided cells. Divided cells in unstimulated samples were subtracted from divided cells 
in K562+cytokine stimulated samples for each participant. (B) Percentage of NK cells divisions in HIV 
negative and HIV infected individuals. Participants were further stratified to show percentage of NK 
cells divided in HIV negative (C) and HIV infected (D) individuals by DARC trait. Dots indicate 
individual data points. Medians are indicated and extended to interquartile range (IQR) with whiskers. 
The p-values as indicated by ns refer to no significant differences by HIV or DARC status. (E) 
Correlations between absolute neutrophil counts (ANCs) and NK cells divisions in HIV negative and 
HIV infected individuals. Dots indicate individual data points. Abbreviations: DARC, Duffy antigen 
receptor for chemokines; CC, DARC-null; TC/TT, DARC-positive; ANC, Absolute Neutrophil Count; 





Our previous data as part of the current investigation showed that the DARC-null 
polymorphism and lower ANCs were associated with lower peripheral NK cell numbers in 
HIV negative individuals (Chapter 3). Reduced NK cell count and/or dysfunction can arise 
from modulation of NK cell homeostatic activities. In an effort to explain our previous 
findings, we here investigated the possible influence of the DARC-null trait on NK cell 
survival and proliferation in HIV negative and HIV-1 infected persons in a DARC prevalent 
population.  
We observed no differences in spontaneous (unstimulated) NK cell survival by HIV status. 
Conversely, activated NK cells from HIV infected subjects exhibited lower survival compared 
to NK cells from HIV negative individuals. Moreover, examination by DARC genotype 
indicated that absence of DARC may be a contributing factor in reduced NK cell survival 
following activation in HIV infection but not in HIV negative individuals. Further assessment 
of this cohort showed that NK cell proliferation did not differ by HIV status or DARC trait.     
The pathological changes in NK cell homeostatic activities during chronic HIV infection have 
been previously described (Mikulak et al., 2017). Past studies have indicated progressive loss 
of NK cells through programmed cell death during HIV infection (Douglas et al., 2001, Meier 
et al., 2005, Kottilil et al., 2007) where NK cell death susceptibility has been attributed to the 
upregulation of genes that promote apoptosis as a consequence of HIV envelope protein 
exposure (Kottilil et al., 2006, Kottilil et al., 2007). In vitro assays revealed that activation-
induced apoptosis contributes mostly to this accelerated cell death in viremic individuals, 
whereas spontaneous NK cell death accounted for less than 5% ex vivo irrespective of HIV 
status (Kottilil et al., 2007). Here we report similar findings in our participant cohort. We 
observed minimal spontaneous cell death in HIV negative and chronically infected individuals. 
Furthermore, upon NK cell activation with MHC devoid cell line and cytokines, NK cells from 
HIV infected individuals exhibited reduced survival in comparison to NK cells from HIV 
negative subjects.    
NK cell proliferation rates are dependent on opposing factors during HIV infection. 
Upregulation of IL-15 serum levels during retroviral infection are known to drive rapid NK 
cell expansion and result in higher NK cell numbers (Zhao and French, 2012, Littwitz-Salomon 
et al., 2016). On the other hand, soluble protein modulation and various cell interactions in 
viremic individuals have been shown to reduce proliferation of NK cells (Mavilio et al., 2006, 
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Gasteiger et al., 2013). Furthermore HIV encoded proteins have been demonstrated to directly 
decrease NK cell proliferation. Experiments mimicking the HIV envelope concentrations 
detected in AIDS patients demonstrated diminished NK cell proliferation responses through 
upregulation of genes associated with suppression of cellular expansion (Kottilil et al., 2006). 
In comparison, we did not observe different levels of cytokine-induced NK cell proliferation 
between HIV negative and infected subjects. Since HIV viremia is a contributing factor to 
either supressing or inducing NK cell expansion, the especially low viral loads measured in 
the cohort participants could explain the absence of differences in proliferation levels by HIV 
status.    
The impact of low peripheral neutrophils on NK cell homeostasis in humans is lacking. In 
experiments conducted by Jaeger and colleagues (2012), mice that were deficient of peripheral 
neutrophils were shown to have impaired NK cell homeostasis. This was exhibited by higher 
NK cell proliferation rates that were counterbalanced by increased sensitivity to cell death. 
Interestingly, these changes in cellular homeostasis were limited to NK cells, whereas T cell 
and B cell compartments were unaffected. Though these NK cell homeostatic alterations were 
demonstrated in mouse models, the authors indicated a conserved role for neutrophils in NK 
cell biology across species that was independent of the genetic aetiology responsible for the 
neutropenic phenotype (Jaeger et al., 2012). Thus we hypothesised that low circulating 
neutrophils due to the DARC-null polymorphism would confer altered NK cell survival and 
proliferation levels. However, surprisingly, we detected no changes in most homeostatic 
activities in the absence of DARC. The only exception was that activated NK cells from 
DARC-null HIV infected individuals exhibited reduced survival than NK cells from their 
DARC-positive counterparts. While only two of our DARC-null participants had neutrophil 
counts that were indicative of ethnic neutropenia (<1500 cells/mm3), no association was made 
between absolute neutrophil counts and NK cell survival or proliferation in either HIV negative 
or HIV infected subjects. It has been suggested that deficiency of neutrophils in both bone 
marrow and circulation are required to observe severe modifications within the NK cell 
compartment (Jaeger et al., 2012). The relatively higher neutrophil counts in our cohort 
compared to individuals with other types of neutropenia could explain the unaltered 
observations in most NK cell homeostatic activities measured in our study.        
Here we were limited by a small sample size and that many of the chronically infected patients 
studied had moderately lower viral loads (<1000 RNA copies/ml) than previously described 
chronic patients. Experiments executed in this chapter were planned according to findings in 
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the previous chapter. In order to maintain the same sampling cohort, we were restricted by the 
availability of cryopreserved cells from each participant.  
In summary we deduce that lower absolute neutrophil counts associated with the DARC-null 
polymorphism have marginal effect on the survival of NK cells. Further we attest that the 
capacity of activation-induced NK cell proliferation is unaffected in DARC-null persons. We 
conclude that any NK cell homeostatic defects associated with neutropenia are either mild or 
not apparent in African persons with the DARC-null trait. Overall these results indicate that 
the reduced NK cell counts observed in HIV negative DARC-null individuals (Chapter 3) was 
not due to impaired cell survival or proliferation. This work focused on the impact of low 
circulating neutrophils on NK cell survival and proliferation. Beyond the scope of this study, 
other factors that drive lower peripheral NK cell counts may be at play including diminished 
NK cell release from the bone marrow or altered trafficking of NK cells between tissues and 
circulation (Sun and Lanier, 2011). Nonetheless, the observations presented here are in line 
with our earlier results which suggested that the DARC-null trait does not have a detrimental 
effect on NK cell functionality. Altered NK cell homeostasis has been associated with NK cell 
hypo-responsiveness. Together with our Chapter 3 results we demonstrate that there is no 
evidence for either NK cell functional or homeostatic impairments due to the DARC-null 
polymorphism or lower ANCs in persons of African ethnicity. The findings presented here 
support previous literature that suggest that ethnic neutropenia does not confer clinical 
disadvantage (Haddy et al., 1999, Grann et al., 2008, Hsieh et al., 2010), indicating that 
individuals with the DARC-null polymorphism are able to mount an appropriate NK cell 
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5.1 GENERAL DISCUSSION 
The DARC-null allele is the principal genetic factor contributing to benign ethnic neutropenia 
which is common in 25-50% persons of African ethnicity (Reich et al., 2009, Haddy et al., 
1999). Whilst the condition does not confer a clinical disadvantage (Hsieh et al., 2010), 
literature advocates that the DARC-null polymorphism and the associated neutropenia 
predisposes individuals to increased HIV susceptibility (He et al., 2008, Ramsuran et al., 2011) 
and mother-to-child transmission (Kourtis et al., 2012). Conversely, the effect of the DARC-
null trait in relation to HIV disease progression is controversial. Few studies suggest slower 
HIV disease progression in the absence of DARC (He et al., 2008, Kulkarni et al., 2009). This 
is highly debated by reports of no association between DARC-null polymorphism and rate of 
disease progression (Horne et al., 2009, Julg et al., 2009, Walley et al., 2009).  
Several proposed mechanisms have attempted to clarify the possible associations between the 
DARC genotype and progression to AIDS. Among these, Thobakgale and Ndung’u (2014) 
suggested a role for DARC-null linked ethnic neutropenia in HIV disease progression. While 
lower ANCs in DARC-null individuals may plausibly confer inadequate pathogen killing, it 
was further postulated that absence of the DARC allele may further compromise other 
unknown mechanisms. Additionally, it was hypothesised that lower circulating neutrophils 
would result in fewer immuno-regulatory interactions and inefficient priming of other cellular 
compartments. In the context of HIV infection, these immune deficiencies would lead to 
suboptimal pathogen clearance and failure to control pathogen spread, thus adversely 
contributing to disease progression (Thobakgale and Ndung'u, 2014). 
This study aimed to explore the question of whether DARC-null genotype compromises 
immune responses in African individuals with and without HIV infection; in particular we 
investigated the impact of the DARC-null genotype and its associated low ANCs on key 
neutrophil effector functions. We further assessed the role of DARC-null on NK cell priming 
by measuring NK cell phenotypic maturation / differentiation markers and functional activity. 
Lastly, we examined the capacity of NK cells to survive and proliferate in DARC-null 
individuals.  
Our results demonstrated the following main findings; firstly, enhanced neutrophil 
phagocytosis was observed in DARC-null individuals with and without HIV infection 
demonstrating that this function was a common characteristic in individuals with the DARC-
null allele irrespective of infection. Other neutrophil functions such as ROS and NET release 
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did not differ significantly by DARC state, with the exception that we detected lower NET 
formation in DARC-null HIV infected persons following sustained stimulus exposure (Chapter 
2). Secondly, HIV negative individuals with the DARC-null trait displayed lower NK cell 
frequencies which strongly associated with lower ANCs. Furthermore, lack of the DARC 
phenotype in HIV negative subjects associated with a less differentiated NK cell profile. 
However, examination of NK cell functionality in these DARC-null HIV negative individuals 
showed no measurable impact on NK cell degranulation or cytokine expression. The 
differences observed in HIV negative persons by DARC state were undetectable in HIV 
infected individuals where no differences in NK cell frequency, differentiation or function were 
observed (Chapter 3). To determine the mechanistic link between DARC-null and lower NK 
cell counts in HIV negative persons, we lastly demonstrated that NK cell survival was lower 
in DARC-null individuals, although this outcome was only observed in individuals with HIV 
infection. Moreover, we found no differences in proliferation of NK cells by DARC state in 
individuals with and without HIV infection (Chapter 4). The findings from this study are 
discussed in detail below with reference to literature:   
 
5.1.1 DARC-null polymorphism imparts differential neutrophil functionality 
Neutrophils are recognized for their killing mechanisms and disorders of neutrophil count and 
function are associated with recurrent pathogenic infections (Hsieh et al., 2010, Mocsai, 2013, 
Nauseef and Borregaard, 2014). While the absence of the DARC genotype is associated with 
lower circulating ANCs that is characteristic of ethnic neutropenia (Reich et al., 2009), studies 
exploring the influence of this polymorphism on neutrophil function are lacking. Thus, in an 
analysis of 20 HIV negative and 22 HIV-1 infected individuals, we set out to determine the 
possible impact of the DARC-null trait and ethnic neutropenia on key neutrophil effector 
mechanisms namely, Fc receptor mediated phagocytosis, ROS and NET production.  
Impairment of neutrophil responses manifest during late stages of HIV infection when HIV-1 
plasma concentrations escalate and CD4 lymphocyte counts are significantly reduced 
(Michailidis et al., 2012, Casulli and Elbim, 2014). Evaluation of participants in this study 
indicated a trend for lower phagocytic activity in HIV infected individuals; however, neither 
ROS nor NET production were altered in HIV infection. Clinically, the individuals studied 
here exhibited low viral loads and moderate CD4 counts which are not reflective of advanced 
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disease, and this could partly explain our observation of no significant differences in neutrophil 
phagocytosis or levels of ROS production in HIV infection.  
Unlike other neutrophil functions, data on NET formation with respect to HIV infection is 
lacking and whether this mechanism is altered following infection remains unclear. No 
differences in NET release were detected here between HIV negative and infected subjects. It 
is worth mentioning that individuals in the HIV infected group presented with lower viral loads 
than that typical of chronic infection while it has been reported that higher viral load 
concentration is a major factor in relation to neutrophil deterioration (Mastroianni et al., 1999). 
Thus, our results need to be interpreted with caution as the effect of HIV infection on NET 
formation may be under estimated in this cohort and requires further investigation.  
Stratification of our study cohort by DARC trait indicated high occurrence of the DARC-null 
polymorphism in the Zulu/Xhosa African population which is in agreement with past studies 
(Julg et al., 2009, Ramsuran et al., 2011). We further assessed neutrophil functionality by 
DARC state, hypothesising that neutrophil responses would be impaired in the absence of the 
DARC genotype. Conversely, we demonstrated rapid and enhanced Fc receptor mediated 
phagocytosis in DARC-null individuals. Interestingly, this activity was more prominent in HIV 
infected individuals suggesting that this heightened function was a common characteristic in 
individuals with the DARC-null polymorphism.  Fc receptor upregulation in DARC-null 
neutrophils from HIV negative individuals has been previously described (Duchene et al., 
2017) and may explain the heightened phagocytic activity demonstrated in DARC-null 
Africans in our study. Overall this superior response may be advantageous by promoting faster 
pathogen clearance in DARC-null individuals. 
Examination of ROS and NET formation indicated higher median activity in response to 
stimulus in the presence of the DARC-null polymorphism in individuals with and without HIV 
infection. This result suggested that neutrophil activation was more easily induced in 
neutrophils from DARC-null persons, an observation that is supported by previous data that 
indicated marginally activated neutrophil profiles in DARC-null individuals with benign ethnic 
neutropenia (Charles et al., 2018). However, statistical analysis of ROS and NET production 
generally displayed no significant differences by DARC trait irrespective of HIV status. An 
exception to this observation was the lower NET production exhibited after prolonged 
activation in DARC-null neutrophils from HIV infected individuals. This finding suggests that 
persistent inflammation during HIV infection may induce accelerated neutrophil cell 
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exhaustion and/or death in DARC-null individuals. Though lower NET production in these 
individuals would reduce pathogen killing, diminished NET formation could minimise tissue 
damage by NETs in these individuals (Chen and Nunez, 2010, Barnado et al., 2016). 
 
5.1.2 DARC-null polymorphism does not adversely affect NK cell priming 
NK cells are innate lymphoid cells that are crucial for cytolytic killing and bridging innate and 
adaptive immunity (Lanier, 2005, Vivier et al., 2008). Recent data suggests that NK cell 
priming is dependent on immune-regulatory interactions with mature neutrophils (Jaeger et al., 
2012). We thus investigated the possible impact of DARC-null associated neutropenia on NK 
cell profiles, hypothesising that low circulating neutrophils would adversely affect NK 
responses and homeostasis.  
Assessment of NK cell dynamics in our study participants showed similar NK cell counts 
irrespective of HIV status, although HIV-1 infected individuals displayed NK cell subset 
redistribution marked by higher CD56 negative cells. Past studies including from our group of 
African individuals have described diminished CD56 bright NK cells and an accumulation of 
the aberrant CD56 negative subset in HIV infection (Alter et al., 2005, Jost and Altfeld, 2012, 
Zulu et al., 2017). To determine NK cell maturity during HIV infection, we profiled NK cells 
comprehensively using three NK cell maturation / differentiation models. Past studies have 
described higher proportions of mature NK cells in HIV infected individuals in relation to 
CD57 expression (Hong et al., 2010, Kaczmarek et al., 2017) and lower proportions of NKG2A 
and CD27 expressing NK cells (Beziat et al., 2010, Kaczmarek et al., 2017). In contrast, we 
associated HIV infection with marginally higher frequencies of less mature NK cells. We 
reasoned that dissimilarities in our and past reports was owing to our different profiling 
approaches. Most studies report on CD56 positive NK cell repertoires whilst our analyses 
incorporated total NK cells including the dysfunctional CD56 negative subset. We previously 
noted reduced CD57 expression on the CD56 negative subset of NK cells from chronically 
infected persons (Zulu et al., 2017). These phenotypic alterations within this CD56 negative 
subset could account for the differences observed between past reports and our observations in 
this cohort.   
Consistent with previous studies (Kuri-Cervantes et al., 2014, Beldi-Ferchiou et al., 2016), we 
demonstrated higher expression of markers of activation (HLA-DR) and exhaustion (PD-1) on 
NK cells from HIV infected subjects. However, in contrast to literature (Alter et al., 2004b, 
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Wong et al., 2010), the phenotypic alterations observed in NK cells during HIV infection was 
accompanied by lower cytolytic potential (measured by degranulation marker CD107a) and no 
differences in cytokine production (IFN-ɣ and TNF-α) of these cells. Chronic HIV infection is 
characteristically associated with higher cytolytic potential and cytokine secretion which tend 
to correlate with plasma viremia (Mikulak et al., 2017). Unusually low viral loads exhibited by 
chronically infected individuals and higher proportions of the dysfunctional CD56 negative 
NK cell subset in our cohort probably contributed to our contradictory findings.  
Limited reports describe the effect of neutrophil deficiency on NK cell dynamics (Sporri et al., 
2008, Jaeger et al., 2012, Ueda et al., 2016), and to our knowledge, none have explored this 
mechanism in DARC-null African individuals in the context of HIV infection. Jaeger et al. 
(2012) previously examined NK cell profiles in patients diagnosed with severe congenital 
neutropenia (SCN) and autoimmune neutropenia (AIN). Though comparable NK cell counts 
were observed in controls and those with neutrophil deficiency, it was revealed that neutropenia 
associated with higher proportions of less mature CD56 bright subset coupled to impaired cell 
cytotoxicity (Jaeger et al., 2012).  In contrast, we demonstrated lower NK cell counts in HIV 
negative DARC-null individuals with lower ANCs. Similar to SCN and AIN patients (Jaeger 
et al., 2012), DARC-null linked neutropenia associated with elevated frequencies of the CD56 
bright subset and a less mature / differentiated NK cell phenotypic profile in HIV negative 
individuals that was indicative of hypo-responsive NK cells.  
Surprisingly, despite our findings of a less differentiated NK cell profile in DARC-null HIV 
negative individuals, we detected no differences by activation and exhaustion status ex vivo in 
NK cells from these individuals compared to their DARC-positive counterparts. Furthermore, 
we demonstrated that cytolytic potential, cytokine production and antibody dependent 
cytotoxicity were unaffected by the DARC-null trait in HIV negative subjects. Interestingly, it 
has been reported that hypo-responsive NK cells can be re-educated and become fully 
functional following cytokine stimulation (Beziat et al., 2010). While HIV negative DARC-
null individuals here exhibited a less differentiated NK cell repertoire ex vivo, it is plausible 
that in vitro cytokine stimulation culminated in fully differentiated NK cells with optimal 
effector activities, and may account for comparable NK cell cytotoxicity and cytokine secretion 
by DARC state.     
Interestingly, most of the observations made in the context of HIV infection above were not 
associated with absence of the DARC trait. The observed phenotypic and functional differences 
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associated with HIV infection were lost upon stratification by DARC genotype and NK cell 
frequencies, differentiation and functionality were comparable in DARC-null and DARC-
positive HIV infected individuals. 
Jaeger et al. (2012) previously reported that neutrophil deficient mouse models demonstrated 
increased cell death sensitivity which was counterbalanced with hyper-proliferative capacity, 
resulting in unaltered NK cell frequencies (Jaeger et al., 2012). As earlier mentioned, analysis 
of HIV negative individuals here showed reduced NK cell counts associated with lower ANCs 
in DARC-null HIV negative subjects, suggesting modified peripheral NK cell homeostasis in 
DARC-null HIV negative individuals. Thus in an effort to explain our previous findings, we 
here investigated the possible influence of the DARC-null trait on NK cell survival and 
proliferation in HIV negative and HIV-1 infected.  
Past studies have shown that NK cells are more susceptible to cell death with progressive loss 
of these cells in HIV infection (Douglas et al., 2001, Meier et al., 2005). Furthermore, modified 
cytokine-induced NK cell proliferation has been noted in chronically infected individuals 
(Mavilio et al., 2006, Zhao and French, 2012). Here we report lower NK cell survival upon 
activation amongst infected subjects. However, in contrast to literature, we observed no 
differences in cytokine induced NK cell expansion by HIV status. HIV viremia contributes to 
altered NK cell expansion (Kottilil et al., 2006) and thus our unexpected observation was 
probably a consequence of the low plasma viremia exhibited by infected individuals in our 
cohort.  
Further analysis of NK cell survival and proliferation by DARC trait indicated a trend of lower 
NK cell survival in HIV infected DARC-null persons, however, this difference was not 
measured by DARC state in HIV negative subjects. Thus, contradictory to our hypothesis, we 
concluded that absence of DARC had no apparent or mild effects on NK survival. Lastly, we 
found that NK cell expansion was not altered by DARC-null neutropenia irrespective of HIV 
status. Deficiency of neutrophils in both the bone marrow and circulation are required to detect 
severe modifications within the NK cell compartment (Jaeger et al., 2012). The relatively 
higher neutrophil counts in our cohort compared with other types of neutropenia could account 
for the intact NK cell homeostatic activities (survival and proliferation) measured in our study. 
Furthermore, other factors that drive lower peripheral NK cell counts may play a role including 
diminished NK cell release from the bone marrow or altered trafficking of NK cells between 
tissues and circulation (Sun and Lanier, 2011). 
136 
    
5.2 STUDY LIMITATIONS 
While the data presented here provides evidence of immune variation in the absence of the 
DARC allele, particularly in relation to neutrophil function, our study was limited by numerous 
factors. Neutrophils are a fragile immune cell subset and research on these cells has been 
previously hindered due to their experimentally inflexible nature (Amulic et al., 2012). The 
time interval between blood collection and processing was longer than the ideal conditions 
when assessing neutrophil activity; however, this time period was consistent for all samples. 
Many of the limitations of this study were cohort driven. Since this was intended as a cross 
sectional, pilot study, our cohort size was small and with respect to our NK cell experiments, 
we were restricted to cryopreserved samples. We were further restricted by the availability of 
HIV chronically infected samples from antiretroviral therapy naïve individuals, and the time 
of infection was unestablished in these infected individuals. Since many changes to immune 
cell dynamics occur during early infection, it is plausible that advantages, specifically in terms 
NK cell frequency and maturation that were found in DARC-positive HIV negative individuals 
were lost during chronic infection. However, without longitudinal data, we were unable to fully 
appreciate the effect of DARC-null neutropenia on NK cells from infected persons and whether 
these effects contributed to HIV disease progression. We also noted that our infected cohort 
consisted of individuals with relatively lower viral loads than those previously described in 
HIV chronically infected patients. Thus our observations in this HIV infected group may not 
be representative of typical disease progression in the absence of antiretroviral therapy. Further 
sample collection from treatment naïve individuals became increasingly challenging during the 
study due to the implementation of the HIV test and treat policy. The DARC-null 
polymorphism is a predictor of ethnic neutropenia, however many of our DARC-null subjects 
were not neutropenic as defined by ANC measurements of <1500 cells/mm3. Furthermore, 
these patients were not followed longitudinally, and since repeated ANC measurements are 
lacking, we cannot determine which patients possessed neutropenic characteristics. Despite 
these limitations, our study was able to detect and, for the most part, confirm past observations 
pertaining HIV-1 infection. Further, we were able to detect neutrophil response variation in the 
absence of DARC, and NK cell phenotypic differences that associated with the DARC-null 





    
5.3 FUTURE DIRECTIONS 
Neutrophils are primarily identified for their killing mechanisms that contribute to first line 
immunity. Our study focused on three key neutrophil killing responses (phagocytosis, ROS 
and NET production), although other mechanisms such as degranulation and soluble protein 
production should be assessed in the context of the DARC-null trait in futures studies. Our 
study suggested no detrimental impact of the DARC-null genotype on the above mentioned 
neutrophil functions. In fact, phagocytic data suggest that this activity is enhanced in the 
presence of the DARC-null polymorphism.  
Recent HIV vaccine studies have highlighted the importance of Antibody-Dependent Cellular 
Cytotoxicity (ADCC) responses in HIV protection. Interestingly, neutrophils have been found 
to mediate both HIV-specific Antibody-Dependent Phagocytosis (ADP) and ADCC responses 
in vitro; and these responses were exhibited much faster than monocyte or NK cell-mediated 
responses (Worley et al., 2018). Furthermore, passive immunotherapy administration in mouse 
models revealed that neutrophils, while limited in controlling viral propagation, were crucial 
inducers of a potent host humoral antiviral response (Naranjo-Gomez et al., 2018). Together, 
these studies offer insight into the key role of neutrophils in protective immunity induction and 
suggests the importance of neutrophil activity in an effective HIV vaccine or immunotherapy. 
Ultimately, preservation of neutrophil functions and counts may be significant in successful 
protective immunity strategies.  
Here we presented favourable neutrophil functionality in the absence of DARC in HIV 
uninfected and infected individuals. While these findings offers promise that vaccines or 
immunotherapy centred on neutrophil-mediated induction of protective immune responses may 
still be plausible in the African setting, the issue of DARC-null neutropenia still requires 
extensive consideration. Lower circulatory neutrophil counts may prove ineffective in these 
circumstances as these interventions may not offer the anticipated protection against HIV. 
Indeed, the mechanisms behind DARC-null neutropenia requires better understanding. But 
even then, therapies aimed to overcome neutropenia such as enhancing neutrophil mobilisation 
and migration from the bone marrow be prove unfeasible.  
Besides their effector mechanisms, neutrophils are more recently recognised as important 
immune regulators (Nathan, 2006). Here we focused on neutrophil / NK cell dynamics by 
investigating the impact of the DARC-null allele and lower ANCs on NK cell phenotype and 
function. Neutrophils interact with numerous immune cells including macrophages, dendritic 
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cells, T cells and B cells (Nathan, 2006, Mantovani et al., 2011, Amulic et al., 2012). It may be 
worth profiling these cell types in the context of DARC-null and ethnic neutropenia.  
An interesting observation in our cohort was the association of lower NK cell counts with lower 
ANCs in HIV negative DARC-null individuals. In an attempt to ascertain the mechanism 
behind this lower NK cell count, we assessed for possible changes in NK cell survival and 
expansion. However, our proposed hypothesis that lower ANCs in DARC-null individuals 
could modify NK cell survival and / or proliferation proved incorrect. NK cells are important 
cytolytic cells and are also critical to the development of adaptive immune response. Thus 
recent HIV prophylactic and therapeutic vaccine strategies have focused on enhancing NK cell 
activity (Alter and Altfeld, 2009, Florez-Alvarez et al., 2018). Such interventions could prove 
less efficient in the context of lower NK cells in ethnic neutropenic populations. Other factors 
including reduced NK cell release from the bone marrow or modified NK cell trafficking 
between tissues and circulation may contribute to lower peripheral NK cell counts (Sun and 
Lanier, 2011), these and other possible mechanisms should be further investigated.   
Time of infection in our HIV positive group was unknown, thus we were unable to fully 
appreciate the effect of DARC-null genotype on neutrophils or NK cells from infected persons 
in terms of HIV pathogenesis. Longitudinal data from HIV infected persons may better define 
the immune responses examined here in relation to time of infection and disease progression. 
However, because of the newly implemented policy of initiating antiretroviral therapy on 
diagnosis, this may not be possible. 









    
5.4 CONCLUSION 
DARC-null associated ethnic neutropenic populations are at higher risk to HIV-1 acquisition. 
However, the role of lower neutrophil counts in the absence of the DARC-null trait on HIV 
disease progression is unclear. Thus, in this series of studies we examined neutrophil and NK 
cell responses in DARC-null individuals, hypothesising that the absence of DARC would 
impair neutrophil and NK cell responses and contribute adversely to HIV pathogenesis.  
Conversely, we demonstrate to our knowledge for the first time the advantageous effect of the 
DARC-null polymorphism in conferring superior neutrophil phagocytic activity irrespective of 
HIV status. Furthermore, we attest that the DARC-null trait does not affect ROS production, 
and only marginally reduces NET formation in HIV infected individuals. The data suggests 
that the DARC-null genotype does not adversely affect neutrophil functionality irrespective of 
HIV state. From the data presented here, it is probable that any disadvantage DARC-null 
individuals may display pre or post infection is likely due to reduced neutrophil counts rather 
than impaired neutrophil functions.   
While reduced NK cells frequencies with a less differentiated phenotype were observed in HIV 
negative DARC-null subjects, overall NK cell functional responses were not impaired. 
Differences observed by DARC state in HIV negative individuals were absent in HIV infection, 
suggesting that any advantage that DARC-positive HIV negative persons may exhibit in 
relation to NK cells are lost during infection. The condition does not impede downstream NK 
cell functionally, suggesting that NK cell priming is not hindered by lower ANCs. Lastly, NK 
cell survival and proliferation were not hampered in either HIV negative or chronically infected 
individuals by DARC state, suggesting that the DARC-null polymorphism does not impair 
these homeostatic activities.  
Overall, the data presented here suggests that the DARC-null trait and the associated lower 
neutrophil counts does not adversely affect neutrophil function or compromise NK cell 
dynamics. This is encouraging as it suggests that the absence of DARC does not diminish 
neutrophil or NK cell responses and does not contribute adversely to HIV pathogenesis in this 
manner. We provide mechanistic evidence in support of the asymptomatic clinical 
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Supplementary Figure 1 Neutrophil Reactive Oxygen Species (ROS) production 
Summary lines for ROS production over time is shown for the studied groups. Unstimulated controls 
for all groups are represented as black circles; PMA stimulated samples for HIV negative individuals 
are represented as grey circles (DARC-null) or triangles (DARC-positive); PMA stimulated samples 
for HIV positive individuals are represented as orange circles (DARC-null) or triangles (DARC-
positive). Summary lines were calculated as the average of unstimulated or PMA stimulated samples of 
all participants within each studied group. Abbreviations: ROS, reactive oxygen species; DARC, Duffy 
Antigen Receptor for Chemokines.   
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Supplementary Figure 2 Correlation between CD69, HLA-DR or PD-1 expression on total NK 
cells with ANC 
Correlations between ANC and percentage of NK cells expressing either CD69 in HIV negative (A) 
and HIV infected (B) persons; HLA-DR in HIV negative (C) and HIV infected (D) persons; or PD-1 in 
HIV negative (E) or HIV infected (F) persons. Dots indicate individual data points.   Abbreviations: 
ANC, Absolute neutrophil count; r, Spearman rho. 
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Supplementary Figure 3 IFN-ɣ and CD107a expression in NK cells following whole blood 
stimulation with HIV-1 peptides gp120 and gp41 
Representative gating strategy employed for the analysis of IFN-ɣ and CD107a expression in NK cells after 
stimulation with gp120 and gp41. Frequencies of no stimulation samples were used to subtract background from 
stimulated gp120 and gp41 samples. 
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Supplementary Figure 4 Expression of CD107a relative to absolute neutrophil count (ANC) 
following whole blood stimulation with HIV-1 peptides gp120 or gp41 
Correlations between percentage of NK cells expressing CD107a and absolute neutrophil count (ANC) 
in HIV negative and HIV infected individuals after stimulation with gp120 or gp41. Dots indicate 
individual data points. The p-values as indicated by ns refer to no significant differences. Abbreviations: 






    
 
Supplementary Figure 5 Expression of IFN-ɣ relative to absolute neutrophil count (ANC) 
following whole blood stimulation with HIV-1 peptides gp120 or gp41 
Correlations between percentage of NK cells expressing IFN-ɣ and absolute neutrophil count (ANC) in 
HIV negative and HIV infected individuals after stimulation with gp120 or gp41. Dots indicate 







    
Supplementary Table 1 Flow Cytometry Antibodies 
The table indicates the monoclonal antibodies used for NK cell phenotype, intracellular staining (ICS) 
or whole blood staining for assessment by flow cytometry. The species, isotype and clone for each 
antibody is specified. Details of manufacturer and the final titrated volumes used for staining is supplied. 
Abbreviations: µl, microliter; ICS, intracellular staining.    
 
Panel Marker Fluorochrome Species Isotype Clone Manufacturer Volume (µl)
Phenotype/ICS CD3 PE-CF594 Mouse BALB/c IgG1, κ UCHT1 BD Biosciences 2
Whole Blood CD3 PE-Cy5.5 Mouse IgG2a, κ 7D6 Invitrogen 2
Phenotype CD14 V500 Mouse IgG2a, κ M5E2 BD Biosciences 2
ICS CD14 BV650 Mouse IgG2a, κ M5E2 Biolegend 2
Whole Blood CD14 Pacific Blue Mouse IgG2a, κ TuK4 Invitrogen 2
Phenotype CD19 V500 Mouse IgG1, κ HIB19 BD Biosciences 2
ICS CD19 BV650 Mouse IgG1, κ HIB19 Biolegend 2
Whole Blood CD19 Pacific Blue Mouse IgG2a, κ SJ25-C1 Invitrogen 2
All panels CD16 APC-Cy7 Mouse BALB/c x DBA/2 3G8 BD Biosciences 1.5
All panels CD56 Alexa-Fluor-700 Mouse IgG1, κ B159 BD Biosciences 1
Phenotype CD69 FITC Mouse IgG1, κ FN50 BD Biosciences 5
Phenotype CD38 PE Mouse IgG1, κ HB7 BD Biosciences 4
Phenotype HLA-DR BV711 Mouse IgG2a, κ L243 Biolegend 2
Phenotype CD27 BV605 Mouse IgG1, κ O323 Biolegend 2.5
Phenotype CD11b/Mac-1 PE-Cy5 Mouse IgG1, κ ICRF44 BD Biosciences 10
Phenotype PD-1 BV421 Mouse IgG1, κ EH12.2H7 Biolegend 2
Phenotype CD57 APC Mouse IgM, κ NK-1 BD Biosciences 2.5
ICS CD158a PE Mouse BALB/c IgM HP-3E4 BD Biosciences 5
ICS CD158b PE Mouse BALB/c IgG2b, κ CH-L BD Biosciences 5
ICS CD158e1/e2 PE Mouse IgG1, κ Z27.3.7 Beckman Coulter 5
ICS NKG2A APC Mouse IgG2b, κ Z199.1 Beckman Coulter 5
ICS/Whole Blood CD107a PE-Cy7 Mouse BALB/c IgG1, κ H4A3 BD Biosciences 3.5
ICS TNF-α PerCP-Cy5.5 Mouse IgG1, κ Mab11 Biolegend 5
ICS/Whole Blood IFN-ɣ PE-Cy7 Mouse IgG1, κ B27 Biolegend 5
